AU2018254437A1

AU2018254437A1 - Methods for the treatment of subjects having a hepatitis B virus (HBV) infection

Info

Publication number: AU2018254437A1
Application number: AU2018254437A
Authority: AU
Inventors: Thomas MICHLER; Ulrike Protzer; Laura Sepp-Lorenzino
Original assignee: Technische Universitaet Muenchen; Alnylam Pharmaceuticals Inc
Current assignee: Technische Universitaet Muenchen; Alnylam Pharmaceuticals Inc
Priority date: 2017-04-18
Filing date: 2018-04-18
Publication date: 2019-11-28
Also published as: WO2018195165A8; TWI801377B; MA50278A; KR20200015895A; EP3612219A1; WO2018195165A1; CN110913898A; TW201906617A; PH12019550220A1; SG11201909572QA; CA3059446A1; BR112019021852A2; CN110913898B

Abstract

The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.

Description

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 12, 2018, is named 121301-07220_SL.txt and is 429,841 bytes in size.

BACKGROUND OF THE INVENTION

Hepatitis B virus (HBV) is an enveloped DNA virus that infects the liver that causes hepatocellular necrosis, inflammation, and is a major risk factor for development of cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization (WHO) estimates that there are 240 million chronically HBV infected individuals worldwide largely in low to middle income countries and that about 650,000 people will die annually of complications from HBV infection. Although an effective HBV vaccine is available and efforts to vaccinate infants at birth have been effective in reducing incidence and prevalence of HBV infection, such programs do not have a demonstrable effect on death rates for years (WHO Guidelines for prevention, care and treatment of persons with chronic Hepatitis B Infection, 2015 at apps.who.mt/iris/bitstream/10665/154590/l/9789241549059_eng.pdf?ua=l&ua=l).

A number of therapeutic agents have been developed for the treatment of HBV that effectively reduce the disease burden of HBV infection, but they are not typically curative as they do not fully eliminate all replicative forms of the virus including the covalently closed circular DNA (cccDNA) that resides in the hepatocyte nucleus and becomes a template for viral replication and transcription of viral RNAs. Nucleotide and nucleoside analogs, typically considered to be the gold standard for treatment of chronic HBV infection due to their safety and efficacy, are effective in suppressing HBV replication, but they do not eliminate cccDNA, do not prevent expression of viral proteins, must be dosed chronically, and can result in the development of resistance. Further, treatment with nucleot(s)ide inhibitors does not fully mitigate the risk of the development of hepatocellular carcinoma (HCC) which remains significant (about 7% in 5-7 years despite treatment). Interferon-based therapies can result in sero-conversion and cure of about 10-15% of patients allowing discontinuation of treatment, but the agents have severe side effects and must be refrigerated

WO 2018/195165

PCT/US2018/028116 for long term storage making them less desirable for use in countries where HBV infection is most prevalent.

Treatment of chronic HBV is further complicated by the ability of HBV to evade or suppress the immune response resulting in persistence of the infection. The HBV proteins have immuneinhibitory properties, with hepatitis B s antigen (HBsAg) comprising the overwhelming majority of HBV protein in the circulation of HBV infected subjects. Additionally, while the removal (via seroconversion) of hepatitis B e antigen (HBeAg) or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and seroconversion) in HBV infection is a well-recognized prognostic indicator of antiviral response to treatment which will lead to control of HBV infection off treatment. However, this only occurs in a small fraction of patients receiving immunotherapy. Therefore, it is possible, although rare, for patients to mount a sufficiently robust immune response to suppress or clear an HBV infection resulting in at least a functional cure of the disease.

SUMMARY OF THE INVENTION

The invention provides RNAi agents and HBV vaccines for use in treatment of hepatitis B virus (HBV) infection and methods for the treatment of a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, which includes a combination therapy or treatment regimen including an RNAi agent targeting at least one HBV transcript and a therapeutic vaccination.

Accordingly, in one aspect, the present invention provides RNAi agents and HBV vaccines for use in treatment of hepatitis B virus (HBV) infection and methods for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The methods include a regimen which includes administering, e.g., sequentially administering, to the subject having the HBV infection, an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBeAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBeAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine, thereby treating the subject.

In another aspect, the present invention provides a regimen for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The regimen includes the use of an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBeAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBeAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine.

In one embodiment, the HBeAg protein, or immunogenic fragment thereof, shares an epitope with the HBV core antigen (HBeAg) polypeptide, or immunogenic fragment thereof, present in the protein-based vaccine and/or the HBsAg protein, or immunogenic fragment thereof, shares an epitope

WO 2018/195165

PCT/US2018/028116 with the HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof, present in the protein-based vaccine.

In certain embodiments, the RNAi agent comprises at least one modified nucleotide.

In certain embodiments, the nucleic acid-based vaccine comprises an expression construct encoding an HBcAg and an HBsAg.

In certain embodiments, the RNAi agent targeting HBV is administered to the subject at least two times.

In certain embodiments, the RNAi agent targeting HBV administered to the subject decreases HBsAg in the serum of the subject by at least 0.5 log 10 lU/ml. In certain embodiments, the subject has at least a 0.5 loglO lU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has at least a 1 loglO lU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has an HBsAg of 2 log 10 lU/ml or less in serum prior to administration of the vaccine.

In certain embodiments, the RNAi agent is administered to the subject no more than once per week. In certain embodiments, the RNAi agent is administered to the subject no more than once every four weeks.

In certain embodiments, the RNAi ageint is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg; or 0.5 mg/kg to 50 mg/kg; or 10 mg/kg to 30 mg/kg. In certain embodiments, the RNAi agent is administered to the subject at a dose selected from 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg. In some embodiments, a dose of the RNAi agent is administered to the subject about once per week; about one every two weeks; about once every three weeks; about once every four weeks; or a dose of the RNAi agent is administered to the subject not more than once per week; or a dose of the RNAi agent is administered to the subject no more than once every four weeks.

In certain embodiments, the protein-based vaccine comprises an amino acid sequence of at least one determinant of HBsAg and at least one determinant of HBcAg.

In certain embodiments, the nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg encodes an amino acid sequence comprising at least one determinant of HBsAg or at least one determinant of HBcAg

In certain embodiments, the determinant of HBsAg comprises a sequence at least 90% identical to amino acids 124 to 147 of SEQ ID NO: 22. In certain embodiments, the determinant of HBsAg comprises a sequence at least 90% identical to amino acids 99 to 168 of SEQ ID NO: 23.

In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 80 of SEQ ID NO: 24. In certain embodiments, the sequence comprising amino acid 80 of SEQ ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 138 of SEQ ID NO: 24. In certain embodiments, the sequence comprising

WO 2018/195165

PCT/US2018/028116 amino acid 80 of SEQ ID NO: 14 comprises an amino acid sequence at lest 90% identical to at least amino acids 128 to 143 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises an amino acid sequence at least 90% identical to at least 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence at least 90% identical to amino acids 18 to 143 of SEQ ID NO: 24.

In certain embodiments, the protein-based vaccine administered to the subject comprises a dose of 0.1 qg to 1.0 mg of the HBcAg and a dose of 0.1 qg to 1.0 mg of HBsAg. In some embodiments, a dose of the protein-based vaccine is administered to the subject about once per week; about one every two weeks; about once every three weeks; about once every four weeks; or a dose of the protein-based vaccine is administered to the subject no more than once per week; or a dose of the protein-based vaccine is administered to the subject no more than once every four weeks.

In certain embodiments, the HBcAg protein and the HBsAg protein are present in a single formulation. In certain embodiments, the HBcAg protein and the HBsAg protein are not present in a single formulation. In certain embodiments, the protein-based vaccine comprises an adjuvant. In some embodiments, the adjuvant stimulates a balanced Thl/Th2 response. In certain embodiments, the adjuvant is selected from monophosphoryl lipid A (MPL), poly(I:C), polylCLC adjuvant, CpG DNA, polylCLC adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)), alum, virosomes, cytokines, IL-12, AS02, AS03, AS04, MF59, ISCOMATRIX®, IC31®, or Rig-I ligand. In certain embodiments, the adjuvant is selected from polyLC adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant.

In certain embodiments, the protein based vaccine is administered to the subject at least two times. In certain embodiments, the protein-based vaccine is administered to the subject no more than once every two weeks. In certain embodiments, the protein-based vaccine is administered to the subject no sooner than the day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein-based vaccine is administered to the subject on the same day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than one month after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than two months after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than three months after the final dose of the RNAi agent has been administered to the subject.

In certain embodiments the methods of the invention further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

WO 2018/195165

PCT/US2018/028116

In certain embodiments the methods of the invention further comprise determining the serum

HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBeAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

In certain embodiments the methods of the invention further comprise determining the serum HBsAg level and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

In certain embodiments, the nucleic acid-based vaccine comprises at least one expression vector construct encoding both an HBeAg and an HBsAg. In certain embodiments, the expression construct promotes expression of HBeAg and HBsAg from a single promoter. In other embodiments, the expression construct promotes expression of HBeAg and HBsAg from separate promoters.

In certain embodiments, at least one promoter is selected from a respiratory syncytial virus (RSV) promoter, a cytomegalovirus (CMV) promoter, a PH5 promoter, and an Hl promoter. In certain embodiments, the expression construct comprises a viral vector. In certain embodiments, the viral vector is selected from adenovirus vector; retrovirus vector, lentiviral vector, moloney murine leukemia virus vector, adeno- associated virus vector; herpes simplex virus vector; SV 40 vector; polyoma virus vector; papilloma virus vector; picornavirus vector; pox virus vector, orthopox virus vector, vaccinia virus vector, modified vaccinia virus Ankara (MVA) vector, avipox vector, canary pox vector, fowl pox vector, adenovirus vector, and Epstein Barr virus vector. In certain embodiments, the viral vector is an MVA vector.

In certain emboidments, the nucleic acid-based vaccine administered to the subject comprises a tissue-culture infectious dose (TCID₅₀) of 10⁶ to 10¹⁰ TCID50; or 10⁶ to 10⁹ TCID50; or 10⁶ to 10⁸TCID₅₀

In certain embodiments, the nucleic acid-based vector is administered to the subject no sooner than two weeks after administration of the final dose of the protein-based vaccine is administered to the subject.

In certain embodiments, the methods further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBsAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.

WO 2018/195165

PCT/US2018/028116

In certain embodiments, the methods further comprise determining the serum HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBeAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.

In certain embodiments, the methods further comprise determining the serum HBsAg level and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBsAg and serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.

In certain embodiments, the methods further comprise administering a nucleot(s)ide analog to the subject at least prior to administration of the iRNA targeted to HBV. In certain embodiments, the nucleot(s)ide analog is administered throughout the entire regimen. In certain embodiments, the nucleot(s)ide analog is selected from Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir, besifovir (ANA-38O/LB-8O38O), and tenofovirexaliades (TLX/CMX157).

In certain embodiments, the subject has serum HBsAg below 3000 lU/ml prior to administration of the RNAi agent. In certain embodiments, the subject has serum HBsAg below 4000 lU/ml prior to administration of the RNAi agent. In certain embodiments, subject has serum HBsAg below 5000 lU/ml prior to administration of the RNAi agent.

In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales and a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine.

In certain embodiments, the subject has a reduction of HBsAg level to 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based

WO 2018/195165

PCT/US2018/028116 vaccine. In certain embodiments, the subject has a reduction of HBsAg level to 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level to 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

In certain embodiments, the subject has a reduction of HBeAg level to 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least three months after the end of the dose of the nucleic acid-based vaccine. In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.

In certain embodiments, serum HBsAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acidbased vaccine.

In certain embodiments, the methods further comprise administration of an immune stimulator to the subject. In certain embodiments, the immune stimulator is selected from the group pegylated interferon alfa 2a (PEG-IFN-alpha-2a), Interferon alfa-2b, PEG-IFN-alpha-2b, Interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor, Myrcludex, an oligonucleotide that inhibits the secretion or release of HBsAg, REP 9AC, a capsid inhibitor, Bay41-4109, NVR-1221, a cccDNA inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-L1 inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.

In certain embodiments of the regimen, the subject is human.

WO 2018/195165

PCT/US2018/028116

In certain embodiments of the regimen, the RNAi agent targets four transcripts of HBV. In certain embodiments, the RNAi agent is selected from an iRNA in Appendix A. In certain embodiments, the RNAi agent is selected from any of the agents in any one of Tables 2-11 in Appendix A. In certain embodiments, the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 206-228, 207-229, 210-232, 212-234, 214-236, 215-237, 216-238, 226-248, 245-267, 250-272, 252-274, 253-275, 254-276, 256-278, 258-280, 263-285, 370-392, 373-395, 375-397, 401423, 405-427, 410-432, 411-433, 422-444, 424-446, 425-447, 426-448, 731-753, 734-756, 11741196, 1250-1272, 1255-1277, 1256-1278, 1545-1567, 1547-1569, 1551-1571, 1577-1597, 1579-1597, 1580-1598, 1806-1825, 1812-1831, 1814-1836, 1829-1851, 1831-1853, 1857-1879, 1864-1886, 22592281, 2298-2320, or 2828-2850 of SEQ ID NO: 1 (NC_003977.1). In certain embodiments, the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1). In certain embodiments, the RNAi agent targets nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).

In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26).

In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28).

In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of

WO 2018/195165

PCT/US2018/028116

UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27).

In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28).

In certain embodiments of the regimen, substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3’-terminus. In certain embodiments, the ligand is one or more GalNAc derivatives attached through a monovalent linker, bivalent branched linker, or trivalent branched linker. In certain embodiments, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3’-terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2’-amino-modified nucleotide, a 2’-O-allylmodified nucleotide, 2’-C-alkyl-modified nucleotide, 2’-hydroxly-modified nucleotide, a 2’methoxyethyl modified nucleotide, a 2’ -O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5’-phosphate, and a nucleotide comprising a 5’-phosphate mimic.

In certain embodiments, at least one strand of the RNAi agent comprises a 3’ overhang of at least 1 nucleotide. In certain embodiments, at least one strand if the RNAi agent comprises a 3’ overhang of at least 2 nucleotides. In certain embodiments, the double-stranded region of the RNAi agent is 15-30 nucleotide pairs in length; 17-23 nucleotide pairs in length; 17-25 nucleotide pairs in length; 23-27 nucleotide pairs in length; 19-21 nucleotide pairs in length; 21-23 nucleotide pairs in length.

In certain embodiments, each strand of the RNAi agent has 15-30 nucleotides.

In certain embodiments, each strand of the RNAi agent has 19-30 nucleotides.

In certain embodiments, the ligand is

WO 2018/195165

PCT/US2018/028116

and the RNAi agent is optionally conjugated to the ligand as shown in the following schematic

wherein X is O or S.

In certain embodiments, the sense strand comprises the nucleotide sequence 5’gsusguGfcAfCfUfucgcuucaca-3’ (SEQ ID NO: 29) and the antisense strand comprises the nucleotide sequence 5’-usGfsugaAfgCfGfaaguGfcAfcacsusu-3’ (SEQ ID NO: 30); or the sense strand comprises the nucleotide sequence 5’-csasccauGfcAfAfCfuuuuucaccu-3’ (SEQ ID NO: 31) and the antisense strand comprises the nucleotide sequence 5’-asGfsgugAfaAfAfaguuGfcAfuggugsusu-3’ (SEQ ID NO: 32), wherein a, c, andu are 2'-O-methyladenosine-3’ -phosphate, 2'-O-methylcytidine3’-phosphate, and 2'-O-methyluridine-3’-phosphate, respectively; as, cs, gs, and us are 2'-Omethyladenosine-3’- phosphorothioate, 2'-O-methylcytidine-3’- phosphorothioate, 2'-Omethylguanosine-3’- phosphorothioate, and 2'-O-methyluridine-3’-phosphorothioate, respectively; Af, Cf, Gf, and Uf are 2’-fluoroadenosine-3’-phosphate, 2’-fluorocytidine-3’-phosphate, 2’fluoroguanosine-3’-phosphate, and 2’-fluorouridine-3’-phosphate, respectively; and Gfs is 2’ fluoroguanosine-3’-phosphorothioate. In certain embodiments, the RNAi agent is AD-66810 or AD66816.

In certain embodiments, the protein-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.

In certain embodiments, the nucleic acid-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.

WO 2018/195165

PCT/US2018/028116

The present invention further provides uses of the RNAi agents and vaccines provided herein for treatment of subjects having a hepatitis B virus infection based on the methods provided herein.

In certain embodiment, the RNAi agents and the HBV vaccines are used in the manufacture of medicaments for treatment of a subject with an HBV infection.

The present invention further provides kits comprising RNAi agents and vaccines provided herein and instructions providing treatment regimens for their use for treatment of subjects having a hepatitis B virus infection.

The present invention is further illustrated by the following detailed description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 schematically depicts the structure of the approximately 3.2 kb double-stranded HBV genome. Replication of the HBV genome occurs through an RNA intermediate and produces 4 overlapping viral transcripts of about 3.5 kb, 2.4 kb, 2.1 kb, and 0.7 kb (termination sites indicated by arrows), and the common 3’ end encoding seven viral proteins (pre-Sl, pre-S2, S, P, X, pre-C, and C) that are translated across three reading frames.

Figures 2A-2E are graphs showing suppression of HBV by siRNA in a transgenic mouse model. The level of (2A) HBsAg, (2B) HBeAg, and (2C) HBV-DNA in serum of HBV1.3-xfs mice (n = 6 per group) after a single subcutaneous 3 mg/kg or 9 mg/kg dose of a control GalNAc-siRNA (an siRNA that does not target HBV), AD-66816, or AD-66810. The level of (2D) total HBV RNA and (2E) 3.5 kb HBV transcripts from liver lysates determined via RT-qPCR and normalized to expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Figure 3 is a schematic showing a dosing regimen for an experiment assaying the effect of pretreatment of HBV1.3-xfs mice with the nucleoside inhibitor, Entecavir, an HBV-shRNA, a control GalNAc-siRNA, AD-66816, or AD-66810 prior to administration of a therapeutic vaccine against HBV.

Figures 4A-4C are graphs showing the level of (4A) HBsAg, (4B) HBeAg, and (4C) HBVDNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3.

Figures 5A-5F are graphs showing T cell immune response in the liver against peptides (5A) HBs(S208), (5B) HBc(C93), and (5C) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figures 5D-5F show a reanalysis of the same data in Figures 5A-5C performed to accommodate for an insufficient exclusion of dead immune cells and shows T cell immune response in the liver against peptides (5D) HBs(S208), (5E) HBc(C93), and (5F) MVA(B8R).

Figures 6A-6C show the level of HBV RNA and protein levels in liver cells in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figure 6A shows total HBV RNA. Figure 6B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR. Figure 6C shows the number of HBeAg positive cells per mm² of liver section detected by immunohistochemical staining.

WO 2018/195165

PCT/US2018/028116

Figure 7 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of HBV1.3-xfs mice with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.

Figures 8A-8C are graphs showing the level of (8A) HBsAg, (8B) HBeAg, and (8C) HBVDNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.

Figures 9A-9D are graphs showing T cell immune response in the liver against peptides (9A) HBs(S208), (9B) HBc(C93), (9C) HBc(Cpool) and (9D) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.

Figures 10A-10C show the level of HBV RNA and protein levels in liver cells of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7. Figure 10A shows total HBV RNA. Figure 10B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR. Figure 10C shows the number of HBeAg positive cells per mm² of liver section detected by immunohistochemical staining.

Figures 11A and 1 IB are graphs showing the level of (11 A) HBsAg and (1 IB) HBeAg in serum of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.

Figures 11C and 11D are graphs showing (11C) anti-HBs antibody response and (11D) T cell immune response in the liver against HBs(S208) of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.

Figure 12 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of mice infected with an AAV vector encoding HBV with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.

Figures 13A-13G are based on the dosing regimen provided in Figure 12. Figures 13A and 13B are graphs showing the level of (13A) HBsAg and (13B) HBeAg in serum of HBV-AAV mice (inset 13C is an exploded portion of the later time points in graph 13B). Figure 13D shows the serum HBV DNA level at week 22. Figures 13D and 13E show the number of copies per liver cell of (13D) total HBV DNA and (13E) AAV-DNA at week 22. Figures 13F and 13G show the relative expression in liver of (13F) HBV 3.5 RNA relative to GAPDH RNA and (13G) total HBV RNA relative to GAPDH RNA.

Figures 14A-14C are graphs showing (14A) anti-HBs antibody response throughout the course of the experiment and (14B) anti-HBe antibody response at day 116 of the experiment based on the dosing regimen provided in Figure 12. Figure 14C is an exploded portion of the later time points in graph 14B.

Figures 15A and 15B show (15A) AFT levels and (15B) body weights of the animals throughout the experiment based on the dosing regimen provided in Figure 12.

A formal sequence listing is provided herewith that forms part of the specification.

WO 2018/195165

PCT/US2018/028116

An Appendix A providing exemplary target sequences for siRNA targeting and iRNA agents is provided herewith and forms part of the specification.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides treatment regimens and methods of use of iRNA agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of one or more HBV genes (open reading frames/ transcripts) and hepatitis B vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV infection. The treatment regimens and methods preferably provide a functional cure within a defined period of time.

The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of an HBV gene as well as compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition or reduction of the expression of an HBV gene.

I. Definitions

In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.

The term including is used herein to mean, and is used interchangeably with, the phrase including but not limited to.

The term or is used herein to mean, and is used interchangeably with, the term and/or, unless context clearly indicates otherwise.

The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as within 2 standard deviations from the mean. In certain embodiments, “about” means +/-10%. In certain embodiments, “about” means +/-5%. When about is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

The term “at least” prior to a number or series of numbers is understood to include the number adjacent to the term “at least”, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 18 nucleotides of a 21 nucleotide nucleic acid molecule” means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a

WO 2018/195165

PCT/US2018/028116 series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range.

As used herein, “no more than” or “less than” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of “no more than 2 nucleotides” has a 2, 1, or 0 nucleotide overhang. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.

In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence.

Various embodiments of the invention can be combined as determined appropriate by one of skill in the art.

As used herein, “Hepatitis B virus,” used interchangeably with the term “HBV” refers to the well-known non-cytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family.

The HBV genome is partially double-stranded, circular DNA with overlapping reading frames (see, e.g., Figure 1).

There are four transcripts (that may be referred to herein as “genes” or “open reading frames”) based on size, encoded by the HBV genome. These contain open reading frames called C, X, P, and S. The core protein is coded for by gene C (HBcAg). Hepatitis B e antigen (HBeAg) is produced by proteolytic processing of the pre-core (pre-C) protein. The DNA polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigens (HBsAg). The HBsAg gene is one long open reading frame which contains three in frame start (ATG) codons resulting in polypeptides of three different sizes called large, middle, and small S antigens, pre-Sl + pre-S2 + S, pre-S2 + S, or S. Surface antigens in addition to decorating the envelope of HBV, are also part of subviral particles, which are produced at large excess as compared to virion particles, and play a role in immune tolerance and in sequestering anti-HBsAg antibodies, thereby allowing for infectious particles to escape immune detection. The function of the non-structural protein coded for by gene X is not fully understood, but it plays a role in transcriptional transactivation and replication and is associated with the development of liver cancer. Exemplary protein sequences are provided in the attached sequence listing (see, e.g., SEQ ID NOs:l, 3, 16, and 20).

HBV is one of the few DNA viruses that utilize reverse transcriptase in the replication process which involves multiple stages including entry, uncoating, and transport of the virus genome to the nucleus. Initially, replication of the HBV genome involves the generation of an RNA intermediate that is then reverse transcribed to produce the DNA viral genome.

Upon infection of a cell with HBV, the viral genomic relaxed circular DNA (rcDNA) is transported into the cell nucleus and converted into episomal covalently closed circular DNA (cccDNA), which serves as the transcription template for the viral mRNAs. After transcription and nuclear export, cytoplasmic viral pregenomic RNA (pgRNA) is assembled with HBV polymerase and

WO 2018/195165

PCT/US2018/028116 capsid proteins to form the nucleocapsid, inside which polymerase-catalyzed reverse transcription yields minus-strand DNA, which is subsequently copied into plus-strand DNA to form the progeny rcDNA genome. The mature nucleocapsids are then either packaged with viral envelope proteins to egress as virion particles or shuttled to the nucleus to amplify the cccDNA reservoir through the intracellular cccDNA amplification pathway. cccDNA is an essential component of the HBV replication cycle and is responsible for the establishment of infection and viral persistence.

HBV infection results in the production of two different particles: 1 ) the infectious HBV virus itself (or Dane particle) which includes a viral capsid assembled from the HBeAg and is covered by an envelope consisting of a lipid membrane with HBV surface antigens, and 2) sub viral particles (or SVPs) which contain the small and medium forms of the hepatitis B surface antigen HBsAg which are non-infectious. For each viral particle produced, over 10,000 SVPs are released into the blood. As such, SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).

Eight genotypes of HBV, designated A to H, have been determined, and two additional genotypes I and J have been proposed, each having a distinct geographical distribution. The virus is non-cytopathic, with virus-specific cellular immunity being the main determinant for the outcome of exposure to HBV- acute infection with resolution of liver diseases with 6 months, or chronic HBV infection that is frequently associated with progressive liver injury.

The term “HBV” includes any of the genotypes of HBV (A to J). The complete coding sequence of the reference sequence of the HBV genome may be found in for example, GenBank Accession Nos. GI:21326584 (SEQ ID NO:1) and GI:3582357 (SEQ ID NO:3). Antisense sequences are provided in SEQ ID NO: 2 and 4, respectively. Amino acid sequences for the C, X, P, and S proteins can be found, for example at NCBI Accession numbers YP_009173857.1 (C protein); YP_009173867.1 and BAA32912.1 (X protein); YP_009173866.1 and BAA32913.1 (P protein); and YP_009173869.1, YP_009173870.1, YP_009173871.1, and BAA32914.1 (S protein) (SEQ ID NOs: 5-13) . Protein and DNA sequences from HBV genotype D, strain ayw are provided in SEQ ID NOs.: 14-17. Protein and DNA sequences from HBV genotype A, strain adw are provided in SEQ ID NOs.: 18-21.

Additional examples of HBV mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, and OMIM. The International Repository for Hepatitis B Virus Strain Data can be accessed at http://www.hpa-bioinformatics.org.uk/HepSEQ/main.php.

The term “HBV,” as used herein, also refers to naturally occurring DNA sequence variations of the HBV genome, i.e., genotypes A-J and variants thereof.

As used herein, “epitope” also referred to as “an antigenic determinant,” or “determinant,” is understood as the part of a protein antigen that is recognized by the immune system, specifically by antibodies, B cells, and/or T cells. Epitopes include conformational epitopes and linear epitopes. Proteins share an epitope when they share an amino acid sequence of sufficient length or size and

WO 2018/195165

PCT/US2018/028U6 antigenicity to be recognized by an antibody, B cell, and/or T cell. T cell epitopes presented by MHC class I molecules are typically peptides about 8 to 11 amino acids in length, whereas MHC class II molecules present longer peptides about 13 to 17 amino acids in length. Conformational epitopes are typically discontinuous and span a longer amino acid sequence.

As used herein, the term “nucelot(s)ide analog” or “reverse transcriptase inhibitor” is an inhibitor of DNA replication that is structurally similar to a nucleotide or nucleoside and specifically inhibits replication of the HBV cccDNA and does not significantly inhibit the replication of the host (e.g., human) DNA. Such inhibitors include Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, besifovir (ANA-38O/LB-8O38O), and tenofvirexaliades (TLX/CMX157). In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV). Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript, including mRNA that is a product of RNA processing of a primary transcription product. In one embedment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript. In one embodiment, the target sequence is within the protein coding region of an HBV transcript.

The target sequence may be from about 9-36 nucleotides in length, e.g., about 15-30 nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 1828, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 2021, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T,” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing

WO 2018/195165

PCT/US2018/028116 properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.

As used herein, an “RNAi agent”, an “iRNA agent”, an “siRNA agent”, and the like, is a double stranded RNA that preferably target regions in the HBV genome that are conserved across all serotypes of HBV and are preferably designed to inhibit all steps of the HBV life cycle, e.g., replication, assembly, secretion of virus, and secretion of viral antigens, by inhibiting expression of more than one HBV transcript. In particular, since transcription of the HBV genome results in polycistronic, overlapping RNAs, an RNAi agent for use in the invention targeting a single HBV transcript preferably results in significant inhibition of expression of most or all HBV transcripts. All HBV transcripts are at least partly overlapping and share the same polyadenylation signal. Therefore, all viral transcripts have an identical 3'end and, thus, an RNAi agent of the invention targeting the X gene will target all viral transcripts and should result in inhibition of not only X gene expression but also the expression of all other viral transcripts, including pregenomic RNA (pgRNA). Furthermore, the RNAi agents of the invention have been designed to inhibit HBV viral replication by targeting pgRNA, HBV structural genes, polymerase, and the HBV X gene. In addition, they have been designed to mediate the silencing of SVP and other viral protiens that play a role in immune tolerance, thereby permitting a subject’s immune system to detect and respond to the presence of viral antigens such that an immune response to control and to clear an HBV infection is mounted. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites and/or the specific modifications in these RNAi agents confer to the RNAi agents of the invention improved efficacy, stability, safety, potency, and durability. Such agents are provided, for example, in PCT Publication Nos. WO 2016/077321, WO 2012/024170, WO 2017/027350, and WO 2013/003520, the entire contents of each of which is incorporated herein by reference. Exemplary target sites for RNAi agents and exemplary RNAi agents are provided in Appendix A, filed herewith, which forms a part of the specification. The term RNAi agents further includes shRNAs, e.g., adeno-associated virus (AAV) 8 vectors for delivery of an shRNA in an artificial mi(cro)RNA under a liver-specific promoter; optionally co-delivered a decoy (“TuD”) directed against the shRNA sense strand to curb off-target gene regulation are provided in Michler et al., 2016 (EMBO Mol. Med., 8:1082-1098, incorporated herein by reference).

The majority of nucleotides of each strand of an iRNA agent may be ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an

WO 2018/195165

PCT/US2018/028116 “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides.

As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, and/or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this specification and claims.

As used herein, a “therapeutic HBV vaccine,” and the like, can be a peptide vaccine, a DNA vaccine including a vector-based vaccine, or a cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV serotypes, preferably all HBV serotypes. A number of therapeutic HBV vaccines are known in the art and are at various stages of pre-clinical and clinical development. Protein based vaccines include hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) vaccines (e.g., Li et al., 2015, Vaccine. 33:4247-4254, incorporated herein by reference). Exemplary DNA vaccines include HB-110 (Genexine, Kim et al., 2008. Exp Mol Med. 40: 669-676.), pDPSC18 (PowderMed), ING-1800 (Inovio Pharmaceuticals), HB02 VAC-AND (ANRS), and CVI-HBV-002 (CHA Vaccine Institute Co., Ltd.). Exemplary protein based vaccines include Theravax/DV-601 (Dynavax Technologies Corp.), εΡΑ-44 (Chongqing Jiachen Biotechnology Ltd.), and ABX 203 (ABIVAX S.A.). Exemplary cell based vaccines include HPDCs-T immune therapy (Sun Yat-Sen University). Combination vaccines and products are also known and include HepTcell™ (FP-02.2 vaccine (peptide) + IC31® Adjuvant (a combination peptide-oligonucleotide adjuvant),(see U.S. Patent Publication Nos. 2013/0330382, 2012/0276138, and 2015/0216967, the entire contents of each of which is incorporated herein by reference)); GS-4774 (Gilead, a fusion protein S. core X vaccine + Tarmogen T cell immune stimulator), pSG2.HBs/MVA.HBs (protein prime/viral vector boost, Oxxon Therapeutics), and a protein-prime/modified vaccinia virus Ankara vector-boost (HBsAg and HBsAg protein + HBcAg and HBsAg in MVA expression vector, Backes et al., 2016, Vaccine. 34:923-32, and WO2017121791, both of which are incorporated herein by reference).

As used herein, the term “adjuvant” is understood to be an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself. Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), polylCLC adjuvant, CpG DNA, c-diAMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) RIG-1 ligand, and emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger

WO 2018/195165

PCT/US2018/028116 early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets. Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells. Combination adjuvants (e.g., AS02, AS03, and AS04 (all GSK); MF59 (Novartis); ISCOMATRIX® (CSL Limited); and IC31® (Altimmune) elicit multiple protective immune responses. Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together.

In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral as well as a cellular immune response. For this, a balanced Thl/Th2 helper T cell response is desired to support neutralizing antibody responses as well as effector cytotoxic T cell responses. Preferably the adjuvant provides a balanced Thl/Th2 response. In certain embodiments, the adjuvant is one or more of a polyTC adjuvant, a polylCLC adjuvant, a CpG adjuvant, a STING agonist (a c-diAMP adjuvant, a c-di-GMP adjuvant, or a c-di-CMP adjuvant), an ISCOMATRIX® adjuvant, a PCEP adjuvant, and a Rig-I-ligand adjuvant. In certain embodiments, the adjuvant is a polyLC adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant. In certain embodiments, the adjuvant is not alum.

As used herein, an “immune stimulator” is an agent that stimulates an immune response that may or may not be administered independently of an antigen. Immune stimulators include, but are not limited to, pegylated interferon alfa 2a (PEG-IFN-alpha-2a), interferon alfa-2b, PEG-IFN-alpha2b, interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR1221), a cccDNA inhibitor (e.g., IHVR-25). In certain embodiments, an immune stimulator can include a viral capsid, optionally an empty viral capsid, e.g., MVA capsid.

Immune stimulators can also include immune checkpoint regulators. Immune checkpoint regulators can be stimulatory or inhibitory. As used herein, immune checkpoint regulators potentiate an immune response. Immune checkpoint regulators include, but are not limited to, CTLA-4 inhibitors, such as ipilimumab, PD-1 inhibitors, such as Nivolumab, Pembrolizumab, and the BGBA317 antibody. PD-L1 inhibitors include atezolizumab, avelumab, and durvalumab, in addition to an affimer biotherapeutic.

As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (e.g., a mouse model or other animal model that can be infected with HBV). In an embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. In certain embodiments, the subject has a chronic hepatitis B virus (HBV) infection. In certain embodiments, the subject has both a chronic hepatitis B virus (HBV) infection and a hepatitis D virus (HDV) infection.

WO 2018/195165

PCT/US2018/028116

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, alleviation of one or more signs or symptoms in a subject with HBV infection including, but not limited to, the presence of serum HBV DNA or liver HBV ccc DNA, the presence of serum or liver HBV antigen, e.g., HBsAg or HBeAg. Diagnostic criteria for HBV infection are well known in the art. Treatment can also mean prolonging survival as compared to expected survival in the absence of treatment, or lower risk of HCC development.

In certain embodiments, an HBV-associated disease is chronic hepatitis B (CHB). In certain embodiments, subjects have been infected with HBV for at least five years. In certain embodiments, subjects have been infected with HBV for at least ten years. In certain embodiments, subjects became infected with HBV at birth. Subjects having chronic hepatitis B disease are immune tolerant, have an active chronic infection accompanied by necroinflammatory liver disease, have increased hepatocyte turn-over in the absence of detectable necroinflammation, or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic. Subjects having chronic hepatitis B disease are HBsAg positive and have either high viremia (>10⁴ HBV-DNA copies / ml blood) or low viremia (<10³ HBV-DNA copies / ml blood). Patients with chronic active hepatitis, especially during the high replicative state, may have symptoms similar to those of acute hepatitis. The persistence of HBV infection in CHB subjects is the result of ccc HBV DNA persistence. In certain embodiments, a subject having CHB is HBeAg positive. In other embodiments, a subject having CHB is HBeAg negative.

In preferred embodiments, treatment of HBV infection results in a “functional cure” of hepatitis B. As used herein, the term “functional cure” is understood to be clearance of circulating HBsAg and is preferably accompanied by conversion to a status in which HBsAg antibodies become undetectable using a clinically relevant assay. For example, undetectable antibodies can include a signal lower than 10 mIU/ml as measured by Chemiluminescent Microparticle Immunoassay (CMIA) or any other immunoassay, and may be called anti-HBs seroconversion. Functional cure does not require clearance of all replicative forms of HBV (e.g., cccDNA from the liver). Anti-HBs seroconversion occurs spontaneously in about 0.2-1% of chronically infected patients per year. However, even after anti-HBs seroconversion, low level persistence of HBV is observed for decades indicating that a functional rather than a complete cure occurs. Without being bound to mechanism, it is proposed that the immune system is able to keep HBV in check. A functional cure permits discontinuation of any treatment for the HBV infection. However, it is understood that a “functional cure” for HBV infection may not be sufficient to prevent or treat diseases or conditions that result from HBV infection, e.g., liver fibrosis, HCC, cirrhosis.

The term “lower” in the context of the level of HBV gene expression or HBV replication in a subject, or a disease marker or symptom, refers to a statistically significant decrease in such level. The decrease can be, for example, at least 70%, 75%, 80%, 85%, 90%, 95%, or more. In monitoring of HBV infection, a loglO scale is typically used to describe the level of antigenemia (e.g., HBsAg level in serum) or viremia (HBV DNA level in serum). It is understood that a 1 loglO decrease is a

WO 2018/195165

PCT/US2018/028116

90% decrease (10% remaining), a 2 loglO decrease is a 99% decrease (1% remaining), etc. In certain embodiments, a disease marker is lowered to below the level of detection.

In certain embodiments, the expression of a disease marker is normalized, i.e., decreased to a level accepted as within the range of normal for an individual without such disorder, e.g., the level of a disease marker, such as, ALT or AST, is decreased to a level accepted as within the range of normal for an individual without such disorder. When the disease associated level is elevated from the normal level, the change is calculated from the upper level of normal (ULN). When the disease associated level is decreased from the normal level, the change is calculated from the lower level of normal (LLN). The lowering is the percent difference in the change between the subject value and the normal value. For example, a normal AST level can be reported as 10 to 40 units per liter. If, prior to treatment, a subject has an AST level of 200 units per liter (i.e., 5 times the ULN, 160 units per liter above the upper level of normal) and, after treatment, the subject has an AST level of 120 units per liter (i.e., 3 times the ULN, 80 units per liter above the upper level of normal), the elevated AST would be lowered towards normal by 50% (80/160).

The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating”, “suppressing”, and other similar terms, and includes any level of inhibition. Preferably inhibiting includes a statistically significant or clinically significant inhibition.

The phrase “inhibiting expression of an HBV gene” is intended to refer to knockdown of any HBV transcript (e.g., 3.5 kb, 2.4 kb, 2.1 kb, or 0.7 kb transcript) encoding one or more HBV viral proteins (such as, e.g., preSl/2-S, preS, S, P, X, preC, and C), as well as variants or mutants of an HBV gene.

“Inhibiting expression of an HBV gene” includes any significant level of inhibition of an HBV gene or transcript, e.g., at least partial suppression of the expression of an HBV gene S, P, X, or C, or any combination thereof, e.g., S, P, and C. The expression of the HBV gene may be assessed based on the level, or the change in the level, of any variable associated with HBV gene expression, e.g., an HBV mRNA level, an HBV protein level, and/or an HBV cccDNA level. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject, e.g., levels may be monitored in serum.

In some embodiments of the methods of the invention, expression of an HBV gene is inhibited by at least 70%, 75%, 80%, 85%, 90%, 95%, or to below the level of detection of the assay. In preferred embodiments, the inhibition of expression of an HBV gene results in a clinically relevant inhibition of the level of gene expression, e.g., sufficiently inhibited to permit an effective immune response to a vaccine against an HBV protein.

Inhibition of the expression of an HBV gene may be manifested by a reduction of the amount of RNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an HBV gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an RNAi agent of the invention, or by administering an RNAi agent of the invention to a subject in which the cells are or were present) such that the expression of

WO 2018/195165

PCT/US2018/028116 an HBV gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). In preferred embodiments, the inhibition is assessed by the rtPCR method provided in Example 2 of PCT Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), with in vitro assays being performed in an appropriately matched cell line with the duplex at a 10 nM concentration, and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:

(RNA in control cells) — (RNA in treated cells) _# 100%

RNA in control cells

Alternatively, inhibition of the expression of an HBV gene may be assessed in terms of a reduction of a parameter that is functionally linked to HBV gene expression, e.g., as described herein. HBV gene silencing may be determined in any cell expressing an HBV gene, either constitutively or by genomic engineering, and by any assay known in the art.

Inhibition of the expression of an HBV protein may be manifested by a reduction in the level of an HBV protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells or in serum.

A control cell or group of cells that may be used to assess the inhibition of the expression of an HBV gene includes a cell or group of cells that has not yet been contacted with an RNAi agent of the invention. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent. In alternative embodiments, the level may be compared to an appropriate control sample, e.g., a known population control sample.

The level of HBV RNA that is expressed by a cell or group of cells, or the level of circulating HBV RNA, may be determined using any method known in the art for assessing mRNA expression, preferably using the rtPCR method provided in Example 2 of PCT Publication No. WO 2016/077321,or Example 1 provided herein. In one embodiment, the level of expression of an HBV gene (e.g., total HBV RNA, an HBV transcript, e.g., HBV 3.5 kb transcript) in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., RNA of the HBV gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kits (Qiagen®) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton et al., Nuc. Acids Res. 12:7035), northern blotting, in situ hybridization, and microarray analysis. Circulating HBV mRNA may be detected using methods the described in PCT Publication No. WO 2012/177906, the entire contents of which are hereby incorporated herein by reference.

WO 2018/195165

PCT/US2018/028116

In one embodiment, the level of expression of an HBV gene is determined using a nucleic acid probe. The term “probe”, as used herein, refers to any molecule that is capable of selectively binding to a specific HBV gene. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated RNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses, and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to an HBV mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix® gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of an HBV mRNA.

An alternative method for determining the level of expression of an HBV gene in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of, for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, US Patent No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., US Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of an HBV gene is determined by quantitative Anorogenic RT-PCR (i.e., the TaqMan™ System), e.g., using the method provided herein.

The expression levels of an HBV RNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads, or fibers (or any solid support comprising bound nucleic acids). See U.S. Patent Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195, and 5,445,934, the entire contents of each of which are incorporated herein by reference. The determination of HBV expression level may also comprise using nucleic acid probes in solution.

In preferred embodiments, the level of RNA expression is assessed using real time PCR (qPCR). The use of these methods is described and exemplified in the Examples presented herein.

WO 2018/195165

PCT/US2018/028116

The level of HBV protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipiting reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.

In some embodiments, the efficacy of the methods of the invention can be monitored by detecting or monitoring a reduction in a symptom of an HBV infection. Symptoms may be assessed using any method known in the art.

As used herein, the term Hepatitis B virus-associated disease” or “HBV-associated disease,” is a disease or disorder that is caused by, or associated with HBV infection or replication. The term HBV-associated disease” includes a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. Non-limiting examples of HBV-associated diseases include, for example, hepatitis D virus infection,; hepatitis delta; chronic hepatitis B; liver fibrosis; end-stage liver disease; cryoglobulinemia; hepatocellular carcinoma.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject or prepared therefrom, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum, plasma, immune cells, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes, resident liver immune cells). In preferred embodiments, a “sample derived from a subject” refers to blood drawn from the subject or plasma, serum, or selected cell pools derived therefrom (e.g., populations of immune cells). In further embodiments, a “sample derived from a subject” refers to liver tissue (or subcomponents thereof) obtained from the subject.

As used herein, “coding sequence is understood to refer to a DNA sequence that encodes for a specific amino acid sequence. In certain embodiments, the DNA sequence can be reverse transcribed from an RNA sequence. In certain embodiments, an iRNA, e.g., an shRNA, targets a coding sequence.

The terms, suitable regulatory sequences, and the like, are used herein is to refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' noncoding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

Promoter as used herein refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter

WO 2018/195165

PCT/US2018/028116 sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. A promoter may be selected to promote expression of a coding sequence in a particular cell type or at different stages of development, or in response to different environmental conditions. In certain embodiments, the promoter is a promoter that is active in liver, e.g., a liver-specific promoter. Many promoter sequences are known in the art and selection of an appropriate promoter sequence for a specific context is within the ability of those of skill in the art.

The term operably linked refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).

The term expression as used herein refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA, or an RNAi agent (e.g., an shRNA) derived from the nucleic acid fragment of the subject technology. Over-expression refers to the production of a gene product in transgenic or recombinant organisms that exceeds levels of production in normal or non-transformed organisms.

“Expression vector” or “expression construct,” as used herein, refers to a nucleic acid in which a coding sequence is operably linked to a promoter sequence to permit expression of the coding sequence under the control of the promoter. Expression vectors include, but are not limited to, viral vectors or plasmid vectors. Methods for delivery of expression vectors into cells are known in the art.

II. Treatment Methods of the Invention

The present invention provides treatment regimens and methods for the sequential use of an agent to reduce the expression of an HBV gene, e.g., iRNA agents which effect the RNA-induced silencing complex (RlSC)-mediated cleavage of one or more HBV transcripts, and hepatitis B vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV infection. The treatment regimens and methods preferably provide a functional cure of HBV within a defined period of time.

The treatment regimens and methods provided herein include the ordered administration of therapeutic agents to provide treatment, and preferably a functional cure, for HBV infection. The agents used in the methods are known in the art. However, the agents alone fail to consistently and durably decrease HBV disease burden, e.g., reducing HBsAg levels to below 2 loglO, preferably 1 loglO lU/ml or to below the level of detection, in most subjects. Significantly reducing HBV disease burden, e.g., reducing HBsAg levels to below 2 loglO, preferably 1 loglO lU/ml or to below the level of detection, will provide the opportunity of discontinuation of administration of therapeutic agents and provide a functional cure for HBV in a substantial number of subjects. Without being bound by mechanism, it is proposed that the treatment regimens and methods provided herein, including administration of an iRNA agent targeted to HBV, substantially reduces HBV antigens and nucleic

WO 2018/195165

PCT/US2018/028116 acid for a sufficient magnitude and duration in a subject to allow an effective immune response induced by administration of multiple doses of a therapeutic vaccine. The regimens and methods, provided herein, consistently provide a substantial reduction of disease burden and a functional cure in a significant number of subjects, preferably at least 30%, 40%, 50%, 60%, or 70% of subjects.

A transgenic mouse model of HBV infection, HBV 1.3 xfs was used to assess the combination therapy provided herein. Primary studies demonstrated the efficacy of two different chemically modified GalNAc- iRNA agents targeted to HBV (AD-66816 and AD-66810) to inhibit the level of HBsAg and HBeAg proteins, and HBV DNA in serum for at least 21 days with a single subcutaneous dose at 3 mg/kg or 9 mg/kg, with similar efficacy. No significant knockdown was observed with a non-HBV iRNA control (see Figure 2). Based on this result, the lower dose of 3 mg/kg was selected for combination therapy studies.

In the first combination therapy trial (see Figure 3), mice were pretreated with one of six treatment regimens (n= 6 per group):

(1) No pretreatment;

(2) Entecavir at 1 pg/ml in water throughout the course of the study beginning on the first day of Week 0;

(3) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of the control iRNA agent.

(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of AD-66816 or AD-66810 (generically, HBV-siRNA).

On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 pg) and E. coll expressed HBeAg (15 pg) adjuvanted with 31.9 pg synthetic phosphorothioated CpGODN 1668 (CpG) and 25 pg poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein prime vaccination (Backes, 2016).

On the first day of week 16, a mixture of modified vaccinia virus Ankara expressing HBsAg or HBeAg (5 χ 10⁷ particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).

Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and were assayed for levels of HBsAg, HBeAg, and HBV DNA. Results observed for HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar (Figure 4A and 4B). The HBV-shRNA or HBV-siRNAs alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum. The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA and HBV-siRNA groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control

WO 2018/195165

PCT/US2018/028116 siRNA all decreased HBV DNA levels, and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, the combination of RNAi and subsequent vaccination have a greater effect on HBsAg and HBV DNA levels than either agent alone.

On the final day of the experiment (the first day of week 17), mice were sacrificed and their livers were harvested. Intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. Mice treated with the HBV-shRNA or the HBV-siRNAs were able to generate a CD8+ immune response against the HBsAg and HBcAg (Figure 5A and 5B). No significant immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. However, a similar immune response against the MVA virus was observed in all animals independent of pretreatment or viral antigen levels (Figure 5C) showing that vaccination had worked equally well in all animals, demonstrating the presence of a competent immune system. The data shown in Figure 5A-C were reanalyzed to accomodated for an insufficient exclusion of dead immune cells during the first analysis. The data obtained from the second analysis (shown in Figure 5 D-F) again shows that only the mice pretreated with the HBV-shRNA or the HBV-siRNAs were able to generate HBV-specific CD8+ T cell responses after therapeutic vaccination, but that MVA-specific responses were not influenced by the pretreatment. The reduced variances in the second analysis are attributed to the more rigorous exclussion of dead cells. These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity and enable the induction of HBV-specific CD8 T cell responses after therapeutic vaccination.

Serum was also assessed for antibody immune response to HBV antigens. Although the vaccine was able to induce a T-cell immune response only in animals which had received HBVsiRNA or HBV-shRNA pretreatment, antibody responses against HBsAg and HBcAg were similar across all groups regardless of pretreatment at the time points evaluated until week 17. No HBeAg antibody responses could be detected. These data demonstrate that high HBV antigen loads preferentially inhibit HBV-specific T cell, not B cell responses.

Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Mice treated with the HBV-shRNA or the HBV-siRNAs demonstrated a significant decrease in HBV transcript levels (Figure 6A and 6B). No significant difference was observed between the mock and Entecavir or control siRNA groups. Liver sections were analysed by immunohistochemical stainings for expression of core antigen to assess the antiviral effect in the liver (Figure 6C). In animals that were not pre treated before vaccination, there were, on average, 83 hepatocytes per mm² with cytoplasmic expression of HBc. This number was not significantly changed in animals that were pretreated with Entecavir or the control siRNA. However, the number of cytoplamic HBcAg positive cells was significantly reduced in AAV-shRNA or HBV siRNA pretreated animals. These data demonstrate that a combinatorial RNAi/vaccination therapy suppresses not only antigens in the serum, but also viral antigen expression in the liver.

WO 2018/195165

PCT/US2018/028116

Having demonstrated that suppression of expression of HBV antigens using shRNA or siRNA is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the duration of HBV antigen suppression had an effect on the potentiation an HBV immune response. Using the HBV 1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816, or the control siRNA for 8 weeks, subcutaneously administered at 3 mg/kg/dose, followed by administration of the prime-boost vaccine regimen as set forth above, except 10 pg c-di-AMP was used as an adjuvant rather than PCEP + CPG (n= 6 per 8 and 3 group, n = 6 for 6 week group) (see Figure 7).

A significant decrease in the levels of each of HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 log 10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 loglO) of HBV DNA and no further reduction in HBeAg levels. These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8 T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment resulting in more HBsAg knockdown than a 3 week pretreatment.

Similarly, T-cell responses against HBsAg and HBeAg in liver corresponded with the duration of HBV antigen knockdown, with longer duration of HBV antigen suppression resulting in greater T-cell responses (Figure 9A-9C). Similar responses to MVA virus antigens were observed across all groups independent of pretreatment (Figure 9D). Antibody responses were similar across all groups.

Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Longer pretreatment durations trended to higher levels of HBV RNA knockdown (Figure 10A and 10B).

Liver sections were also analysed by immunohistochemical staining for cytoplasmic expression of HBeAg to assess the antiviral effect of the treatment in the liver (Figure 10C). In animals pretreated with the control siRNA before vaccination, there were, on average, 172 hepatocytes per mm² which showed cytoplasmic expression of HBc. With longer duration of HBV suppression before vaccination, there was a gradual decrease of cytoplasmic HBeAg positive hepatocytes with an average of only 12 cytoplasmic HBeAg positive hepatocytes per mm² in the 8 week pretreatment group. These data demonstrate that the increasing HBV-specific CD8+ T cell response observed with longer antigen suppression before vaccination led to decreased HBV antigen expression in the liver. To assess the durability of response, blood samples were collected from mice (n = 6) pretreated with the AD-66816 HBV-siRNA for six weeks at 2 and 3 weeks after administration of the boost vaccination. In three of the six mice, HBsAg levels continued to dropped to below the level of detection of the assay (Figure 11A and 1 IB). Specifically, the three animals which had the highest HBsAg and HBeAg levels at start of vaccination (2, 4, and 5) did show a

WO 2018/195165

PCT/US2018/028116 decline of antigen titers after vaccination, but rebounded with antigen titers towards the end of the experiment. In contrast, the three animals with the lowest antigen titers at start of vaccination (1,3, and 6) showed a further decline of HBsAg to below the detection limit. These data demonstrate that a functional cure is possible using the treatment regimens provided herein. These data also suggest that the antigen levels at start of vaccination can affect the response to therapeutic vaccination. Finally, without being bound by mechanism, these data suggest that the decline of antigen levels after therapeutic vaccination is mediated, at least in part, by CD8+ T cells. These data demonstrate that knockdown of circulating HBV antigens (e.g., HBsAg, HBcAg), but not inhibition of HBV DNA replication alone, potentiates immune response to HBV therapeutic vaccine, e.g., a prime boost therapeutic vaccination regimen. That is, an immune response can be potentiated by pretreatment with an siRNA, but not with nucleot(s)ide inhibitors alone as the immune response is a CD8+ T-cell based immune response.

The magnitude and duration of knockdown required depends on, for example, the level of disease burden in the subject. The higher the level of circulating antigen, the greater the magnitude and duration of HBV antigen knockdown required to potentiate an immune response. Knockdown of HBsAg in serum should be at least 0.5 log 10 (lU/ml), preferably Ilog 10 (lU/ml), 1.5 log 10 (lU/ml), 2 log 10 (lU/ml), or more from the level in the subject prior to treatment with the therapeutic vaccine. In certain embodiments, the level of serum HBsAg is no more than 2.5 log 10 (lU/ml), 2 log 10 (lU/ml), 1.5 log 10 (lU/ml) prior to vaccine administration.

Further, as demonstrated herein, a longer duration of HBV antigen knockdown trended towards a more robust immune response. Therefore, knockdown of serum HBsAg to a sufficiently low level for a duration of at least four weeks, six weeks, or eight weeks is preferred prior to administration of the vaccine.

A second series of experiments were designed to study the combination siRNA/vaccination treatment regimen in a mouse model of aquired HBV infection using an adeno-associated virus infection system. For these studies, wildtype C57/B16 mice (9 weeks of age) were injected i.v. with 2xlO¹⁰ genome equivalents of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (see, e.g., Yang, et al. (2014) Cell andMol Immunol 11:71). Starting 4 weeks after AAV-transduction (on day -28), animals were treated with three doses of either a control siRNA, or HBV siRNA (HBV AD-66816 or AD-66810) on days 0, 29, and 57, and subsequently half of the animals in each group were treated with a vaccine regimen consisting of prime protein vaccination with HBsAg, HbcAg, and 10 pg c-di-AMP at days 57 and 70, and boosted with MVA-HBs and MVA-HBc at day 84. The treatment regimen is shown in Figure 12.

Following AAV-HBV1.2 transduction, HBsAg and HBeAg values rose to levels comparable to the levels seen in HBV transgenic mice (HBVxfs) (see, e.g., Figures 13A and 13B). Mice treated with the HBV siRNAs showed mean reductions of HBsAg levels of about 2 logio scales and of HBeAg levels greater than 1 logio scale such that HBsAg and HBeAg levels dropped to less than about 500 lU/per ml, whereas the control siRNA had no effect on antigen levels. Animals treated with

WO 2018/195165

PCT/US2018/028116 one of the HBV siRNAs that did not receive the vaccine regimen showed slowly rebounding antigen levels after the last application of the siRNA. Antigenemia returned to baseline levels after 18 weeks. The combination treatment with the HBV-siRNA and vaccine regimen resulted in a durable response with a decrease in HBsAg and HBeAg to below the limit of detection through the duration of the experiment. A decrease in HBsAg and HBeAg levels was observed prior to the administration of the MVA boost, suggesting that the protein vaccination may be sufficient to affect a cure. Both serum and liver HBV DNA and RNA were significantly decreased after combination treatment with the HBVsiRNA and vaccine regimen (Figures 13D-13H). This demonstrates, that RNAi-mediated suppression can strongly reduce antigen expression, but that treatment with the vaccine regimen extends the durability of response.

The vaccine regimen alone in animals that received the control siRNA produced a transient decline of antigen levels which rebounded towards the end of the experiment. In contrast, all animals that received an HBV-siRNA and vaccination, HBsAg and HBeAg levels decreaased to below the detection limit after start of vaccination. Antigen levels remained largely undetectable at all through the last time point measured at least 22 weeks after the last siRNA application (Figures 13A and 13B). The durable loss of antigenemia in HBV siRNA pretreated animals, in contrast to the antigen rebound in control siRNA pretreated animals, further demonstrates that immune control was only achieved in animals which had lowered antigen titers before vaccination.

Coinciding with the loss of antigenemia, animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and resulted in anti-HBs and anti-HBe seroconversion in all vaccinated animals (Figure 14). siRNA-pretreated animals developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg. Interestingly, 3/12 mice vaccinated after HBV siRNA treatment showed a transient drop in anti-HBe levels between week 15 and 22 resulting in a low-level relapse of HBeAg (Figure 13C) that was again controlled. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies. Taken together, functional cure was not achieved by the siRNA treatement regimen or the therapeutic vaccination regimen alone. However, the loss of antigenemia, as well as development of anti-HBs and anti-HBe antibodies, demonstrates that the combination HBV siRNA plus vaccine regimen can achieve a functional cure.

Throughout the experiment, ALT and body weight of the animals were monitored. The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A). These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. Without being bound by

WO 2018/195165

PCT/US2018/028116 mechanism, it is suggested that the CD8+ T cells induced by the combinatorial HBV siRNA-vaccine regimen killed HBV-expressing hepatocytes resulting in elevated ALT.

The body weight of the animals was measured throughout the experiment to assess tolerability of the treatments. There was steady increases throughout the experiment independent of siRNA treatment. Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days, and subsequently gained weight comparable to the control groups (Figure 15B). Taken together, both, ALT activity and body weight data demonstrate that all examined treatments, including siRNA only, vaccine only, as well as the combinatorial siRNA/vaccine regimen are well tolerated.

The number and timing of doses of siRNA to knockdown HBsAg level in serum depends, for example, on the specific agent used. Due to the duration and potency of the exemplary GalNAc siRNAs used in the methods herein and provided, for example, in Appendix A and in PCT Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), a single dose of siRNA may be sufficient to provide the level and duration of knockdown required prior to administration of the therapeutic vaccine. As shown in Figure 4, a single dose of an AAV vector encoded shRNA was sufficient to provide durable knockdown of HBV antigens and HBV DNA. Those of skill in the art are able to monitor HBV disease status, e.g., by measuring HBsAg levels in blood, to determine the timing and level of siRNA and vaccine administration appropriate for a specific subject.

A number of therapeutic HBV vaccines are known in the art and discussed herein. In preferred embodiments, a prime-boost vaccination protocol, such as the protocol that is used herein, is preferred. However, the HBV antigen knockdown method provided herein can be used in combination with other therapeutic HBV vaccines known in the art, including those found to be insufficient when administered alone. Vaccinations include at least two doses of an antigen in protein or nucleic acid form. In certain embodiments, the vaccination includes three doses of a protein-based vaccine. In preferred embodiments, the methods include heterologous vaccine administration, i.e., at least one protein-based vaccine dose and at least one nucleic-acid based vaccine dose. Exemplary embodiments of vaccines and dosing regimens are provided, for example, in PCT Publication No. WO 2017/121791, the entire contents of which are incorporated herein by reference.

The methods provided herein include the use of a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine. Therefore, it is clearly understood that neither the nucleic acid-based vaccine nor the protein-based vaccine are required to provide the full length protein. The nucleic acid-based vaccine and the protein-based vaccine are required to provide at least one shared epitope that is present in HBcAg or HBsAg, and does not require that the full length protein be provided. As noted above, epitopes may be relatively short, MHC class I molecules that are typically peptides about 8 to 11 amino acids in length, whereas MHC class II molecules present longer peptides about 13 to 17 amino acids in length, with conformational epitopes being

WO 2018/195165

PCT/US2018/028116 longer. However, it is understood that the use of protein antigens and coding sequences for protein antigens that encode multiple epitopes is preferred. Further, it is understood that the antigens present in the protein-based vaccine and encoded by the nucleic-acid based vaccine may or may not be identical. It is also obvious that antigens should also be selected for their immunogenicity. Such antigens are well known in the art.

In certain embodiments, the order of administration of the protein-based vaccine and the nucleic acid-based vaccine are reversed as compared to the order exemplified in the methods provided herein. That is, the nucleic acid-based vaccine is administered first and the protein-based vaccine is administered second. In certain embodiments, a total of three doses of vaccine are administered, two doses of the nucleic acid-based vaccine followed by a single dose of the protein-based vaccine. In alternative embodiments, a single dose of the nucleic acid-based vaccine is followed by two doses of a protein based vaccine. In other embodiments, one dose of each vaccine is administered.

In preferred embodiments, the prime-boost vaccination method includes the use of an adjuvant with protein antigens. Appropriate adjuvants for use in the methods promote a cell-based response to the antigens. Adjuvants preferably provide a balanced Thl/Th2 response.

The siRNA + vaccine methods provided herein can be used in combination with administration of nucleot(s)ide inhibitors which are the standard of care for treatment of HBV. In certain embodiments, subjects are treated with nucleot(s)ide inhibitors prior to treatment with the siRNA + vaccine treatment regimen. In certain embodiments, subjects are treated throughout the siRNA + vaccine treatment regimen with nucleot(s)ide inhibitors. In certain embodiments, the nucleot(s)ide inhibitor is dosed to reduce pre-existing inflammation associated with HBV infection prior to administration of the nucleic acid therapeutic targeted to HBV (e.g., siRNA, shRNA, antisense oligonucleotide).

In certain embodiments, subjects may be pretreated, or concurrently treated, with other agents used for the treatment of HBV. Such agents include, but are not limited to an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HbsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), a Rig-I ligand, or an immune checkpoint regulator. In certain embodiments, the immune stimulator is a Rig-I ligand or an immune checkpoint regulator. A functional cure includes a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 lU/ml, or a detectable antibody response to HBsAg. In preferred embodiments, a functional cure includes both a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 lU/ml and a detectable antibody response to HBsAg.

A. RNAi Agents For Use in the Methods of the Invention

The present invention includes the use of iRNAs, which inhibit the expression of at least one HBV transcript, and preferably three or four HBV transcripts (open reading frames, sometimes

WO 2018/195165

PCT/US2018/028U6 referred to herein as genes). Due to the highly condensed structure of the HBV genome, it is possible to design single iRNAs that will inhibit the expression of three or four HBV transcripts (see Figure 1). For the sake of simplicity, the text herein refers to “an HBV transcript” or “the HBV transcript.” It is understood that preferred embodiments include inhibition of more than one HBV transcript (or open reading frame), preferably at least three HBV transcripts (or open reading frames). Further, it is understood that there are eight HBV genotypes, and two proposed additional genotypes, that may further include mutations from published sequences. Therefore, certain iRNA agents may inhibit different numbers of genes based on the specific genotype and subject infected with HBV.

In some embodiments, the iRNA agent includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression or decreasing the level of an HBV transcript in a cell in a subject with an HBV infection. The dsRNA includes an antisense strand having a region of complementarity, which is complementary to at least a part of an mRNA formed in the expression of an HBV transcript. The region of complementarity is about 30 nucleotides or less in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the HBV gene, the iRNA selectively inhibits the expression of at least one, preferably three or four HBV genes. In preferred embodiments, inhibition of expression is determined by the qPCR method in an appropriate cell line as provided in the examples. For in vitro assessment of activity, percent inhibition is determined using the methods provided in Example 2 of PCT Publication No.WO 2016/077321 at a single dose at a 10 nM duplex final concentration. For in vivo studies, the level after treatment can be compared to, for example, an appropriate historical control or a pooled population sample control to determine the level of reduction, e.g., when a baseline value is not available for the subject. An appropriate control must be carefully selected by one of skill in the art.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an HBV gene. As multiple HBV genotypes are known, iRNA agents are preferably designed to inhibit expression of HBV genes across as many genotypes as possible. It is understood that an siRNA that is perfectly complementary to one or more HBV genotypes will not be perfectly complementary to all genotypes. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as selfcomplementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is 15 and 30 base pairs in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 1833

WO 2018/195165

PCT/US2018/028U6

26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23,

19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 2129, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

Similarly, the region of complementarity to the target sequence is 15 and 30 nucleotides in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 1517, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 2024,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

In some embodiments, the dsRNA is about 15 to 20 nucleotides in length, or about 25 to 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 9 to 36 base pairs, e.g., about 10-36, 11-36, 12-36,

13- 36, 14-36, 15-36, 9-35, 10-35, 11-35, 12-35, 13-35, 14-35, 15-35, 9-34, 10-34, 11-34, 12-34, 1334, 14-34, 15-34, 9.33, 10-33, 11-33, 12-33, 13-33, 14-33, 15-33, 9-32, 10-32, 11-32, 12-32, 13-32,

14- 32, 15-32, 9-31, 10-31, 11-31, 12-31, 13-32, 14-31, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 1525,15-24,15-23,15-22,15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 1921, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target HBV gene expression is not generated in the target cell by cleavage of a larger dsRNA.

The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 1530 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28,

WO 2018/195165

PCT/US2018/028116

15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 1827, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 2130, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3’-end of one strand and the 5’-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides.

In some embodiments, a dsRNA agent of the invention comprises a tetraloop. As used herein, tetraloop in the context of a dsRNA refers to a loop (a single stranded region) consisting of four nucleotides that forms a stable secondary structure that contributes to the stability of adjacent Watson-Crick hybridized nucleotides. Without being limited to theory, a tetraloop may stabilize an adjacent Watson-Crick base pair by stacking interactions. In addition, interactions among the four nucleotides in a tetraloop include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., Nature 1990 Aug 16;346(6285):680-2; Hens and Pardi, Science 1991 Jul 12;253(5016): 191-4). A tetraloop confers an increase in the melting temperature (Tm) of an adjacent duplex that is higher than expected from a simple model loop sequence consisting of four random bases. For example, a tetraloop can confer a melting temperature of at least 5 5 °C in lOrnM NaHPO₄ to a hairpin comprising a duplex of at least 2 base pairs in length. A tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Examples of RNA tetraloops include the UNCG family of tetraloops (e.g., UUCG), the GNRA family of tetraloops (e.g., GAAA), and the CUUG tetraloop. (Woese et al., Proc Natl Acad Sei USA. 1990 Nov;87(21):8467-71 ; Antao et al., Nucleic Acids Res. 1991 Nov 11; 19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) family of tetraloops (e.g., d(GTTA), the d(GNRA)) family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG) family of tetraloops, the d(TNCG) family of tetraloops (e.g., d(TTCG)). (Nakano et al. Biochemistry, 41 (48), 14281 -14292, 2002; Shinji et al. Nippon Kagakkai Koen Yokoshu vol.78th; no.2; page.731 (2000).)

In certain embodiments of the invention, tetraloop- and modified nucleotide- containing dsNAs are contemplated as described, e.g., as described in U.S. Patent Publication No. 2011/0288147, the entire contents of which are incorporated by reference herein. In certain such embodiments, a dsNA of the invention possesses a first strand and a second strand, where the first strand and the

WO 2018/195165

PCT/US2018/028116 second strand form a duplex region of 19-25 nucleotides in length, wherein the first strand comprises a 3' region that extends beyond the first strand-second strand duplex region and comprises a tetraloop, and the dsNA comprises a discontinuity between the 3' terminus of the first strand and the 5' terminus of the second strand.

Optionally, the discontinuity is positioned at a projected Dicer cleavage site of the tetraloopcontaining double stranded nucleic acid (dsNA). It is contemplated that, as for any of the other dupexed oligonucleotides of the invention, tetraloop-containing duplexes of the invention can possess any range of modifications disclosed herein or otherwise known in the art, including, e. g·, comethyl, 2'- fluoro, inverted base, GalNAc moieties, etc. Typically, every nucleotide on both strands of the tetraloop-containing dsNA is chemically modified if the tetraloop-containing dsNA is going to be delivered without using lipid nanoparticles or some other delivery method that protects the dsNA from degradation during the delivery process. However, in certain embodiments, one or more nucleotides are not modified.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3’end of one strand and the 5’-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5’-end, 3’end or both ends of either an antisense or sense strand of a dsRNA. In certain embodiments, longer, extended overhangs are possible.

A dsRNA can be synthesized by standard methods known in the art. iRNA compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. In certain embodiments, the iRNA compound is produced from an expression vector delivered into a cell.

In one aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences

WO 2018/195165

PCT/US2018/028116 provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of the Tables in Appendix A.

In some embodiments, the sense strand is selected from the group of sequences provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of the Tables in Appendix A. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an HBV gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of the Tables in Appendix A and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of the Tables in Appendix A. In one embodiment, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.

It is understood that, although some of the sequences in the Tables in Appendix A are described as modified or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA of the invention, may comprise any one of the sequences set forth in the Tables in Appendix A that is un-modified, unconjugated, or modified or conjugated differently than described therein. Additional target sites are provided, for example, in PCT Publication Nos. WO 2016/077321, WO 2012/024170, WO 2017/027350, and WO 2013/003520; and in Michler, 2016, the entire contents of wach of which are incorporated herein by reference.

The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of the Tables in Appendix A, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of any one of the Tables in Appendix A minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences of any one of the Tables in Appendix A and differing in their ability to inhibit the expression of an HBV gene by not more than 5, 10, 15, 20, 25, or 30 % inhibition from a dsRNA comprising the full sequence.

An iRNA as described herein can contain one or more mismatches to the target sequence, or to one or more HBV target sequences due, e.g., to sequence variations among the HBV genotypes. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch is not located in the center of the region of complementarity. If the antisense strand of the iRNA

WO 2018/195165

PCT/US2018/028116 contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5’- or 3’-end of the region of complementarity. For example, for a 23 nucleotide iRNA agent the strand which is complementary to a region of an HBV gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of an HBV gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of an HBV gene is important, especially if the particular region of complementarity in an HBV gene is known to have polymorphic sequence variation within various genotypes and the population.

i. Modified iRNAs For Use in the Methods of the Invention

In some embodiments, the RNA of the iRNA for use in the invention e.g., a dsRNA, is unmodified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein, e.g., when produced from an expression vector. In other embodiments, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which “substantially all of the nucleotides are modified” are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.

The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S.L. et al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5’-end modifications (phosphorylation, conjugation, inverted linkages) or 3’-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.)·, base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2’-position or 4’position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl

WO 2018/195165

PCT/US2018/028116 phosphonates including 3’-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’2’. Various salts, mixed salts and free acid forms are also included.

Representative US patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, US Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6, 239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and US Pat RE39464, the entire contents of each of which are hereby incorporated herein by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative US patents that teach the preparation of the above oligonucleosides include, but are not limited to, US Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.

In other embodiments, suitable RNA mimetics are contemplated for use in iRNAs, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, US Patent Nos. 5,539,082; 5,714,331;

WO 2018/195165

PCT/US2018/028116 and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference.

Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.

Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-CH₂-, —CH₂-N(CH₃)O-CH₂-[known as a methylene (methylimino) or MMI backbone], —CH₂-O-N(CH₃)-CH₂-, — CH₂N(CH₃)-N(CH₃)-CH₂-and -N(CH₃)-CH₂-CH₂-[wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above-referenced US Patent No. 5,489,677, and the amide backbones of the above-referenced US Patent No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced US Patent No. 5,034,506.

Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2’-position: OH; F; O-, S-, or Nalkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to Cw alkyl or C₂ to Cw alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO] _mCH₃, O(CH₂)._nOCH₃, O(CH₂)_nNH₂, O(CH₂) _nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃)]₂, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2’ position: Ci to Cw lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2’-methoxyethoxy (2’-OCH₂CH₂OCH₃, also known as 2’-O-(2-methoxyethyl) or 2’-M0E) (Martin et al., Help. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2’dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2’-DMA0E, as described in examples herein below, and 2’-dimethylaminoethoxyethoxy (also known in the art as 2’-Odimethylaminoethoxyethyl or 2’-DMAE0E), i.e., 2’-O-CH₂-O-CH₂-N(CH₂)₂.

Other modifications include 2’-methoxy (2’-OCH₃), 2’-aminopropoxy (2’OCH₂CH₂CH₂NH₂) and 2’-fluoro (2’-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3’ position of the sugar on the 3’ terminal nucleotide or in 2’-5’ linked dsRNAs and the 5’ position of 5’ terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, US Patent Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873;

WO 2018/195165

PCT/US2018/028116

5,670,633; and 5,700,920, certain of which are commonly owned with the instant application,. The entire contents of each of the foregoing are hereby incorporated herein by reference.

The RNA of an iRNA can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxythymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in US Patent No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. andLebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2’-O-methoxyethyl sugar modifications.

Representative US patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted US Patent Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.

The RNA of an iRNA can also be modified to include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. This structure effectively locks the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has

WO 2018/195165

PCT/US2018/028116 been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(l):439-447; Mook, OR. et al., (2007) Mol Cane Ther 6(3):833843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193).

In some embodiments, the iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked sugar residue. In one example, UNA also encompasses monomer with bonds between Cr-C4' have been removed (i.e. the covalent carbonoxygen-carbon bond between the Cl' and C4' carbons). In another example, the C2'-C3' bond (i.e. the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 hereby incorporated by reference).

The RNA of an iRNA can also be modified to include one or more bicyclic sugar moities. A “bicyclic sugar” is a furanosyl ring modified by the bridging of two atoms. A“bicyclic nucleoside”(“BNA”) is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2’ and 4’ carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4’-CH2-O-2’ bridge. This structure effectively “locks” the ribose in the 3’-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(l):439-447; Mook, OR. Et al., (2007) Mol Cane Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to 4'-(CH2)—O-2' (LNA); 4'-(CH2)—S-2'; 4'-(CH2)2—O-2' (ENA); 4'-CH(CH3)—O-2' (also referred to as “constrained ethyl” or “cEt”) and 4'-CH(CH2OCH3)—O-2' (and analogs thereof; see, e.g., US Patent No. 7,399,845); 4'-C(CH3)(CH3)—O-2' (and analogs thereof; see e.g., US Patent No. 8,278,283); 4'CH2—N(OCH3)-2' (and analogs thereof; see e.g., US Patent No. 8,278,425); 4'-CH2—O—N(CH3)2' (see, e.g.,US20040171570); 4'-CH2—N(R)—O-2', wherein R is H, C1-C12 alkyl, or a protecting group (see, e.g., US Patent No. 7,427,672); 4'-CH2—C(H)(CH3)-2' (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH2—C(=CH2)-2' (and analogs thereof; see, e.g., US Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.

WO 2018/195165

PCT/US2018/028116

Additional representative US patents and US patent publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: US Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133;7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 20080039618; and US 20090012281, the entire contents of each of which are hereby incorporated herein by reference.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see WO 99/14226).

The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a constrained ethyl nucleotide or cEt is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH3)-O-2' bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as “S-cEt.”

An iRNA of the invention may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2’and C4’ carbons of ribose or the C3 and -C5' carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, US 20130190383 and WO 2013036868, the entire contents of each of which are hereby incorporated herein by reference.

Potentially stabilizing modifications to the ends of RNA molecules can include N(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-0-deoxythymidine (ether), N(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3- phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in WO 2011005861.

Other modifications of the nucleotides of an iRNA of the invention include a 5’ phosphate or 5’ phosphate mimic, e.g., a 5’-terminal phosphate or phosphate mimic on the antisense strand of an RNAi agent. Suitable phosphate mimics are disclosed in, for example US20120157511, the entire contents of which are incorporated herein by reference.

In certain specific embodiments, the RNAi agent for use in the methods of the invention is an agent selected from the group of agents listed in any one of the Tables in Appendix A. These agents may further comprise a ligand.

ii. iRNAs Conjugated to Ligands

Another modification of the RNA of an iRNA of the invention involves chemically linking to the RNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a

WO 2018/195165

PCT/US2018/028116 cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecylrac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).

In one embodiment, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic poly amino acid. Examples of poly amino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactideco-gly colied) copolymer, di vinyl ether-maleic anhydride copolymer, N-(2hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-poly amine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid, or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, monovalent or multivalent galactose, N-acetylgalactosamine, N-acetyl-gulucoseamine multivalent mannose, multivalent fucose, glycosylated poly aminoacids, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.

WO 2018/195165

PCT/US2018/028116

In certain embodiments, ligands include monovalent or multivalent galactose. In certain embodiments, ligands include cholesterol.

Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,03(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridineimidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include nonpeptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, monovalent or multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-kB.

The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell’s cytoskeleton, e.g., by disrupting the cell’s microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

WO 2018/195165

PCT/US2018/028116

Ligand-conjugated oligonucleotides of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligandbearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

1. Lipid Conjugates

In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.

A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

WO 2018/195165

PCT/US2018/028116

In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue.

However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

In another preferred embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.

In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).

2. Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 33). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 34) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 35) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 36) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such

WO 2018/195165

PCT/US2018/028116 as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PEC AM-1 or VEGF.

A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α-helical linear peptide (e.g., LL-37 or Ceropin Pl), a disulfide bondcontaining peptide (e.g., a -defensin, β-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).

3. Carbohydrate Conjugates

In some embodiments of the compositions and methods of the invention, an iRNA oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).

WO 2018/195165

PCT/US2018/028116

In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:

H Formula III,

NHAc Formula IV,

NHAc Formula V,

HO ,^0H

HO OH ^{NHAc 0} ^{N H}

NHAc O Formula VI,

WO 2018/195165

PCT/US2018/028116

WO 2018/195165

PCT/US2018/028116

WO 2018/195165

PCT/US2018/028116

In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as

WO 2018/195165

PCT/US2018/028116

Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,

(Formula XXIII), when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker.

In one embodiment, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent. In another embodiment, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.

In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3’-end of one strand and the 5’-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.

WO 2018/195165

PCT/US2018/028116

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.

Additional carbohydrate conjugates suitable for use in the present invention include those described in WO 2014179620 and WO 2014179627, the entire contents of each of which are incorporated herein by reference.

4. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term linker or “linking group” means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO₂, SO₂NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO₂, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include:

WO 2018/195165

PCT/US2018/028116 redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

a. Redox cleavable linking groups

In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA

WO 2018/195165

PCT/US2018/028116 moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

b. Phosphate-based cleavable linking groups

In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -O-P(O)(ORk)-O-, -OP(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -OP(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, -O-P(S)( Rk)-S-. Preferred embodiments are -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -OP(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O, -S-P(S)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-. A preferred embodiment is -O-P(O)(OH)-O-. These candidates can be evaluated using methods analogous to those described above.

c. Acid cleavable linking groups

In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

d. Ester-based linking groups

In another embodiment, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells.

WO 2018/195165

PCT/US2018/028116

Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula -C(O)O-, or -OC(O)-. These candidates can be evaluated using methods analogous to those described above.

e. Peptide-based cleaving groups

In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (-C(O)NH-). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula - NHCHRAC(O)NHCHRBC(O)-, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

In one embodiment, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,

WO 2018/195165

PCT/US2018/028116

(Formula XXX), and

WO 2018/195165

PCT/US2018/028116

(Formula XXXI), when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXII) - (XXXV):

Formula XXXII

Formula XXXIII

p2A_Q2A_p2A

γ2Α_|_2Α

_q3A γ3Α_|_3Α _____γ2Β |_2B q^2B

p3B_Q3B_p3B γ3Β_|_3Β ,p4A q4A r4A

4Β_ρ4Β _____γ4Α_|_4Α q^4A

γ4Β_|_4Β _q3B

Formula XXXIV

Formula XXXV wherein:

q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

p2A p2B p3A p3B p4A p4B p5A p5B p5C ψ2Α ψ2Β y,3A y,3B ψ4.\ ψ4Β ψ4.\ ψ5Β y,5C each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O; Q2a, Q^2B, Q^3A, Q^3B, Q^4A, Q^4B, Q^5a, Q^5b, Q^5c are independently for each occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(Rⁿ), C(R’)=C(R”), C=C or C(O);

WO 2018/195165

PCT/US2018/028116 r2a, R^2B, R^3A, R^3B, R^4A, R^4B, R^5a, R^5b, R^5c are each independently for each occurrence absent, NH, O,

S, CH₂, C(O)O, C(O)NH, NHCH(R^a)C(O), -C(O)-CH(R^a)-NH-, CO, CH=N-O,

L^2A, L^2B, L^3A, L^3B, L^4A, L^4B, L^5a, L^5b and L^5C represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; andR^a is H or amino acid side chain.Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXV):

Formula XXXV

ρ5Α_θ5Α_ρ5Α ^Jq p5B_Q5B__R5B ____γ5Α_|_5Α ,5A

---T^5B-L

5B

5B p5C_Q5C__R5C

-|-5C_|_5C wherein L^5A, L^5B and L^5C represent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

Representative US patents that teach the preparation of RNA conjugates include, but are not limited to, US Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, preferably dsRNAs, which contain two or more chemically distinct regions, each made

WO 2018/195165

PCT/US2018/028116 up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNa:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNa strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Atm. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (SaisonBehmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

iii. Delivery of an iRNA of the Invention

The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject infected with HBV can be achieved in a number of different ways. Delivery may also

WO 2018/195165

PCT/US2018/028116 be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian RL. (1992) Trends Cell. Biol. 2(5):139-144 and WO9402595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo. Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim SH., et al (2008) Journal of Controlled Release 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, DR., et al (2003) J. Mol. Biol 327:761-766; Verma, UN., et al (2003) Clin. Cancer Res. 9:1291-1300; Arnold, AS et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., et al (2003), supra; Verma, UN., et al (2003), supra), Oligofectamine, solid nucleic acid lipid particles (Zimmermann, TS., et al (2006) Nature 441:111-114), cardiolipin (Chien, PY., et al (2005) Cancer Gene Ther. 12:321-328; Pal, A., et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet ME., et al (2008) Pharm. Res. Aug 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, DA., et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in US Patent No. 7,427,605, which is herein incorporated by reference in its entirety. In certain embodiments, the iRNA agents can be administered with amphipathic peptides to facilitate pH62

WO 2018/195165

PCT/US2018/028116 dependent endosomal escape (see, e.g., Bartz et al., 2011. Biochem. J. 435:475-87, incorporated herein by reference)

1. Vector encoded iRNAs for use in the Invention iRNA targeting an HBV gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A., et al., WO 00/22113, WO 00/22114, and US Patent No. 6,054,299). Exemplary expression vectors for expression of shRNA targeted to HBV are provided in Michler et al., 2016 which discloses adeno-associated virus (AAV) 8 vectors for delivery included (i) embedded the shRNA in an artificial mi(cro)RNA under a liver-specific promoter; (ii) co-expressed Argonaute-2, a rate limiting cellular factor whose saturation with excess RNAi triggers can be toxic; or (iii) co-delivered a decoy (“TuD”) directed against the shRNA sense strand to curb off-target gene regulation. The plasmids expressing shRNAs shHBV4 to 7 that were used in the cell culture studies were cloned by direct insertion of the respective shRNAencoding oligonucleotides into a self-complementary AAV vector plasmid previously reported by Grimm et al, 2006 (Nature 441: 537 - 541), containing an Hl promoter followed by two BbsI sites for oligonucleotide insertion as well as an RSV promoter. Such constructs can also be used for the expression of vaccine antigens if appropriately sized for the expression vector.

Expression can be transient (on the order of days to weeks) or sustained (weeks to months, or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).

The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

iRNA expression vectors are generally DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by subcutaneous, intravenous, or intramuscular administration. Such vectors can also be used for expression of viral antigens from nucleic acid-based vaccines.

WO 2018/195165

PCT/US2018/028116

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.·, (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors including modified vaccinia virus Ankara vector or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells’ genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of an iRNA or HBV antigen will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.

Such constructs and vectors can also be used for the expression of vaccine antigens if appropriately sized for the expression vector. Such limitations are well understood by those of skill in the art.

B. Therapeutic HBV Vaccines For Use in the Mehods of the Invention

Therapeutic HBV vaccines for use in the regimens and methods of the invention can be a peptide vaccine, a DNA vaccine including a vector-based vaccine, or cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV serotypes, preferably all HBV serotypes.

A therapeutic vaccine is designed to activate the patient's immune system to recognize and control or eliminate an already established pathogen infection. This is clearly distinct from a prophylactic vaccination which is designed to promote rapid antibody-mediated neutralization of an invading pathogen. Control and elimination of persistent viruses such as hepatitis, herpes, or papilloma viruses requires multi-specific and poly-functional effector T cell responses. These T cell responses are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Therapeutic vaccines are under development for a number of chronic infections. Hepatitis B virus infection is a candidate for treatment by therapeutic vaccination since a spontaneous, immune mediated recovery of chronic hepatitis B and an elimination of the virus has been observed in very rare cases.

Robust T cell responses seem to be essential to achieve HBV cure. While HBV-specific CD4+ and CD8+ T cell responses are readily detectable in patients resolving HBV infection, HBVspecific T cells are scarce and functionally impaired in chronic hepatitis B most likely due to high amounts of circulating viral HBeAg and HBsAg. T cells eliminate HBV infected cells by their cytotoxic activity but also control HBV gene expression and replication in a non-cytolytic fashion.

WO 2018/195165

PCT/US2018/028116

To overcome immune tolerance in chronic hepatitis B different approaches have been investigated in preclinical models using DNA or peptide vaccines, or vector- or cell-based vaccines to induce an effector T cell response. Multi-epitope therapeutic vaccine candidates that cover sufficient different HBV genotypes and most frequent HLA types have been developed. Although proper peptide presentation was demonstrated, immunogenicity was limited and the approach was not translated into the clinics. A non-exhaustive list is provided in the table below.

WO 2018/195165

PCT/US2018/028116

References

(the entire contents of

each of which are

incorporated herein by

reference)

Kim et al., 2008. Exp Mol

Med. 40: 669-676

Yang et al., 2006. Gene

Therapy. 13:1110-1117

[—

50

oo

50

CT

Λ

oo

cc

50

t 1

z

IT)

05

IT)

CC

Η

cc

LL

cc

oo

50

IT)

CT

‘sj

Λ

1 I

o

CT

o

O

o

£

H

U

υ

P£

z

c

ε

a

Φ

>

Φ 0Λ

ase

φ

-C

C

(Λ

a

C3

CJ

73

<D

§

<D C )

φ

C3

fi

X <D

73

_o

8

Φ

a

D

o

-C

ζΛ

o

73

φ

-

<D

-

<D

73

<D

O

<D

O

D

On

O

On

<D

Λ

CL

> Λ ζβ

com

O Φ

com

O a

iting

73

3

73

3

e u

Φ

s

o

Ρ£

<D

Pi

73 <D

1

a g

Λ

ited

ivery

φ CL

C .Φ

d bas

<D a '5 Q

d bas

<D a '5 Q

-C +

ccine

73 <D

’S §

al del

is mid

φ _eg *5

lasmi

> <

lasmi

> <

a <D Οΰ

CT

> <

a C3

73

8 δ

Zd <

Λ

Φ

a

z

a

z

>

u

cc

Q

IT)

Q

C3

CL

57

Q

ΟΛ

ob

X

£

<

<N

0ΰ

Ό

Q

<D

<

Φ Φ

HB

CT

ί/5

Φ Q

Ch

Q ca T¹

g *φ

s Φ

Οΰ <

ΰ C3

O

o

O

o

2221

ob

φ

5 σ

a

8 φ

X o

O CL

z CT

£

CU

5Λ

K

-C

CL

+

K

φ

ε

Λ

ζ

OO

o

φ

o

O o

u w.

o oo

φ φ Λ >

HB-1

CL 73 CL CL

INO-

WO 2018/195165

PCT/US2018/028116

5

04

<D

oo

C

co

CJ

O>

a

Tj·

u

^·

Tb

04

04 OO

oo co

SO

o

uo 04

3

co

_t (

Os

r.

04

os

o

so

SO

uo

nJ

r-

pp

’o

co co

04

o

uo 04

04

1

CJ

o

O

04

nJ

co

04

uo

z

ζυ

<D

’5

Ό

Os

o 04

S

04

cd Οΰ

.s ’o

Cd §

O O 04

ex?

US

us

CO CO

Οΰ cd o

CD ^cd

f—

04

o

f—

Os

uo

so

04

uo

co

Os

O

p**

Ό

SO

04

oo

p**

uo

04

Ό

CO

so

CO

os

nJ

CO

Os

04

Os

nJ

p**

uo

SO

o

nJ

Os

p**

1 (

o

04

1 I

04

_t (

1 I

04

o

O

o

O

o

O

H

U

z

§

jO

-C CJ

<D

CD

Cd

cd

©

cd

-C

<D

-C

Pi

<D

a

p

s

cj

o O

ob

<D a

QQ

© 5

X Cd

o fl

75

Pi

<

Cd

-C

&

s

cd <D

Z

ΖΛ 7j

<D

o

d

<

u

►S j

Q

H

u

<

o

75

o

<D

o

Z O © cd Jd

<D f 75 g <D

d is ffl

O

.s ©

7d 'Sb

hrough

iting

olerated;

a o CL S Td

’cd .s 75 <D

Οΰ a

II naive

a &b a '6 W) a o

Td a cd CD

.s ©

ΰ <D

W) a Cd

.s ©

a cd

<D CJ <D

reakt

Lecru:

a

δ £

atien

g CJ <D

hase

CL O

'a W)

<D CD <D

cd <D

CJ

On

75

>

-C

Pi

Cd

O

Q-

P4

Ph

!Z)

75

fa

< z

75 g

o CL

vant

75 JD a

_—

Q qq 04 c/o

ί u CD a

Cd pd s o

+ L-pamj

in + adju

cd θ’ cd @

<D

a

in +

CD CD H a <D W)

δ cd

§ u &

vacci

8 o Oh

vecto

DNA

Prote

co O

On <D CL

prote

Prote

Tame

stimu

W)

&b

<

ΰ

<

CJ

CD

PP

c/j

o

QQ

-

CL

-

<D

W)

Οΰ

Oi

W)

Oh

<

< u

_O

< X

PP

s

PP

Z5

PP

z

£

04 O

Οΰ <

ύ

o

a)

s

u CQ

<

m

X Cd

75

z

04 O ca

z Q

VI-H

herav

CJ H CL <D

m

cA

<

u

H

SO

o

MEI 27037625v. 1

WO 2018/195165

PCT/US2018/028116

			Cavenaugh et al., 2011. PLoS ONE 6: el4626.	Backes, 2016, Vaccine; WO2017121791
	NCT00869778 NCT02862106	NCT02249988	ISRCTN 67270384
	Phase II	Phase II/III	Phase Ila	Research
	Chongqing Jaichen Biotechnology, Ltd.	ABIVAX S.A.	Oxxon Therapeutics
ΰ o Q- U a o δ X <D	Some seroconversion observed in all groups, no statistical analysis	Ongoing	Well tolerated, but did not control HBV infection
	Multi-peptide vaccine	HBsAg, HBeAg	Protein primeviral vector boost	Adjuvanted protein primeviral vector boost
		HBsAg, HBeAg		HBsAg, HBeAg
	εΡΑ-44	ABX 203	pSG2.HBs/ MVA.HBs

MEI 27037625v. 1

WO 2018/195165

PCT/US2018/028116

Existing prophylactic vaccines have been used to restore HBV-specific immunity in chronically infected patients, but have failed to provide a functional cure. These subviral particlebased vaccines were able to reduce HBV replication in animal models of chronic hepadnaviral infection, but have not been successful in patients with chronic hepatitis B. An antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic vaccine candidate with alum as adjuvant first showed promising results in a double-blind, placebo controlled, phase lib clinical trial, but results of a phase III clinical trial including 450 patients were disappointing. This is most likely due to the fact that subviral particle vaccines with alum-based adjuvants are designed as prophylactic vaccines and preferentially induce antibodies but not cytotoxic T cell responses that would be required for therapeutic efficacy.

Alternatively, DNA vaccines encoding HBV envelope proteins were designed to induce HBV-specific T cells but also had limited success. Since DNA-based vaccines hardly induce antibody responses, they failed to achieve HBeAg or HBsAg seroconversion. An alternative DNA prime, poxvirus-boost vaccine encompassing the HBV preS/S region encoding for the HBV envelope proteins showed promising results in chimpanzees, but also failed in a clinical phase Ila trial neither inducing sustained T cell responses nor reducing viremia in chronic HBV carriers. They may have failed to induce T cell help or broad enough, multi-specific immune responses.

Any vaccines known in the art can be used in the methods and regimens provided herein. Preferred embodiments include the prime-boost vaccination scheme with protein antigens administered twice and a nucleic acid vaccine administered once as provided in the Examples and provided in PCT Publication No. WO 2017/121791 (the entire contents of which are incorporated herein by reference). As discussed above, the sequence of the protein antigen in the vaccine and the amino acid sequence encoded by nucleic acid-based vaccine need not be identical. They simply must share at least one epitope, preferably multiple epitopes, so that the sequential administration of the vaccines has the desired prime-boost effect. Further, as discussed herein, in preferred embodiments, the treatment regimen provided herein would provide a treatment regimen effective across multiple, if not all, HBV serotypes. Therefore, it is understood that the antigen delivered to the subject may not have antigen sequences identical to the antigens expressed by the HBV virus that infected the subject.

It is known in the art that some portions of HBV antigens are the main targets of antibodies generated during the initial immune response to infection with HBV known as determinants. For example the HBsAg includes the a determinant epitope that is located at amino acids 124 to 147 within the major hydrophilic region (MHR, amino acids 100 to 169) of the 226 amino acid S gene (SEQ ID NO: 8 or 22). This a determinant is one of the main targets of anti-HBs antibodies during the course of the initial immune response in acute hepatitis B. In certain embodiments, an immunogenic fragment of HBsAg comprises compared to the full length protein at least amino acids 99 to 168 corresponding to the amino acid positons of the small envelope protein (SEQ ID NO: 23) (see, e.g., Lada et al., J. Virol.(2006) 80:2968-2975, the entire contents of which are incorporated herein by reference).

WO 2018/195165

PCT/US2018/028116

Similarly, determinants have been identified in HBcAg (see, e.g., Salfeld et al., J. Virol. (1989) 63:798-808, the entire contents of which are incorporated herein by reference). The full-length core protein is 183 amino acids in length and consists of an assembly domain (amino acids 1 to 149) and a nucleic acid-binding domain (amino acids 150 to 183). Three distinct major determinants have been characterized. The single conformational determinant responsible for HBc antigenicity in the assembled core (HBc) and a linear HBe-related determinant (HBel) were both mapped to an overlapping hydrophilic sequence around amino acid 80; a second HBe determinant (HBe2) was assigned to a location in the vicinity of amino acid 138 but found to require for its antigenicity the intramolecular participation of the extended sequence between amino acids 10 and 140. Typically, such an immunogenic fragment comprises, compared to the full length core protein, at least amino acids 18 to 143 corresponding to the sequence positions set forth in SEQ ID NO: 24. Analogous sequences can be identified in SEQ ID NO: 10.

In preferred embodiments, the vaccines include an amino acid sequence or encode an amino acid sequence that includes at least one determinant of HBsAg or HBcAg. Specifically, in certain embodiments, a vaccine targeted to HBsAg includes at least the amino acid sequence of amino acids 127 to 147 of HBsAg, e.g., includes at least amino acids 99 to 168 of the amino acid sequence of the small envelope protein (SEQ ID NO: 23). In certain embodiments, a vaccine targeted to a hydrophilic sequence at least around amino acid 80 of HBcAg or an amino acid sequence at least around amino acid 138, e.g., at least a 40 amino acid portion, at least a 50 amino acid portion, at least a 60 amino acid portion, at least a 70 amino acid portion, at least an 80 amino acid portion, at least a 90 amino acid portion, or at least a 100 amino acid portion of SEQ ID NO: 43 including amino acid 80 or amino acid 138, or a coding sequence therefor. In preferred embodiments, the antigen amino sequence of the antigen targeted to HBcAg includes at least 20 amino acids N-terminal and C-terminal to amino acid 80 or 138 of SEQ ID NO: 24. In certain embodiments, a vaccine targeted to HBcAg includes at least the amino acid sequence of amino acids 10 to 140 or 18 to 143 of HBsAg.

In certain embodiments, the vaccine may comprise the entire amino acid sequence or encode the entire amino acid sequence of any one or more of SEQ ID NO: 22, 23, or 24.

It is understood that there are multiple serotypes of HBV with different nucleic acid sequences that encode different amino acid sequences. Therefore, it is understood that the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine may not be 100% identical to the sequences provided in the SEQ ID NOs. In certain embodiments of the invention, the the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, or at least 98% identical to the portion of SEQ ID NO: 22, 23, or 24. Additional exemplary HBsAg and HBcAg amino acid sequenences are provided in the sequence listing. Alignment methods to identify appropriate sequences corresponding to the HBsAg and HBcAg determinants in the sequences indicated above are known in the art.

WO 2018/195165

PCT/US2018/028116

The vaccine preferably comprises MV A viruses in a concentration range of 10⁴ to 10⁹ tissueculture infectious dose (TCID)5o/ml, preferably in a concentration range of 10⁵ to 5xl0⁸ TCID5o/ml, more preferably in a concentration range of 10⁶ to 10⁸ TCID₅o/ml, and most preferably in a concentration range of 10⁷ to 10⁸ TCID₅o/ml.

A preferred vaccination dose for humans comprises 10⁶ to 10⁹ TCID50, most preferably a dose of 10⁶ TCID5o or 10⁷ TCID50 or 10⁸ TCID₅₀.

The preferred methods of the invention include administration of both a protein-based vaccine and a nucleic acid-based vaccine. However, other methods include administration of only protein antigens. Less preferred embodiments include administration of only nucleic acids encoding antigens.

i. Adjuvants

As used herein “adjuvant” is understood as an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself. Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), CpG DNA, emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets. Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells. Combination adjuvants (e.g., AS02, AS03 and AS04 (GSK); MF59 (Novartis); and IC31® (Altimmune) elicit multiple protective immune responses. Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together. In certain embodiments, preferred adjuvants include c-diAMP, c-di-GMP, c-di-CMP, PolylCLC, CpG, ISCOMATRIX®, AS02, AS03, AS04, or a RIG-I ligand such as 5’ 3P-RNA. In certain embodiments, a viral capsid, with or without a nucleic acid expressing an HBV antigen can be used as an adjuvant. For example, a vaccine that preferentially stimulates T cells such as an MVA-only or a DNA prime, MVA boost or an adenovirus vector primeMVA boost can be used in the methods of the invention.

In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral and a cellular immune response as discussed above. In certain embodiments, adjuvants provide a balanced Thl/Th2 response.

ii. Non-adjuvant immune stimulators and additional agents

Methods of the invention can further include administration of additional agents used in the treatment of HBV or to stimulate an immune response. Such agents can include an immune

WO 2018/195165

PCT/US2018/028116 stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 3, 7, 8, or 9 (TLR3, TLR7, TLR8, or TLR9) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), a Rig-I-ligand, a STING agonist, an antibody based immune therapy against HBV (mono-, bi-, or trispecific antibody against HBV), or an immune checkpoint regulator. Such agents are known in the art.

C. Nucleotide and Nucleoside Analogs For Use in the Methods of the Invention

Nucleotide and nucleoside analogs are considered to be the standard of care for HBV infection as they are generally considered safe and inexpensive. However, nucleotide and nucleoside analogs cannot cure HBV infection, may cause the development of resistance, and must be taken indefinitely. Nucleotide analog and nucleoside analogs include, but are not limited to, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, Besifovir (ANA-380/LB-80380), and Tenofvir-Exalidex (TXL/CMX157) . In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV) or Tenofovir or a derivative thereof. In certain embodiments, the nucleot(s)ide analog is not Lamivudine. Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.

III. Antisense Oligonucleotides Targeting HBV

The present invention includes the use of iRNAs which promote cleavage of at least one HBV transcript, and preferably three or four HBV transcripts. Antisense oligonucleotides can similarly be used to promote cleavage of at least one HBV transcript, preferably three or four HBV transcripts, in the methods of the invention provided here. Exemplary antisense oligonucleotides targeted to HBV are provided, for example, in U.S. Patent Publication Nos. 2013/0035366, 2012/0207709, and 2004/0127446, the contents of each of which is incorporated by reference herein in its entirety.

It is understood by those of skill in the art that conjugates, linkers, and formulations for the delivery of siRNAs as provided above can be used for the formulation and delivery of antisense oligonucleotide therapeutic agents to subjects.

IV. Pharmaceutical Compositions of the Invention

The present invention also includes pharmaceutical compositions and formulations which include the iRNAs or vaccines for use in the invention. It is understood that approved therapeutic agents are formulated and administered by the route indicated on their package instructions.

WO 2018/195165

PCT/US2018/028116

In some embodiments, provided herein are pharmaceutical compositions containing an iRNA or a vaccine, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the iRNA or vaccine are useful for treating subject with an HBV infection. Such pharmaceutical compositions are formulated based on the mode of delivery, e.g., for systemic administration via parenteral delivery, e.g., by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery.

The pharmaceutical RNAi compositions for use in the invention may be administered in dosages sufficient to significantly reduce the level of at least one HBV transcript. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. Typically, a suitable dose of an iRNA of the invention will be in the range of about 0.1 mg/kg to about 5.0 mg/kg, preferably about 0.3 mg/kg and about 3.0 mg/kg. A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every other week or once a year. In certain embodiments, the iRNA is administered about once per month to about once per quarter (i.e., about once every three months). In preferred embodiments, the RNAi agent is administered subcutaneously.

Formulation and dosing of the vaccine will depend on the nature of the vaccine administered. In a protein prime-expression vector boost vaccination strategy, the protein-based priming vaccines are administered about 2, 3, or 4 weeks apart with the expression vector vaccine boost being administered about 2, 3, or 4 weeks after the second protein-based vaccine dose. In certain embodiments, it is about two weeks between the first and second doses of the protein-based vaccine. In certain embodiments, it is about two weeks between the second dose of the protein based vaccine and the DNA expression vector vaccine boost. In certain embodiments, the prime and boost vaccinations are administered by routes independently selected from intramuscularly, intradermally, or subcutaneously.

The pharmaceutical nucleic acid-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime agent or a boost agent. The amount of nucleic acid-based vaccine to be administered will depend, for example, on the design of the vaccine. As the regimens provided herein can include the use of existing nucleic acid-based vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.

The pharmaceutical protein-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime or a boost agent. The amount of protein-based vaccine to be administered will depend, for example, on the adjuvant used. Proteinbased vaccines can be dosed, for example, at about 5-100 mg/kg/dose, about 10-50 mg/kg/dose, or about 20-40 mg/kg/dose. As the regimens provided herein can include the use of existing proteinbased vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.

WO 2018/195165

PCT/US2018/028116

After an initial treatment regimen, the treatments can be administered on a less frequent basis.

In preferred embodiments, the treatment regimens and methods provided herein result in a functional cure allowing for discontinuation of treatment after completion of the regimen or after diagnostic criteria indicate a functional cure, e.g., decreased HBsAg levels preferably to below the level of detection of the methods provided herein and a detectable immune response to HBsAg.

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual therapeutic agent used in the methods and regimens invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein and known in the art.

A. iRNA Formulations Comprising Membranous Molecular Assemblies

An iRNA for use in the compositions and methods of the invention can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term “liposome” refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the iRNA composition, although in some examples, it may. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the iRNA are delivered into the cell where the iRNA can specifically bind to a target RNA and can mediate iRNA. In some cases the liposomes are also specifically targeted, e.g., to direct the iRNA to particular cell types.

A liposome containing an iRNA agent can be prepared by a variety of methods. In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The iRNA agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the iRNA agent and condense around the iRNA agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of the iRNA agent.

WO 2018/195165

PCT/US2018/028116

If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.

Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 9637194, the entire contents of which are incorporated herein by reference. Liposome formation can also include one or more aspects of exemplary methods described in Feigner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; US Patent No. 4,897,355; US Patent No. 5,171,678; Bangham, et al. M. Mol. Biol. 23:238, 1965; Olson, et al. Biochim. Biophys. Acta 557:9, 1979; Szoka, et al. Proc. Natl. Acad. Sci. USA 75: 4194, 1978; Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et al. Endocrinol. 115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et al.

Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984). These methods are readily adapted to packaging iRNA agent preparations into liposomes.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap nucleic acids rather than complex with it. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC and egg PC. Another type is formed from mixtures of phospholipid or phosphatidylcholine or cholesterol.

WO 2018/195165

PCT/US2018/028116

Examples of other methods to introduce liposomes into cells in vitro and in vivo include US

Patent Nos. 5,283,185 and 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024; Feigner, J. Biol.

Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci.USA 90:11307, 1993; Nabel, Human Gene Ther.

3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO J. 11:417, 1992.

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al. S.T.P.Pharma. Sci., 1994, 4(6) 466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_Mi, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside G_Mi, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. USA, 1988, 85, 6949). US Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_Mi or a galactocerebroside sulfate ester. US Patent No. 5,543,152 discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sndimyristoylphosphatidylcholine are disclosed in WO 9713499 (Lim et al).

Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Noncationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver iRNA agents to macrophages.

Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated iRNA agents in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and

WO 2018/195165

PCT/US2018/028116

Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

A positively charged synthetic cationic lipid, N-[l-(2,3-dioleyloxy)propyl]-N,N,Ntrimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of iRNA agent (see, e.g., Feigner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987 and US Patent No. 4,897,355 for a description of DOTMA and its use with DNA).

A DOTMA analogue, l,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles. Lipofectin™ Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2bis(oleoyloxy)-3,3-(trimethylammonia)propane (“DOTAP”) (Boehringer Mannheim, Indianapolis, Indiana) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.

Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide (“DOGS”) (Transfectam™, Promega, Madison, Wisconsin) and dipalmitoylphosphatidylethanolamine 5carboxyspermyl-amide (“DPPES”) (see, e.g., US Patent No. 5,171,678).

Another cationic lipid conjugate includes derivatization of the lipid with cholesterol (“DCChol”) which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, California) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Maryland). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.

Liposomal formulations are particularly suited for topical administration. Liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at

WO 2018/195165

PCT/US2018/028116 the desired target, and the ability to administer iRNA agent into the skin. In some implementations, liposomes are used for delivering iRNA agent to epidermal cells and also to enhance the penetration of iRNA agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., Journal of Drug Targeting, 1992, vol. 2,405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988; Itani, T. et al. Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987; Straubinger, R. M. and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc. Natl. Acad. Sci. USA 84:7851-7855, 1987).

Liposomes that include iRNA can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include iRNA agent can be delivered, for example, subcutaneously by infection in order to deliver iRNA agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.

Other formulations amenable to the present invention are described in WO 2008042973.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the head) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and

WO 2018/195165

PCT/US2018/028116 sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

The iRNA for use in the methods of the invention can also be provided as micellar formulations. “Micelles” are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.

B. Lipid particles iRNAs, e.g., dsRNAs of in the invention may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle. Expression vectors or RNAs containing coding sequences for viral antigens under the control of an appropriate promoter can be formulated in lipid particles for delivery.

As used herein, the term LNP refers to a stable nucleic acid-lipid particle. LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include pSPLP, which include an encapsulated condensing agent-nucleic acid complex as set forth in WO 0003683. The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid- lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., US Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; and 6,815,432; US20100324120 and WO 9640964.

In some embodiments, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.

WO 2018/195165

PCT/US2018/028116

The cationic lipid can be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I -(2,3dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(I -(2,3- dioley loxyjpropyl)Ν,Ν,Ν-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3- dioleyloxy)propylamine (DODMA), l,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,Ndimethylaminopropane (DLenDMA), l,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLinC-DAP), l,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (Dlin-DAC), l,2-Dilinoleyoxy-3morpholinopropane (DLin-MA), l,2-Dilinoleoyl-3-dimethylaminopropane (DLinDaP), 1,2Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), l-linoleoyl-2-linoleyloxy-3dimethylaminopropane (DLin-2-DMAP), l,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), l,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPz), or 3-(N,N-Dilinoleylamino)-l,2propanediol (DLinAP), 3-(N,N-Dioleylamino)-l,2-propanedio (DOAP), l,2-Dilinoleyloxo-3-(2-N,Ndimethylamino)ethoxypropane (DLin-EG-DMA), l,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[ 1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aHcyclopenta[d][l,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), l,l'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2hydroxydodecyl)amino)ethyl)piperazin-l-yl)ethylazanediyl)didodecan-2-ol (Tech Gl), or a mixture thereof. The cationic lipid can comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle. In other embodiments, the compound 2,2-Dilinoleyl-4dimethylaminoethyl-[ 1,3]-dioxolane can be used to prepare lipid-siRNA nanoparticles.

In some embodiments, the lipid-siRNA particle includes 40% 2, 2-Dilinoleyl-4dimethylaminoethyl-[ 1,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG (mole percent) with a particle size of 63.0 ± 20 nm and a 0.027 siRNA/Lipid Ratio.

The ionizable/non-cationic lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl- phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-l- carboxylate (DOPEmal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1 -trans PE, 1 -stearoyl-2-oleoyl- phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid can be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.

The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG80

WO 2018/195165

PCT/US2018/028116 dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The

PEG-DAA conjugate can be, for example, a PEG-dilauryloxypropyl (Ci₂), a PEGdimyristyloxypropyl (Ci₄), a PEG-dipalmityloxypropyl (Cig), or a PEG- distearyloxypropyl (C]₈). The conjugated lipid that prevents aggregation of particles can be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.

In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.

In one embodiment, the lipidoid ND98-4HC1 (MW 1487) (see US20090023673, which is incorporated herein by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (i.e., LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml; Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.

H

ND98 Isomer I

Formula 1

LNP01 formulations are described, e.g., in WO 2008042973, which is hereby incorporated by reference.

Additional exemplary lipid-dsRNA formulations are described in Table 1.

WO 2018/195165

PCT/US2018/028U6

Table 1

	lonizable/Cationic Lipid	cationic lipid/non-cationic lipid/cholesterol/PEG-lipid conjugate Lipid: siRNA ratio
SNALP- 1	1,2-Dilinolenyloxy-N,N dimethylaminopropane (DLinDMA)	DLinDMA/DPPC/Cholesterol/PEG-cDMA (57.1/7.1/34.4/1.4) lipid:siRNA - 7:1
2-XTC	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3] dioxolane (XTC)	XTC/DPPC/Cholesterol/PEG-cDMA 57.1/7.1/34.4/1.4 lipid:siRNA - 7:1
LNP05	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3]dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid:siRNA ~ 6:1
LNP06	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3]dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid: siRNA -11:1
LNP07	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3]dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid:siRNA - 6:1
LNP08	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3]dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid: siRNA - 11:1
LNP09	2,2-Dilinoleyl-4-dimethylaminoethyl-[ 1,3]dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP10	(3aR,5s,6aS)-N,N-dimethyl-2,2di((9Z, 12Z) -octadeca-9,12dienyl)tetrahydro-3aHcyclopentafd] [1,3]dioxol-5-amine (ALNI 00)	ALN100/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP11	(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31tetraen-19 -yl 4-(dimethylamino)butanoate (MC3)	MC-3/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP12	l,l'-(2-(4-(2-((2-(bis(2- hydroxydodecyl)amino)ethyl)(2-	Tech Gl/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5

WO 2018/195165

PCT/US2018/028116

	hydroxy dodecyl)amino)ethyl)piperazin-1 yl)ethylazanediyl)didodecan-2-ol (T ech Gl)	Lipid:siRNA 10:1
LNP13	XTC	XTC/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 33:1
LNP14	MC3	MC3/DSPC/Chol/PEG-DMG 40/15/40/5 Lipid:siRNA: 11:1
LNP15	MC3	MC3/DSPC/Chol/PEG-DSG/GalNAc-PEG- DSG 50/10/35/4.5/0.5 Lipid:siRNA: 11:1
LNP16	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP17	MC3	MC3/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP18	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 12:1
LNP19	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/35/5 Lipid:siRNA: 8:1
LNP20	MC3	MC3/DSPC/Chol/PEG-DPG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP21	Cl 2-200	C12-200/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP22	XTC	XTC/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1

DSPC: distearoylphosphatidylcholine

DPPC: dipalmitoylphosphatidylcholine

WO 2018/195165

PCT/US2018/028116

PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of

2000)

PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000)

PEG-cDMA: PEG-carbamoyl-l,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000) SNALP (l,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO 2009/127060, filed April 15, 2009, which is hereby incorporated by reference.

XTC comprising formulations are described in PCT Publication No. WO 2010/088537, the entire contents of which are hereby incorporated herein by reference.

MC3 comprising formulations are described, e.g., in U.S. Publication No. 2010/0324120, the entire contents of which are hereby incorporated by reference.

ALNY-100 comprising formulations are described in PCT Publication No. WO 2010/054406, the entire contents of which are hereby incorporated herein by reference.

C12-200 comprising formulations are described in PCT Publication No. WO 2010/129709, the entire contents of which are hereby incorporated herein by reference.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids or esters or salts thereof, bile acids or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxy cholic acid (UDCA), cholic acid, dehydrocholic acid, deoxy cholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, l-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; poly acrylates; poly alkylacrylates, polyoxethanes, poly alkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan,

WO 2018/195165

PCT/US2018/028116 poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, poly thiodiethylaminomethylethylene P(TDAE), poly aminostyrene (e.g., p-amino), poly (methylcyanoacrylate), poly (ethylcyanoacrylate), poly (butylcyanoacrylate), poly (isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DE AE-methacrylate, DE AE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in US Patent Nos. 6,887,906 and 6,747,014, and US 20030027780, each of which is incorporated herein by reference.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the liver when treating hepatic disorders such as hepatic carcinoma.

The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

V. Uses of the Methods of the Invention

The invention sets forth various methods and treatment regimens. It is understood that the methods can be provided as uses of the RNAi agents and vaccines provided herein. That is, the invention provides

a) an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand;

b) a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV surface antigen (HBsAg); and

c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the proteinbased vaccine; thereby treating the subject for use in methods of treating a subject having a hepatitis B infection.

The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein.

VI. Kits for Practicing the Methods of the Invention

The invention sets forth various methods, treatment regimensm and uses of agents for the treatment of a subject having a hepatitis B infection. It is understood that agents for practicing the

WO 2018/195165 PCT/US2018/028116 methods of the invention can be prepared based in the disclosure provided herein. Such a kit would include,

b) a protein-based vaccine comprising an HBV core antigen (HBeAg) and an HBV surface antigen (HBsAg);

c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBeAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the proteinbased vaccine; thereby treating the subject; and

d) instructions for use in methods of treating a subject having a hepatitis B infection.

The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein. The components of the kit may be provided together, e.g., in a box. In certain embodiments, the components of the invention may be provided separately, e.g., due to different storage requirements, but be provided for use together, e.g., based on package instructions for use.

This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the Figures, Appendix A, and the Sequence Listing, are hereby incorporated herein by reference.

EXAMPLES

Example 1. Materials and methods

Exemplary iRNAs

Exemplary iRNA target sites and unmodified and modified siRNA sequences are provided in the tables in Appendix A.

The chemically modified HBV-siRNA duplexes used in the experiments below have the following sequences:

Unmodified sequences:

DuplexID	Sense Sequence Unmodified (5’ to 3’)	SEQ ID:	Antisense Sequence Umodified (5’ to 3’)	SEQ ID:
AD-66810	GUGUGCACUUCGCUUCACA	27	UGUGAAGCGAAGUGCACACUU	25
AD-66816	CACCAUGCAACUUUUUCACCU	28	AGGUGAAAAAGUUGCAUGGUGUU	26

WO 2018/195165

PCT/US2018/028116

Modified sequences:
DuplexID	Sense Sequence Modified (5’ to 3’)	SEQ ID:	Antisense Sequence Modified (5’ to 3’)	SEQ ID:
AD-66810	gsusguGfcAfCfUfucgcuucacaL96	37	usGfsugaAfgCfGfaaguGfcAfcacsusu	30
AD-66816	csasccauGfcAfAfCfuuuuucaccuL96	38	asGfsgugAfaAfAfaguuGfcAfuggugsusu	32

Abbreviations for nucleotide monomers in modified nucleic acid sequences are provided in Table 1 of Appendix A.

The target site of AD-66810 is GTGTGCACTTCGCTTCACA (SEQ ID NO: 39) which is nucleotides 1579-1597 of NC_003977.1 (SEQ ID NO: 1).

The target site of AD-66816 is CACCATGCAACTTTTTCACCT (SEQ ID NO: 40) which is nucleotides 1812-1832 of NC_003977.1 (SEQ ID NO: 1).

Cell Culture Evaluation ofHBV-siRNA hNTCP-expressing HepG2 cells were infected (100 multiplicity of infection (MOI)) HBV particles/cell (subtype ayw)) in duplicate. At day 4 after infection, cells were trypsinized and reseeded into multiwell plates and transfected with control or HBV-siRNAs AD-66810 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 37 and 30, respectively) or AD-66816 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 38 and 32, respectively) each delivered at 100 nM, 10 nM, or 1 nM using Lipofectamine® RNAiMax. Supernatant was harvested at days 3, 6, 10, 13, and 17 after reseeding and HBeAg and HBsAg levels were determined relative to non-transfected control. HBsAg and HBeAg levels were determined using a chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA).

Mice, siRNA Administration, and Vaccinations

HBV-transgenic mice (StrainHBV1.3xfs (HBV genotype D, subtype ayw)), were derived from in-house breeding under specific pathogen-free conditions following institutional guidelines.

For siRNA administration, mice were subcutaneously administered a 3 mg/kg or 9 mg/kg dose of control siRNA or HBV-siRNA (modified AD-66810 or modified AD-66816); or intravenously administered by tail vein injection 1 x 10¹¹ AAV particles for expression of the HBVshRNA as indicated in the Figures and Examples below.

For protein vaccinations, mice were immunized subcutaneously with recombinant yeast HBsAg and Escherichia coli HBcAg (APP Latvijas Biomedicinas, Riga, Latvia) mixed with 31.91 pg of synthetic phosphorothioated CpG ODN 1668 and 25 pg poly[di(sodiumcarboxylatoethylphenoxyjphosphazene] (PCEP) in 50 pl PBS.

WO 2018/195165

PCT/US2018/028116

Recombinant MVA were generated by homologous recombination and host range selection as described previously (Staib et al., 2003. Biotechniques. 34:694—700). The entire HBeAg (genotype D, subtype ayw) and HBsAg open reading frames (genotype A, subtype ayw or adw) were cloned into MVA transfer plasmids pIIIAHR-PH5 or pIIIAHR-P7.5, thereby placing the HBV proteins under the control of the early/late Vaccinia virus-specific promoters PH5 (HBeAg ayw /HBsAg ayw/HBsAg adw) or P7.5 (HBsAg ayw). After construction of each virus, gene expression, sequence of inserted DNA, and viral purity were verified. For generation of vaccine preparations, MVA were routinely propagated in CEF, purified by ultracentrifugation through sucrose, reconstituted in 1 mM Tris-HCl pH 9.0 and titrated following standard methodology (Staib et al., 2004. Methods Mol Biol. 269:77100). For MVA vaccination, mice were vaccinated intraperitoneally with 1 χ 10⁸ infectious units of respective recombinant MVA in 500 μΐ PBS.

Specific dosing regimens are provided in the Examples below and in Figures 3, 7, and 12.

Serological analysis

Serum levels of HBsAg and HBeAg were determined in 1:33 dilutions; and anti-HBs levels were determined in a 1:100 dilution using chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA). Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology. 43:53947). The amount of HBV DNA was normalized to DNA level prior to treatment.

Levels of anti-HBc antibodies were determined in 1:20 dilution using the Enzgnost anti-HBc monoclonal test on the BEPIII platform (Both Siemens Healthcare, Eschborn, Germany). If a sample was measured outside the linear range, higher or lower dilutions were used as appropiate.

Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology. 43:539-47). The amount of HBV DNA was normalized to DNA level prior to treatment.

ALT activity was measured at the day of bleeding in a 1:4 dilution in phosphate buffered saline (PBS) using the Reflotron GPT/ALT test (Roche Diagnostics, Mannheim, Germany).

Lymphocyte stimulation assay

Liver-associated lymphocytes (LAL) were isolated as described in Stross et al., 2012 (Hepatology 56:873-83) and stimulated with H2-kb-or H-2Db-restricted peptides (see Backes, 2016) for 12 hours in the presence of 1 mg/ml Brefeldin A (Sigma-Aldrich, Taufkirchen,Germany). Cells were live/dead-stained with ethidium monoazidebromide (Invitrogen®, Karlsruhe, Germany) and blocked with anti-CD16/CD32-Fc-Block (BD Biosciences, Heidelberg, Germany). Surface markers were stained with PB-conjugated anti-CD8-alpha and PE-conjugated anti-CD4 (eBiosciences, Eching, Germany). Intracellular cytokine staining (ICS) was performed with FITC anti-IFN-gamma (XMG1.2), PE-Cy7 anti-TNF-alpha and APC anti-IL-2 (eBiosciences, Ech-ing, Germany) using the

WO 2018/195165

PCT/US2018/028116

Cytofix/Cytoperm kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer’s recommendations. The same data were analyzed twice, the second time with a more rigorous exclusion of dead cells.

Immunohistochemical stainingsfor HBc-expressing hepatocytes

Livers were harvested, fixed in 4% paraformaldehyde, and paraffin-embedded. The liver was sectioned (2 pm) and sections were stained with rabbit anti-HBcAg as the primary antibody (Diagnostic Biosystems, Pleasanton, CA; #RP 017; 1:50 dilution; retrieval at 100°C for 30 min with EDTA) and a horseradish peroxide coupled secondary antibody. Incubation in Ventana buffer and staining were performed on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana Instruments) or on a Bond MAX (Leica Biosystems). For analysis, slides were scanned using a SCN 400 slide scanner and positive cells were counted using the integrated Tissue Al software (both Leica Biosystems).

HBV transcripts from liver lysate

For analysis of HBV RNA from liver lysate, RNA was extracted from 30 mg liver tissue with the RNeasy mini kit (Qiagen) and cDNA was synthesized with the Superscript III kit (Thermo Fisher Scientific). HBV transcripts were amplified with primers specific for only the 3.5 kb transcripts (forward primer 5’- GAGTGTGGATTCGCACTCC-3’ (SEQ ID NO: 41); reverese primer 5’GAGGCGAGGGAGTTCTTCT-3’ (SEQ ID NO: 42)), or with primers binding to the common 3' end of all HBV transcripts (forward primer 5’ - TCACCAGCACCATGCAAC-3’ (SEQ ID NO: 43); reverse primer 5’- AAGCCACCCAAGGCACAG-3’ (SEQ ID NO: 44)) (Denaturation: 95°C 5 min; Amplification: 95°C 3s, 60°C 30s (40 cycles)) (Yan et al., 2012). Results were normalised to murine GAPDH expression (forward primer 5’- ACCAACTGCTTAGCCC-3’ (SEQ ID NO: 45); reverse primer 5’- CCACGACGGACACATT-3’ (SEQ ID NO: 46)) (Denaturation: 95°C 5 min; Amplification: 95°C 15s, 60C° 10s, 72°C 25s (45 cycles)). All PCR reactions were performed on a LightCycler 480 (Roche Diagnostics).

AAV-HBV mouse model

For the AAV mouse model, wildtype C57/B16 mice (9 weeks of age; 6 animals per treatment group) were injected i.v. with 2xlO¹⁰ genome equivalents (geq) of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (day -28) (see, e.g., Yang, et al. (2014) Cell and Mol Immunol 11:71). Starting 4 weeks after AAV-transduction (day 0), animals were treated with 3 injections (3 mg/kg bw, n=12 per group) of either a control siRNA, or HBV siRNA (AD-66816 or AD-66810) (days 0, 29, and 57). Each siRNA treatment group was divided into two groups (n = 6 per group) to be not treated or treated with the vaccine regimen consisting of recombinant HBsAg, HBcAg (15 pg of each) and 10 pg c-di-AMP given at day 57 and

WO 2018/195165

PCT/US2018/028116 and boosted with MVA-HBs and MVA-HBc (5xl0⁷ geq of each) at day 84. A schematic showing the treatment regimen is provided in Figure 12.

Example 2 - Evaluation of HBV-siRNA in HepG2-NTCP Cell Culture and Dose Finding Experiments in HBVxfs Mice

Anti-HBV siRNAs were evaluated for efficient knockdown of HBV antigens and DNA in an in vitro infection model using HBV-infected HepG2-NTCP cells treated with 1 nM, 10 nM, or 100 nM of one of modified AD-66810 or modified AD-66816 HBV-siRNA, or a control siRNA as provided above. Supernatants were collected at days 3, 6, 10, 13, and 17 days after siRNA treatment and assayed for HBeAg and HBsAg levels as compared to untransfected control. Both HBV-siRNAs were demonstrated to effectively knockdown expression of both HBeAg and HBsAg with the highest levels of knockdown observed at days 13 and 17. No significant knockdown was observed with the control siRNA. These data demonstrate that the AD-66810 or AD-66816 HBV-siRNAs are effective at knocking down expression of HBV antigens in a sustained manner in an in vitro system of HBV infection.

The HBV and control siRNAs were then tested in the HBVxfs transgenic model of chronic hepatitis B. The HBVxfs mice include an integrated HBV genome that is expressed under the control of a liver-specific promoter. At about 10 weeks of age, mice were administered a 3 or 9 mg/kg dose of one of AD-66810 or AD-66816 HBV-siRNA or a control siRNA (n = 6 per group). Blood samples were collected at days 6, 13, and 21 after siRNA treatment and serum was prepared. HBeAg, HBsAg, and HBV DNA levels in serum (Figures 2A-2C) were determined as provided above. Further, RNA was isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression (Figures 2D and 2E).

Both of the HBV-siRNAs at both doses were demonstrated to effectively knockdown expression of HBsAg and HBeAg and to decrease HBV DNA levels in serum as compared to control levels (see Figures 2A-2C). Futher, total liver HBV RNA relative to GAPDH DNA and 3.5 kb HBV RNA relative to GAPDH RNA levels were strongly decreased by both doses of the HBV siRNAs as compared to control levels (Figures 2D and 2E). Based on these results, the 3 mg/kg dose was selected for use in further experiments.

Example 3 - Comparison of Reducing Antigen Load with siRNA to Nucleot(s)ide Analogs Prior to Therapeutic Vaccine Administration in an HBV Transgenic Mouse Model

Having demonstrated that siRNA targeted to HBV can effectively knockdown expression of HBsAg and HBeAg and decrease HBV DNA levels in serum in the HBVxfs mouse model, the effect of treatment of mice with the nucleoside analog Entecavir or HBV-siRNA prior to therapeutic vaccine administration using a prime-boost regimen was tested. The treatment scheme is shown in Figure 3.

Mice were pretreated with one of six treatment regimens prior to vaccination using a primeboost regimen (n= 6 per group):

WO 2018/195165

PCT/US2018/028116 (1) No pretreatment;

(2) Entecavir at 1 qg/ml in water throughout the course of the study beginning on the first day of Week 0 (expected dose of about 4 mg/day based on calculations provided in Lutgehetmann et al., 2011, Gastroenterology. 140:2074-83);

(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of modified AD-66816 or modified AD-86610 (generically HBV-siRNA).

On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 qg) and E. coli expressed HBcAg (15 qg) adjuvanted with 31.9 qg synthetic phosphorothioated CpGODN 1668 (CpG) and 25 qg poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein-prime vaccination (Backes, 2016).

On the first day of week 16, a mixture of modified vaccinia viruses Ankara expressing HBsAg or HBcAg (5 χ 10⁷ particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).

Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and serum samples prepared therefrom were assayed for levels of HBsAg, HBeAg, and HBV DNA. Results are shown in Figure 4.

HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar. The HBV-shRNA or HBV-siRNAs (AD-66816 or AD-86610) alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum (Figures 4A-4C). The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA and HBV-siRNA groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. Without being bound by mechanism, it is proposed that the decrease in HBsAg, but not HBeAg, results from the immune response induced by the vaccine against the s antigen, but not the e antigen, which is produced by proteolytic processing of the C protein (see Figure 5 discussed below).

HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control siRNA all decreased HBV DNA levels and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. It is unclear why the mock treatment and control siRNA decreased HBV DNA levels in this experiment. No decrease in HBV DNA was observed in response to treatment with control siRNA in other experiments (see, e.g., Figures 2C and 8C). These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, RNAi and subsequent vaccination have a combined effect on HBsAg and HBV DNA levels greater than either agent alone.

WO 2018/195165

PCT/US2018/028116

On the final day of the experiment (first day of Week 17), mice were sacrificed and their livers harvested. Liver associated lymphocytes were isolated from liver and after peptide stimulation CD8+ T cell responses measured via intracellular cytokine staining. Specifically, intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. The data were analyzed twice using two different thresholds for the exclusion of dead immune cells as the exclusion of dead immune cells in the first analysis provided in Figures 5A-5C was determined to be insufficient. The second analysis is presented in Figures 5D-5F. The second analysis confirmed the conclusions from the first analysis.

Mice pretreated with the HBV-shRNA or the HBV-siRNAs before vaccination were able to generate a CD8+ T cell immune response against the HBsAg and HBcAg (Figures 5A, 5B, 5D, and 5E) indicating that cytotoxic T cells able to clear HBV infection are induced when HBV antigen levels are suppressed prior to vaccination. No significant CD8+ T cell immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. A significant and similar CD8+ T cell immune response against the MVA virus in all animals, independent of pretreatment or viral antigen levels, demonstrated that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels, thereby demonstrating the presence of a competent immune system (Figures 5C and 5F). No significant differences in antibody production were observed between mock treated animals and any of the other groups indicating that high HBV antigen levels may induce T cell tolerance.

These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity in the liver and enable the induction of HBV-specific CD8+ T cell responses after therapeutic vaccination. A robust CD8+ effector T cell response has been associated with viral clearance and functional cure (see, e.g., Thimme et al., 2003. J. Virol. 77:68-76, and Backes et al., 2016. Vaccine. 34:923-932).

RNA was also isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression. Treatment of mice with HBV-siRNA or HBV-shRNA prior to vaccine administration resulted in a significant decrease in HBV total RNA and HBV 3.5 kb transcript as compared to the mock treated control (Figures 6A and 6B). No significant change in HBV total RNA and HBV 3.5 kb transcript was observed in the mice treated with Entecavir or the control siRNA prior to vaccination as compared to the mock treated control. These data demonstrate that both HBV siRNAs and the shRNA, in contrast to the control and Entecavir groups, successfully led to a decrease in HBV transcript levels.

Further, expression of HBV antigens in the liver was analyzed by immunohistochemical staining for HBc of liver sections and counting of HBc positive cells per mm² (Figure 6C). Only groups of animals pre-treated with HBV siRNA or shRNA, but not Entecavir or the control siRNA, showed reduced HBc expression following vaccination.

Throughout the experiment, body weight and ALT levels were monitored. No significant differences were observed in any of the treatment groups as compared to mock treated control.

WO 2018/195165

PCT/US2018/028116

Example 4 - Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to

Immunization in an HBV Transgenic Mouse Model

Having demonstrated that suppression of expression of HBV antigens using shRNA or siRNA is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the length of time of HBV antigen suppression had an effect on potentiation of an HBV immune response. A treatment scheme is shown in Figure 7.

Using the HBV1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816 (modified) or the control siRNA for 8 weeks, administered subcutaneously at 3 mg/kg/dose. siRNA administration was followed by administration of the prime-boost vaccine regimen as set forth above with the exception that c-di-AMP was used as an adjuvant with protein administration rather than PCEP + CPG (n= 6 per group). Therefore, mice in the 8 week group (n = 6) received three doses of siRNA with the third dose being administered on the first day of vaccine administration. The mice in the 6 week group (n = 12) received two doses of siRNA with the second dose being administered two weeks prior to the first day of vaccine administration. Finally, the mice in the 3 week group (n = 6) received one dose of siRNA with the dose being administered three weeks prior to the first day of vaccine administration.

Blood samples were collected on the first day of -8 weeks, -6 weeks, -4 weeks, -2 weeks, 0 weeks, 2 weeks, 4 weeks, and 6 weeks, before (negative numbers) and after the first dose of vaccine administration on the first day of Week 0. Serum was prepared and HBsAg, HBeAg, and HBV DNA levels were assessed as provided above.

A significant decrease in each HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost, with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 log 10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 loglO) of HBV DNA which had been significantly decreased by the siRNA treatment. No further decrease in HBeAg levels was observed in response to the vaccination regimen.

These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8+ T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment rather than a 3 week pretreatment.

On the final day of the experiment, on the first day of Week 6 after the start of immunization, mice were sacrificed and their livers harvested for six mice from each group. Liver associated lymphocytes were isolated and a lymphocyte stimulation assay was performed as provided above. Specifically, intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBeAg, and the MVA virus particle using the method provided in Backes, 2016. T-cell responses against HBsAg and HBeAg in liver corresponded with the duration of HBV antigen knockdown, with a trend of

WO 2018/195165

PCT/US2018/028116 higher levels of immune response observed with longer duration of HBV antigen resulting in greater T-cell response (see Figures 9A-9C). Similar responses to MVA virus antigens were observed across all groups, independent of pretreatment, showing that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels demonstrating the presence of a competent immune system (Figure 9D). No significant differences in antibody production were observed between control siRNA treated animals and any of the other groups. This demonstrates, that reconstitution of HBV-specific CD8+ T cell responses does not occur immediately, with stronger responses seen after therapeutic vaccination if animals had lowered HBV antigen titers for at least 6 or 8 weeks compared to only 3 weeks. It further confirms the previous finding that, in contrast to T cell responses, B cell immunity does not seem to be significant influenced by HBV antigen titers.

RNA was also isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression. Treatment of mice with HBV-siRNA AD-66816 prior to vaccine administration resulted in a significant decrease in HBV total RNA and HBV 3.5 kb transcript in liver lysates as compared to the control siRNA treated control (Figures 10A and 10B). Further, HBV antigen expression in the liver was analyzed by immunohistochemical staning and counting of HBc positive cells per mm² (Figure 10C). Correlating the observed increase in HBV-specific CD8 responses with increased duration of siRNA pretreatment, decreased numbers of HBc expressing cells where observed in the liver. These results demonstrate that the CD8+ T cell responses did prevent antigen expression in the liver..

To assess the durability of response, blood samples were collected from mice pretreated with the AD-66816 HBV-siRNA using the six week treatment regimen at 2 and 3 weeks after administration of the boost vaccination (Figures 11 A-l ID). In three of the six mice, HBsAg levels continued to drop to below the level of detection of the assay (Figure 11 A). No similar decrease in HBeAg levels were observed during the course of the experiment (Figure 1 IB). These data show that the maximum effect by the siRNA-vaccination combinatorial therapy provided herein is later than 1 week after the MVA vaccination, which was chosen as termination time point to best asses CD8+ T cell responses. Anti-HBs antibody response (Figure 11C) and T cell immune response in the liver against HBs(S208) (Figure 1 ID) at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen. The antibody response varied among animals.

These data demonstrate that a functional cure is possible using the treatment regimens provided herein. Further, these data suggest that a lower HBsAg and HBeAg burden can result in a greater level of immune clearance of HB antigens and potentiate an immune response, at least within the short time course of the experiment.

WO 2018/195165

PCT/US2018/028116

Example 5 - Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to

Immunization in an AAV-HBV Mouse Model

Having demonstrated the efficacy of the siRNA-vaccine combination treatment regimen in a transgenic mouse model, an AAV-HBV infection mouse model was used to study the efficacy of the treatment regimen in acquired infection model (see, e.g., Yang, et al. (2014) Cell Mol Immunol 11:71). This mouse model exhibits sustained HBV viremia after infection with a recombinant adenoassociated virus (AAV) carrying a replicable HBV genome.

There are a number of differences between the HBV-transgenic and AAV-HBV mouse models. The HBV transgenic mice can express HBV antigens essentially from birth, whereas the AAV-HBV model allows for the introduction of the HBV genome at a later time in the life of the mice. This may have an effect on immune tolerance. Further, the HBV transgenic mice carry the transgene in every cell of the body, providing the possibility of “leaky” extrahepatic expression. Although the AAV8 serotype could infect cells outside of the liver, it has a strong liver tropism. Moreover, it is not possible to clear an HBV infection in a transgenic mouse. When a transgenic HBV expressing liver cell is killed, it is replaced by a new HBV expressing cell. In the infection model, if the infected cells are killed, the newly dividing cells are not infected at the time of cell division.

Nine week old C57/B16 mice were infected with AAV-HBV (- 28 days). Mice were then treated with one of control siRNA, or one of two HBV-siRNAs, modified AD-66816 or modified AD66810 at 3 mg/kg administered subcutaneously on days 0, 29, and 57 (i.e., 0 weeks, 4 weeks, 8 weeks) (n=12 per group). Each siRNA treatment group was divided into two groups (n=6 per group). One group was treated with the HBV vaccine protocol (protein prime on days 57 and 70, and MVA boost on day 84, i.e., weeks 8, 10, and 12, respectively) and one group was not. A schematic showing the dosing regimen is provided in Figure 12. Mice were monitored throughout the experiment for serum HBsAg, HBeAg, anti-HBs antibodies, body weight, and ALT. Anti-HBe antibody levels were also periodically tested.

Figures 13A and 13B show an increase in HBsAg and HBeAg levels comparable to that seen in transgenic mice within two weeks of transduction with the AAV-HBV virus. Mice treated only with the control siRNA replicated HBV for greater than 8 months at levels comparable to chronically infected humans (HBsAg levels around 2,000 lU/ml, HBV viremia 10⁶T0⁷ lU/ml). HBV siRNAs AD-66816 and AD-66810 reduced HBsAg by 2 and 2.5 log₁₀, respectively, and HBeAg by >1 log₁₀. The effect persisted for at least 4 weeks after stopping siRNA treatment before antigenemia slowly rebounded to baseline levels after 18 weeks (Figures 13A andl3B).

Intrahepatic HBV DNA (Figure 13D) and AAV DNA (Figure 13E) levels were determined at week 22 by qPCR as described above. The relative expression in liver of HBV 3.5 RNA relative to GAPDH RNA (Figure 13F) and total HBV RNA relative to GAPDH RNA (Figure 13G) were determined using rtPCR. Mice treated with the combined siRNA-vaccine protocol demonstrated a significant decrease in total HBV DNA and AAV DNA as compared to untreated control or siRNA or

WO 2018/195165

PCT/US2018/028116 vaccine treatement alone at the 22 week time point (Figures 13D and 13E). Notably, total HBV DNA levels dropped to less than one copy per cell as a result of the combination treatment (Figure 13D). Mice treated with the combined siRNA-vaccine protocol also demonstrated a significant decrease level of HBV 3.5 kb RNA expression relative to GAPDH RNA expression as compared to all other treatment regimens (Figure 13F). A significant decrease in total HBV RNA relative to GAPDH RNA expression was observed as compared to treatment with vaccine or siRNA alone (Figure 13G). These data suggest that a short course of administration of siRNA alone or a therapeutic vaccine against HBV is insufficient to durably suppress HBV infection. Immune mediated control of HBV after siRNA knockdown of HBV expression is long lasting. At 22 weeks after the last siRNA dose, the effect of the siRNA was waning as seen in the groups which had only received the HBV siRNAs without vaccination. Mice treated with the siRNA-vaccine protocol maintained HBV DNA and RNA suppression long after the end of siRNA administration.

No immune responses were observed in these fully immune competent mice under siRNA treatment alone, but vaccine treatment resulted in anti-HBs seroconversion in all vaccinated animals (Figures 14A and 14B). siRNA-pretreated animals, however, developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg. In contrast, anti-HBe seroconversion was only observed in antimals pretreated with HBV siRNAs. Interestingly, three of the 12 mice vaccinated after HBV siRNA treatment showed a transient relapse of HBeAg between week 15 and 22 co-inciding with decreased levels of anti-HBe (Figure 13C). Without being bound by mechanism, it is proposed that theHBeAg relapse was controlled by a memory immune response induced by the vaccine. Taken together, suppression of HBV antigen expression by an siRNA in combination with a heterologous prime-boost vaccine is sufficient to break immune tolerance to HBV antigens. The sequential therapy achieved long-term functional cure in a mouse model of persistent HBV infection without causing significant liver damage.

Figures 14A and 14B show that animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and anti-HBe antibodies. The level of anti-HBs antibodies continued to increase after the last vaccine dose. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were significantly lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies and achieved anti-HBe seroconversion. The combinatorial therapy using siRNA and vaccine appeared to be well tolerated. All mice equally gained weight and only a mild ALT elevation (<2-fold upper limit of normal) was observed (Figures 15A and 15B). The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A). These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. There was a steady increase in body weight in all animals throughout the experiment independent of siRNA treatment.

WO 2018/195165

PCT/US2018/028116

Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days and subsequently gained weight comparable to the control groups (Figure 15B).

Without being bound by mechanism, the data provided herein strongly suggest that the high level of HBV antigen expression routinely detected as circulating HBsAg and HBeAg prevents HBVspecific CD8+ T cell responses, which has far reaching consequences for future immune therapy of chronic hepatitis B. Using 2 different mouse models for chronic hepatitis B, it is proposed that HBVspecific immunomodulation can be reverted by suppressing HBV protein expression in hepatocytes using an RNAi-based therapy. Such reduction of HBV antigens by RNAi, in contrast to standard-of10 care nucleo(t)side analogues, allows for induction of strong HBV-specific CD8+ T cell responses by therapeutic vaccination that are required for control of HBV infection.

WO 2018/195165

PCT/US2018/028116

APPENDIX A

Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.

Abbreviation	Nucleotide(s)
A	Adenosine-3 ’ -phosphate
Af	2’ -fluoroadenosine-3 ’ -phosphate
Afs	2’ -fluoroadenosine-3 ’ -phosphorothioate
As	adenosine-3 ’ -phosphorothioate
C	cytidine-3 ’ -phosphate
Cf	2’ -fluorocytidine-3 ’ -phosphate
Cfs	2’ -fluorocytidine-3 ’ -phosphorothioate
Cs	cytidine-3 ’ -phosphorothioate
G	guanosine-3 ’ -phosphate
Gf	2’ -fluoroguanosine-3 ’ -phosphate
Gfs	2’ -fluoroguanosine-3 ’ -phosphorothioate
Gs	guanosine-3 ’ -phosphorothioate
T	5 ’ -methyluridine-3 ’ -phosphate
Tf	2’ -fluoro-5-methyluridine-3 ’ -phosphate
Tfs	2 ’ -fluoro-5 -methyluridine-3 ’ -phosphorothioate
Ts	5-methyluridine-3 ’ -phosphorothioate
U	Uridine-3 ’ -phosphate
Uf	2’ -fluorouridine-3 ’ -phosphate
Ufs	2’ -fluorouridine -3 ’ -phosphorothioate
Us	uridine -3’-phosphorothioate
N	any nucleotide (G, A, C, T or U)
a	2'-O-methyladenosine-3 ’ -phosphate
as	2'-O-methyladenosine-3 ’ - phosphorothioate
c	2'-O-methylcytidine-3 ’ -phosphate
cs	2'-O-methylcytidine-3 ’ - phosphorothioate
g	2'-O-methylguanosine-3 ’ -phosphate
gs	2'-O-methylguanosine-3 ’ - phosphorothioate
t	2’ -O-methyl-5 -methyluridine-3 ’ -phosphate
ts	2’-O-methyl-5-methyluridine-3’ -phosphorothioate
u	2'-O-methyluridine-3 ’ -phosphate
US	2'-O-methyluridine-3 ’ -phosphorothioate
s	phosphorothioate linkage

WO 2018/195165

PCT/US2018/028116

Abbreviation	Nucleotide(s)
L96	N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol Hyp-(GalNAc-alkyl)3
(dT)	2' -deoxythy midinc-3' -phosphate
Y34	2-hydroxymethyl-tetrahydrofurane-4-methoxy-3 -phosphate (abasic 2'-0Me furanose)
Y44	2-hydroxymethyl-tetrahydrofurane-5-phosphate
(Agn)	Adenosine-glycol nucleic acid (GNA)
(Tgn)	Thymidine-glycol nucleic acid (GNA) S-Isomer
(Cgn)	Cytidine-glycol nucleic acid (GNA)
P	Phosphate
VP	Vinyl-phosphate

WO 2018/195165

PCT/US2018/028116

Table 2. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in WO2016/077321, incorporated herein by reference)

Position in NC.003977.1

731.753

373.395

250.272

252.274

250.272

254.276

250.272

252.274

250.272

252.274

250.272

254.276

04 04 1 o in 04

SEQ ID NO:

263

264

265

266

267

268

269

270

04

272

273

04

275

276

04

278

279

280

281

282

283

284

285

SO oo 04

Antisense Sequence (5’ to 3’)

UACCACAUCAUCCAUAUAACUGA

UAAAACGCCGCAGACACAUCCAG

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGUCCACCACGAGU

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGUCCACCACGA

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGUCCACCACGAUU

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGUCCACCACGAUU

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGUCCACCACGA

UGAGAGAAGUCCACCACGAGUCU

Antisense Oligo Name

A-123464

A-123488

A-127897

A-127906

A-127925

A-127934

A-127942

A-127906

A-127926

A-127936

A-127906

A-127901

A-127906

A-127919

04 Os 04 <

A-127940

A-127903

A-127906

A-127920

A-127928

A-127938

04 OS 04 <

SEQ ID NO

47

CO

o>

50

in

52

cn DO

in

55

56

in

oo in

59

60

5

62

63

65

99

SO

68

69

O

Sense Sequence (5’ to 3’)

AGUUAUAUGGAUGAUGUGGUA

GGAUGUGUCUGCGGCGUUUUA

ACUCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCTCUCA

ACUCGUGGUGGACUUCUCUCA

UCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCUCUCA

GUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCUCUCA

UCGUGGUGGACUUCUCUCAUU

ACUCGUGGUGGACUUCUCUCA

UCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCUCUCA

UAUUUCCUAGGGUACAA

ACUCGUGGUGGACUUCUCUCA

Sense Oligo Name

A-123463

A-123487

A-127896

A-127909

A-127917

A-127905

A-127933

A-127944

A-127910

A-127918

A-127905

A-127935

A-127944

A-127900

A-127911

A-127905

A-127945

A-127902

A-127912

A-127905

A-126619

in OS 04 <

Duplex Name

AD-61522

AD-61547

AD-63938

AD-63939

AD-63940

AD-63941

AD-63942

AD-63943

AD-63945

AD-63946

AD-63947

AD-63948

AD-63949

AD-63950

AD-63951

AD-63952

AD-63953

AD-63955

AD-63956

AD-63957

AD-63958

AD-63959

AD-63960

5 Os cn so Q <

MEI 27037625V.1

100

WO 2018/195165

PCT/US2018/028U6

Position in NC_003977.1

252_274

250_272

250 272

254 276

258 280

SEQ ID NO:

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

312

313

rn © w © © s © 5 σ © © fi © fi

UGAGAGAAGUCCACCACGAUU

UGAGAGAAGUCCACCACGAGUCU

UGAGAGAAGTCCACCACGAGUCU

UGAGAGAAGUCCACCACGAGUCU

AAAUUGAGAGAAGUCCACCACGA

AAAUUGAGAGAAGUCCACC

Antisense Oligo Name

A-127904

A-127906

A-127921

A-127929

A-127940

A-127906

A-127922

A-127930

A-127942

A-127947

A-127906

A-127923

A-127931

A-127906

A-127924

A-127932

A-127940

A-127956

A-127977

A-127987

SEQ ID NO

C7

cn

74

r?

77

co

80

oo

82

cc oo

OO

IT) OO

86

OO

OO oo

89

06

©>

92

93

©>

95

96

rn © w © © s © 5 O' © © s ©

UCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCTCUCA

ACUCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCTCUCA

ACUCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCTCUCA

ACUCGUGGUGGACUUCUCUCA

ACUCGUGGUGGACUUCTCUCA

ACUCGUGGUGGACUUCUCUCA

GUGGUGGACUUCUCUCAAUUU

UGGACUUCUCUCAAUUU

Sense Oligo Name

A-127902

A-127913

A-127905

A-127939

A-127945

A-127905

A-127914

A-127905

A-127941

A-127946

A-127915

A-127905

A-127917

A-127943

A-127908

A-127916

A-127905

A-127917

A-127944

A-127961

A-127969

A-127955

A-127986

Duplex Name

AD-63962

AD-63963

AD-63964

AD-63965

AD-63966

AD-63967

AD-63968

AD-63969

AD-63970

AD-63971

AD-63972

AD-63973

AD-63975

AD-63976

AD-63977

AD-63978

AD-63979

AD-63980

AD-63981

AD-63982

AD-63983

AD-63985

AD-63986

AD-63987

AD-63988

MEI 27037625V.1

101

WO 2018/195165

PCT/US2018/028116

Position in NC_003977.1

254_276

256_278

254 276

256 278

254 276

256 278

254 276

258 280

254 276

256 278

254 276

Q go

IT)

SO

oo

OS

o

rq

cr

IT)

SO

OO

σ>

o

rq

cn

in

SO

OO

05

o

1 |

1 I

_t (

1 I

rq

cn

kJ

& z

cn

cr

cn

< ο υ < υ

cuu

CACGA

CAC

CACGA

cuu

CACGA

u

CACGA

cuu

< o u < u

CACGA

υ

u

<

υ

u

Φ

υ

u

<

H

ο

o

<

φ

ο

o

5

<

σ'

ο

o

&

<

φ

ο

o

g·

φ

<

Έ

<

a) 5

rq

so

o

oo

cr

so

OS

σ>

so

rq

o

in

so

cn

rq

oo

so

cr

IT)

in

oo

σ>

IT)

oo

o

tn

in

oo

σ>

in

oo

σ>

in

Μ /Γ 0)

05

os

Os

os

Os

os

Os

C5

05

<Λ Φ •-S w

CJ

<N

rq

cq

ο

<

ο οζ w a

οο

σ>

o o

o

cq o

cr o

o

IT) O

so O

o

oo o

OS O

o

T—<

cq

cn

in

<o

oo

05

o cq

cq

cq cq

cn cq

rq

κ

05

< <

uuuuu

AAUUU

uuu

AAUUU

uuu

AAUUU

uuu

< <

AAUUU

<

AAUUU

υ

<

U

<

U

<

U

<

u

U

(J

U

Ζ“S

<

cn

υ

u

<

u

(J

u

φ

<

υ

u

(j

u

Γη

H

u

H

S

υ

u

U

u

S

<

u

<

5

ο

u

o

u

o

u

o

u

o

σ'

ο

<

o

<

o

<

o

<

o

φ

o

u

o

ο

o

<

o

Ss

ο

o

C

o

%

ο

o

φ .2?

SO

o

rq

IT)

so

rq

cr

IT)

so

rq

in

o

so

in

o

so

σ>

in

so

IT)

oo

σ>

IT)

so

IT)

oo

σ>

in

st;

in

σ>

in

so

in

σ>

in

so

05

OS

os

Os

os

OS

os

Os

05

φ 3έ S §

CJ

<N

rq

cq

Β « Μ Ζ

<

σ>

o

rq

cr

IT)

so

σ>

o

rq

cn

in

so

oo

σ>

o

cq

cn

in

οο

σ>

o

σ>

o

1 I

_t (

1 I

_t (

05

os

σ\

o

cn

cr

>sj

kj

so

SO

so

SO

so

SO

so

α S S Λ

Q

Q Ζ

<

MEI 27037625V.1

102

WO 2018/195165

PCT/US2018/028U6

Position in NC_003977.1

254_276

254 276

256 278

254 276

1577 1599

215 237

214 236

256 278

2259 2281

1857 1879

1255 1277

375 397

1545 1567

1831 1853

245 267

1256 1278

207 229

Q

go

04

co

uo

SO

OO

Os

o

04

CO

uo

SO

OO

Os

o

04

CO

uo

SO

kJ

kj

kJ

kj

kJ

kj

uo

UO

uo

SO

so

SO

so

SO

c/j Z

co

<

u

<

o

u

<

u

o

u

o

L>

o

u

o

<

u

<

o

u

<

U

<

u

<

u

<

o

<

L>

o

<

o

<

u

o

<

o

<

o

u

o

<

u

<

U

o

<

u

<

u

ϋ

u

<

u

<f-

u

<

o

<

o

<

D

L>

u

<f-

<

o

u

o

<

u

o

O

L>

<

o

<

L)

u

o

©

u

<

D

o

u

o

<

O

L>

<

r'

u

H

u

H

u

<

D

u

<

(j

L>

<

o

<;

<

If)

o

D

<

L>

<

u

0

o

u

©

<

u

D

o

(j

u

o

<

(j

o

<

o

D

<

o

u

o

<

©

o

<

D

o

(J

o

u

o

<

(J

<

u

5

<

o

<

o

u

σ'

o

u

o

u

<

o

&

<

L>

<

o

D

u

o

<

u

<

D

©

o

<

L>

<

o

u

D

g·

D

o

<

L>

u

<

D

o

D

©

D

<

o

<

u

o

<

o

<

o

u

D

<

o

D

o

<

o

u

o

<

u

D

<

D

<

u

<

u

<

D

<

u

<

D

<

o

D

a) 5

rq

co

so

uo

co

so

uo

04

oo

so

o

so

o

so

oo

so

p-*

oo

Os

IT)

uo

p-*

oo

Os

uo

p-*

oo

O>

O

SO

p-*

OS

o

04

co

oo

os

1 I

04

co

so

Μ Z

Os

os

Os

os

OS

os

Os

os

OS

O

co

kJ

kj

kJ

co

kJ

kj

kJ

co

p-*

OO

oo

OO

oo

OO

oo

04

o

<

o oz

IT)

so

oo

Os

o

04

co

uo

so

oo

Os

o

04

co

uo

so

oo

Os

o

w a tn S

04

Γ4

04

co

uo

in

D

L>

D

L>

D

L>

D

o

L>

<

<f-

L>

u

<

D

L>

D

L>

D

L>

D

<

D

o

L>

o

<

D

<

L>

D

L>

D

L>

D

L>

D

u

D

u

U

o

<

<f-

U

D

o

<

D

<

U

<

D

L>

O

u

D

(J

L>

u

o

<

D

<

u

<

u

D

L>

<

o

D

L>

<

u

<

u

U

u

U

u

U

u

<

u

<

D

(J

O

o

<

/““S

D

L>

D

L>

D

L>

D

<

D

u

O

u

D

L>

o

<

rn

u

U

u

U

u

U

u

O

u

<

o

L>

D

u

U

©

D

L>

D

L>

D

L>

D

L>

u

D

L>

u

(j

U

o

<

u

U

u

U

u

U

u

L>

<

u

o

u

<

o

Q

L>

o

if)

D

H

D

H

D

H

D

U

<

D

u

o

O

U

L>

<

D

u

D

o

<

u

o

u

L>

o

u

D

s

u

U

u

U

u

U

u

D

u

<

D

<

L>

o

<

u

o

s

<

D

<

L>

<

D

o

<

D

U

L>

D

s

o

u

o

L>

<

u

o

u

o

u

(J

L>

u

<

D

σ

o

<

o

U

u

<

L>

u

<

o

u

©

D

o

D

<

o

L>

u

o

<

o

u

D

o

u

o

D

o

L>

o

Q

L>

<

u

D

Ss

o

D

o

D

L>

o

u

U

L>

o

D

c

D

o

D

o

U

u

U

u

L>

D

tn

o

D

o

D

<

D

<

u

o

D

u

D

IT)

oo

o

Os

uo

oo

o

oo

uo

o

co

CO

uo

Os

uo

Os

uo

IT)

so

Os

IT)

so

uo

so

o>

so

uo

oo

0's

o

so

p-*

os

o

04

co

p-*

os

o

04

co

so

Ό

Os

os

Os

os

Os

os

o

co

<u

p-*

oo

OO

oo

OO

oo

1 §

04

B « n z

<

SO

oo

Os

o

04

co

uo

so

oo

04

uo

so

oo

Os

o

04

co

uo

1 I

_t (

04

p-*

oo

X

o

O

o

O

o

O

o

04

SO

Λ s

S Λ

Q

Q Z

<

MEI 27037625V.1

103

WO 2018/195165

PCT/US2018/028116

Position in NC_003977.1

426_448

206_228

1829 1851

226 248

212 234

1814 1836

2828 2850

253 275

411 433

370 392

405 427

210 232

734 756

405 427

1577 1599

216 238

1864 1886

401 423

410 432

425 447

1547 1569

04 04

2298 2320

1250 1272

215 237

214 236

256 278

Q

go

οο

cr

Ο

04

CO

Ό

SO

ΟΟ

σ\

Ο

04

CO

uo

SO

OO

σ>

o

04

CO

so

οο

ΟΟ

οο

oo

OO

oo

OO

oo

OS

Os

os

σ>

c/j Z

CO

co

<

υ

Ο

<

Ο

<

(J

<

υ

<

o

<

u

<

o

u

ο

υ

<

ο

<

ο

<

u

o

<

o

u

<

υ

ο

<

ο

υ

ο

<

υ

<

o

u

<

u

<

ο

<

ϋ

υ

ο

<

o

<

u

ο

<

υ

ο

<

υ

<

υ

ο

<

ο

υ

u

<

u

<

ϋ

<

υ

ο

<

ϋ

o

u

o

<

o

u

<

u

<

ο

<

ο

υ

<

(J

<

υ

o

<

o

<

o

u

ο

<

ο

<

υ

ο

υ

(J

ο

<

o

©

<

ο

υ

<

υ

ο

<

ΰ

ο

<

o

u

o

u

o

<

υ

<

(J

<

o

<

1/4

υ

<

ο

<

υ

<

υ

<

υ

ο

<

u

<

u

<

Φ

<

υ

ο

<

υ

<

ο

<

(J

ο

4

υ

ο

υ

o

u

o

u

o

<

ο

υ

<

υ

<

Ο

<

ο

<

u

o

<

o

<

o

<

©

υ

<

ο

<

ο

υ

4

<

υ

<

o

<

u

<

o

u

<

o

5

υ

ο

<

ο

υ

ο

<

o

<

u

o

u

<

u

o

u

o

<

σ'

<

ο

<

υ

<

ο

<

u

o

u

o

<

o

<

o

&

<

ο

<

ο

υ

o

<

o

<

o

©

ο

<

ο

<

υ

<

υ

<

ο

u

o

<

o

u

o

<

g·

<

υ

ο

<

υ

ο

<

υ

<

υ

ο

o

u

<

o

<

©

<

υ

<

υ

ο

Ο

ο

<

o

<

o

<

o

<

ο

<

υ

ο

<

υ

ο

Ο

<

ο

<

o

<

o

<

o

<

ο

<

o

<

o

<

o

<

ο

<

a) 5

04

οο

ο

so

οο

04

οο

ο

o

04

so

04

so

04

uo

co

ΟΟ

so

οο

ο

1 |

kJ

οο

_t 1

04

kj

_t 1

co

kJ

o

04

co

Os

o

04

co

kJ

uo

so

Μ Z

CO

co

kJ

CO

co

kJ

kj

CO

kJ

CO

kJ

kj

kJ

CO

co

kJ

kj

kJ

kj

οο

ΟΟ

οο

ΟΟ

οο

OO

oo

OO

oo

OO

oo

04

o

<

o oz

04

co

υο

so

οο

σ\

ο

04

co

υο

so

oo

σ>

o

04

co

uo

so

oo

w a tn S

UO

to,

UO

υο

ΙΟ,

Ό

υο

<ο

<o

c

<

υ

<

υ

Μ

u

<

υ

<

ο

υ

<

ο

υ

Μ

υ

<

u

<

u

<

ο

<

ο

υ

<

υ

<

υ

<

u

(J

u

<

ό

υ

ο

υ

ο

υ

u

<

u

<

o

i)

<

u

υ

<

υ

<

ο

<

Ο

υ

<

o

u

o

<

u

<

υ

<

ο

<

u

<

rn

<

υ

<

υ

ο

<

υ

u

o

u

o

u

(J

u

©

ο

υ

<

υ

<

ο

υ

u

o

u

o

<

u

ο

υ

<

υ

ο

<

ο

u

i)

o

u

o

<

u

υ

<

υ

ο

υ

<

υ

o

u

<

u

ο

υ

<

υ

ο

υ

<

ο

υ

ο

<

u

<

o

u

o

u

<

u

ς>

ο

υ

<

υ

ο

<

ο

υ

<

o

<

u

s

<

ο

<

u

<

u

<

5

υ

<

υ

ο

<

ο

υ

ο

υ

<

u

o

u

o

u

<

u

<

u

σ

υ

<

υ

ο

<

υ

Ο

ο

υ

<

u

<

υ

<

ο

<

u

<

u

<

o

υ

ο

<

ο

υ

ο

<

υ

<

u

o

u

o

u

o

υ

ο

υ

<

ο

4

υ

ο

o

<

u

s

υ

ο

<

u

<

u

o

<

ο

υ

ο

υ

ο

<

u

o

Φ .2f

co

σ>

co

σ\

σ>

υο

σ>

co

Os

uo

co

οο

so

οο

σ\

1 |

co

so

οο

1 |

04

kJ

1 |

04

kJ

o

1 I

co

Os

o

04

co

so

os

Ό

CO

co

kJ

co

kJ

kj

kJ

CO

kJ

kj

kJ

CO

kJ

CO

co

kJ

kj

kJ

co

CO

co

<u ©

οο

ΟΟ

οο

ΟΟ

οο

ΟΟ

οο

oo

OO

oo

OO

oo

1 §

04

Β « <η Ζ

<

so

σ>

ο

04

co

υο

οο

σ>

ο

04

co

uo

oo

σ>

o

04

co

uo

so

οο

σ>

ο

σ>

ο

Ο

ο

o

1 I

_t 1

1 I

_t 1

1 I

X

04

co

CO

co

Φ 0)

SO

Λ s

3 Λ

Q

Q Ζ

<

MEI 27037625V.1

104

WO 2018/195165

PCT/US2018/028U6

Position in NC_003977.1

2259_2281

2259 2281

1857 1879

1255 1277

731 753

375 397

1545 1567

1831 1853

245 267

1256 1278

426 448

263 285

250 272

1577 1599

206 228

1829 1851

226 248

212 234

254 276

1814 1836

2828 2850

04

411 433

370 392

405 427

210 232

373 395

Q go

UO

ΟΟ

©>

Ο

οι

CO

υο

ΟΟ

©>

Ο

ΟΙ

CO

uo

<C>

OO

©5

o

©5

ο

Ο

ο

Ο

ο

Ο

ο

1 |

_t (

1 I

_t (

1 I

Ol

c/j Z

CO

< ο < ο

AGAC

GAGG

CUGA

AUCC

GGAG

1CGAG

GACU

AGAG

AUGA

AAGU

GUCU

υ < υ <

ACCC

AGAG

GAUU

< < ο <

ACGA

< u o

CCAA

GAGG

< o o <

< o u

AAGA

vvvv

CCAG

< <

< U

< υ

< <

υ <

Ο Ο

<

U Ο

AG

Ο <

< Ο

υ ο

< <

υ Ο

Ο <

< υ

U u

u

AU

u o

< (J

UG

o <

<

ο

υ

ο

<

Ο

υ

<

Ο

<

o

O

<

Q

<

u

<

ο

<

υ

Ο

<

ο

<

u

<

o

<

u

O

u

<

w

(J

ο

υ

ο

<

ο

<

ο

υ

<

Ο

ο

υ

u

<

o

<

o

<

u

0

<

Ο

<

υ

<

O

<

u

<

υ

ο

υ

<

ο

<

ο

o

<

u

<

u

o

υ

ο

υ

ο

<

υ

ο

<

υ

ο

<

u

o

<

ο

υ

Ο

<

υ

ο

<

υ

<

o

u

<

o

u

υ

ο

<

υ

ο

<

υ

<

υ

<

ο

o

u

o

<

o

u

o

5

<

υ

ο

υ

<

ο

<

υ

ο

<

o

<

o

<

o

u

Φ

υ

ο

υ

<

ο

<

ο

<

ο

υ

<

o

u

<

u

<

u

Ή

υ

ο

<

υ

<

ο

<

o

u

o

Φ

<

υ

<

ο

υ

ο

υ

<

ο

o

<

u

<

u

β

<

υ

<

υ

ο

<

υ

<

ο

<

υ

ο

u

<

u

<

u

<

ο

υ

<

ο

<

ο

υ

<

υ

ο

<

υ

<

u

o

(7

o

<

ο

υ

ο

<

υ

ο

υ

<

ο

<

υ

ο

<

o

<

U

o

<

Έ

υ

<

υ

<

υ

ο

<

o

<

ο

υ

<

i a) 5

©>

CO

οι

ο

οο

υο

οο

οι

oo

<©

©5

uo

co

©5

o

<©

οο

kJ

UO

οο

υο

ο

οο

kJ

υο

<©>

uo

oo

kJ

<c>

oo

uo

<c>

Εί f·

kJ

©5

kJ

©5

kJ

οο

ΟΟ

οο

ΟΟ

οο

ΟΟ

οο

ΟΟ

oo

OO

oo

OO

oo

*d

οι

ΟΙ

οι

ΟΙ

οι

ΟΙ

οι

04

Ol

ο

<

ο οζ

©5

ο

οι

co

υο

οο

©>

ο

οι

co

υο

oo

©>

o

Ol

co

uo

w ο

οο

ΟΟ

οο

©5

©>

©5

©>

©5

o

κ

Ol

<

<c

υ

<

<!

Ο

<

ο υ

υ ο

ο ο υ

ο ο

<

< (J

< υ

CUU

< ο ο

UCU

GGG

CUC

2) υ

< < <

GUU

ο <

UCA

AUU

u u o

CAU

CUU

u

o u

u u

uuu

<

ο

1—^

<

υ

3

Ο

υ

<

ο

υ

<

o

3

o

3

<

ο

(J

ο

υ

<

υ

<

υ

u

<

o

<

o

/*“S

ο

υ

ο

<

υ

u

o

u

<

u

co

ο

υ

<

ο

υ

<

u

<

o

<

o

©

ο

υ

(j

υ

ο

<

ο

υ

ο

υ

<

u

<

o

ο

υ

<

ο

ΰ

ο

<

υ

<

u

<

u

o

<

u

υη

ο

υ

<

ο

Ο

υ

<

ο

υ

<

u

o

u

o

ο

υ

ο

υ

i)

ο

υ

ο

υ

<

o

u

<

u

©

<

ο

<

υ

ο

<

υ

<

υ

u

o

<

o

u

S

ο

<

υ

<

ο

<

u

o

5

ο

<

υ

<

υ

ο

υ

<

υ

ο

o

<

u

o

σ

υ

<

ο

υ

<

o

u

o

<

u

o

©

υ

<

ο

<

ο

υ

ο

<

υ

u

<

u

o

ο

υ

<

υ

ο

o

<

u

o

<

u

ο

υ

ο

υ

ο

υ

o

<

o

<

o

u

<

S

ο

υ

u

o

u

o

$

<

υ

ο

υ

<

ο

υ

o

u

o

CO

ίο,

co

©5

υο

©>

υο

co

©>

co

uo

©5

©>

uo

ο

οι

co

©5

ο

οι

co

οο

1 |

ο

οο

©5

_t (

uo

CO

<c>

o

1 I

Ol

kJ

oo

ο

CO

co

©5

ο

co

CO

©5

co

CO

<u Φ

οο

co

ΟΟ

οο

ΟΟ

οο

OO

oo

OO

co

1 §

οι

ΟΙ

οι

04

Ol

$ Ζ

<

οο

©5

ο

οι

co

υο

οο

ο

οι

co

υο

oo

©5

Ol

co

uo

7—Η

τ—Η

οι

co

CO

X

CO

co

CO

co

CO

co

Φ 0)

α S S Λ

Q

Q Ζ

<

MEI 27037625V.1

105

WO 2018/195165

PCT/US2018/028116

Position in NC_003977.1

734_756

405_427

1577 1599

216 238

1174 1196

1864 1886

401 423

410 432

425 447

1547 1569

04 04

2298 2320

1250 1272

250 272

Q go

04

co

uo

SO

OO

O'

o

04

co

uo

SO

OO

Os

o

04

CO

uo

SO

OO

04

co

CO

co

CO

co

kJ

kj

kJ

kj

kJ

tn Z

d^-

u

<

u

<

o

<

u

<

o

<

u

o

<

o

u

<

u

<

o

D

o

ϋ

o

u

<

o

D

o

u

o

<

o

u

<

u

<

o

1—/

o

u

o

<

o

<

o

u

o

<

o

<

o

u

o

u

o

<

w

u

o

<

u

o

u

o

u

o

u

<

o

u

o

<

u

<

u

o

<

D

<

u

<

u

<

u

o

u

<

o

u

o

u

ϋ

u

©

Σ)

<

o

<

u

o

<

o

<

o

u

C )

u

C )

u

C )

u

0)

<

u

<

o

<

u

<

o

u

H

u

H

u

H

u

5

u

o

<

o

<

u

o

u

<

u

o

d

o

σ'

<

o

<

u

o

u

o

<

o

<

u

D

o

<

o

<

u

<

o

u

o

<

o

u

o

gj

<

u

o

u

o

u

<

o

<

D

o

<

o

<

o

<

o

D

<

o

<

o

<

fi

<

D

<

o

<

o

<

o

D

<

D

a) 5

o

OO

Os

O\

uo

04

o

OO

so

04

so

uo

O'

so

OO

so

uo

so

O'

OO

uo

so

OO

UO

SO

so

OO

o

OO

os

OO

o

OO

O\

OO

O\

o

OO

kJ

kj

kJ

kj

kJ

kj

kJ

Os

co

O\

co

O\

co

OO

O'

04

o

<

o oz

SO

OO

O'

o

04

co

uo

so

OO

Os

o

04

co

uo

so

OO

O'

o

04

w a

o

1 I

_t (

1 I

_t (

1 I

_t (

1 I

04

co

CO

c/j K

04

<

u

<

c

<

<!

<

< o o

AUGCCU

ACCUCU

CACAAU

ACGCAA

UGCCUU

UGCUAU

D u < u

uucuuc

UCAUCU

UGGUUC

D u <

u < < u u

ucucuc

UCACUC

u D u < u

UCACUC

ucucuc

u D u H u

ucucuc

u D u < u

ucucuc

co

1—/

u

3

O

o

u

o

u

(J

3

©

o

u

D

u

o

u

o

u

<

u

o

u

o

D

Σ)

u

o

<

u

o

u

D

u

H

o

H

o

H

o

u

o

<

u

<

u

<

o

u

o

u

o

O

o

O

o

©

o

u

<

D

<

D

o

u

H

u

H

u

H

u

c

<

D

<

D

u

<

u

D

<

o

5

o

u

D

<

o

u

o

u

o

u

<

u

o

©

o

u

<

D

<

D

u

<

u

o

u

D

u

<

u

o

<

u

<

u

o

u

o

<

o

<

D

s

<

u

<

u

<

u

tn

D

o

D

u

<

u

o

<

O'

co

O'

co

O\

uo

co

Os

uo

so

o

uo

04

co

uo

1 I

04

kJ

OO

o

1 I

co

Os

o

04

co

o

OO

o

OO

o

Ό

kJ

kj

kJ

CO

co

kJ

CO

co

kJ

kj

kJ

CO

Os

CO

co

O\

co

CO

co

O\

<u ©

OO

Os

O'

1 §

04

B « n Z

<

OO

Os

o

04

co

uo

so

OO

Os

o

04

co

uo

so

OO

O'

o

04

uo

UO

uo

UO

uo

SO

o

O

o

X

co

SO

a S S Λ

Q

Q Z

<

MEI 27037625V.1

106

WO 2018/195165

PCT/US2018/028116

Position in NC_003977.1

250_272

250 272

Q

go

Os

o

04

CO

tn

s©

OO

Os

o

04

CO

tn

SO

OO

Os

o

04

CO

tn

kj

uo

irj

uo

irj

uo

lOj

uo

SO

Μ z

d·

d^-

u

o

<

o

u

<

w

C )

o

C )

u

C )

o

u

C )

u

o

u

C )

u

o

u

C )

u

C )

u

<

u

©

C )

u

C )

u

C )

u

C )

u

C )

u

C )

u

C )

u

C )

0)

H

u

H

u

H

u

H

u

H

u

H

u

H

u

H

5

o

σ'

<

φ

<

o

gj

<

o

<

fi

o

i a) 5

UO

so

o

tn

so

oo

Os

so

04

tn

Os

so

tn

co

oo

Os

so

Os

OO

Os

o

OS

oo

Os

o

os

OO

Os

o

Os

oo

OO

Os

o

oo

os

OO

o

oo

co

Os

co

Os

co

Os

co

Os

co

Os

co

Os

OS

Os

OS

Os

OS

Os

OS

Os

OS

*d w

04

o

<

o oz

co

UO

so

oo

Os

o

04

co

tn

so

oo

Os

o

04

co

tn

so

oo

Os

w a

co

kJ

kj

kJ

kj

kJ

kj

uo

tn

UO

uo

tn

uo

tn

uo

c/j K

04

<

u

<

u

(J

u

C )

(J

u

C )

u

C )

u

(J

u

C )

(J

u

<

u

H

u

H

<

H

u

H

u

<

u

H

<

u

H

o

u

(J

u

(J

u

/““S

rn

©

u

(j

u

(j

u

<

un

o

H

o

H

o

O

o

O

o

©

H

s

o

O

o

O

o

5

o

O

o

O

o

σ

(Λ

o

u

<Λ

S

u

%

<

UO

s©

04

tn

04

tn

co

so

tn

Os

so

tn

Os

04

oo

tn

O

oo

o

1 I

oo

1 I

oo

o

Os

oo

o

Os

oo

o

Ό

OS

co

Os

co

Os

co

Os

co

Os

co

Os

<u ©

OS

Os

OS

Os

OS

Os

OS

Os

OS

1 §

04

$ Z

<

co

UO

so

oo

Os

o

04

co

tn

so

oo

Os

o

04

co

tn

so

oo

Os

o

f—

—

f—

—

04

co

3

Λ s

S Λ

Q

Q Z

<

MEI 27037625V.1

107

WO 2018/195165

PCT/US2018/028116

Position in NC_003977.1	250_272	250_272	250 272
Q io	SO	Γ-»,	OO
Z
	D	D	D
	u	u	u

	o	o	o
	<	<	<
	o	o	o
co	u	u	u
©	<	<	<
w	C )	C )	u
	u	u	u
	<	<	<
0)	u	u	u
	u	u	u
0)	H	H	D
5	o	o	o
σ'	<	<	<
to	<	<	<
0)	o	o	o
gj	<	<	<
	o	o	o
	<	<	<
fi	o	o	o
	D	D	D
i flj SS		un	O'
5 ^z	os co	oo co	oo co
	O'	O'	O'
d w	04	04	04
1 o	<	<	<
o oz w a	o SO		04 kO
to K	04	04	04
	<	<	<
	u	u	u
	u	u
	u	u	u
	D	D	<
	u	u	u
/““S	D	D
co	D	D
Φ	u	u	u
	<	<	<
un	o	o	o
	o	o	o
	u	u	H
fi	o	o	o
5	o	o	o
σ	D	D	D
	o	o	o
	u	u	u
	D	D	D
S	u	u	u
to	<	<	<
Φ .2f	un	co
o	o OS	co	oo co
<u 4)		O'	O'
β 1 η> Λ $ z	04 <	04 <	04 <
		04	ζ·
X
4) 4)	SO	kD	kD
α € S Λ	Q	Q	Q
Q Z	<	<	<

SEQ ID NO:

694

695

696

697

698

699

700

o

702

703

o

705

706

o

708

709

o

Antisense Sequence (5’ to 3’)

usAfscCfaCfaUfcAfuccAfuAfuAfaCfusgsa

usAfsaAfaCfgCfcGfcagAfcAfcAfuCfcsasg

UGAGAGAAGUCCACCACGAGUCU

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsaGfagaAfguccaCfcAfcgaGfuscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfasgsu

usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsaGfagaagUfccaCfcAfcgaGfuscsu

usGfsaGfaGfaAfgUfccaCfcAfcsgsa

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsasGfaGfaAfgUfcCfaCfcAfcGfausu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsaGfaGfaagUfccaCfcAfcGfaGfuscsu

usGfsagagaAfgUfccaCfcAfcgaguscsu

Antisense Oligo Name

A-123464

A-123488

A-127897

A-127906

A-127925

A-127934

A-127942

A-127906

A-127926

A-127936

A-127906

A-127901

A-127906

A-127919

CN Os <

SEQ ID NO:

05

480

482

483

485

486

488

489

490

o>

492

493

o>

495

Sense Sequence (5’ to 3’)

AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96

GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96

Y44ACUCGUGGUGGACUUCUCUCA

ascsucGfuGfgUfGfGfaCfuucUfcucaL96

ascsucguggugdGacuuc(Tgn)cucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

so Os d £ £ d o S S ^Οΰ O d o Q 3

ascsucGfuGfguGfGfaCfuucucucaL96

SO Os U £ Q d u s S o u Q Q

ascsucguGfgUfGfGfacuuCfucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

SO Os d £ £ £ d o d s s o

ascsucGfuGfguGfGfaCfuucucucaL96

Y 44UfcGfuGfgUfgGfaCfuU fcUfcU fc Afusu Y 44

ascsucguGfgUfGfGfaCfuucucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

Sense Oligo Name

A-123463

A-123487

A-127896

A-127909

A-127917

A-127905

A-127933

A-127944

A-127910

A-127918

A-127905

A-127935

A-127944

A-127900

A-127911

A-127905

Duplex Name

AD-61522

AD-61547

AD-63938

AD-63939

AD-63940

AD-63941

AD-63942

AD-63943

AD-63945

AD-63946

AD-63947

AD-63948

AD-63949

AD-63950

AD-63951

AD-63952

AD-63953

108

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

711

<N

CD

714

<o

717

oo

os

720

gj

722

723

gd

725

726

gj

728

729

730

g2

732

cc g2

g2

735

736

Antisense Sequence (5’ to 3’)

usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu

usGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsagaGfaAfgUfccaCfcAfcgaGfuscsu

usGfsaGfagaAfguccaCfcAfcgaguscsu

PusGfsaGfaGfaAfgUfccaCfcAfcsgsa

usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu

PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsaGfaGfaAfgUfccaCfcAfcgaguscsu

usGfsagaGfaaGfuccaCfcAfcgaguscsu

2 o O ^+3 y o Q Q o ^+3 W) O 3

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsagaGfaagUfccaCfcAfcgaGfuscsu

2 Q 3 < O Q Q Sf3 O OS O 3

usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu

usdGsaGfaGfaAfgdTccadCcAfcGfaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsagaGfaAfgUfccaCfcAfcgaguscsu

usdGsagagaaguccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

Antisense Oligo Name

A-127940

A-127903

A-127906

A-127920

A-127928

A-127938

A-127942

A-127904

A-127906

A-127921

A-127929

A-127940

A-127906

A-127922

A-127930

A-127942

A-127947

A-127906

A-127923

A-127931

A-127906

SEQ ID NO:

496

s>

498

499

500

501

502

503

504

505

506

507

508

509

510

512

513

515

516

518

519

520

521

Sense Sequence (5’ to 3’)

ascsucgugguGfGfacuucucucaL96

Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44

ascsucguGfgUfGfGfacuucucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

SO 05 d < o O < d y y 3

ascsucgugguGfGfacuucucucaL96

Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44

ascsucguggUfgGfacuucucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

so OS Q d o d o d u g o u d o Q

ascsucgugguGfGfacuucucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugGfacuucucucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

SO Os Q u u 1 £ s o 3 o £ o o cd

ascsucguggudGdGacuucucucaL96

ascsucguggUfgGfacuuc(Tgn)cucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugdGacuuc(Tgn)cucaL96

ascsUfcGfuGfguGfGfaCfuUfcUfcUfcaL96

ascsucGfuGfgUfGfGfaCfuucUfcucAfL96

Sense Oligo Name

A-127945

A-127902

A-127912

A-127905

A-126619

A-127945

A-127902

A-127913

A-127905

A-127939

A-127945

A-127905

A-127914

A-127905

A-127941

A-127946

A-127915

A-127905

A-127917

A-127943

A-127908

Duplex Name

AD-63955

AD-63956

AD-63957

AD-63958

AD-63959

AD-63960

AD-63961

AD-63962

AD-63963

AD-63964

AD-63965

AD-63966

AD-63967

AD-63968

AD-63969

AD-63970

AD-63971

AD-63972

AD-63973

AD-63975

AD-63976

AD-63977

AD-63978

AD-63979

MEI 27037625V.1

109

WO 2018/195165

PCT/US2018/028U6

SEQ ID NO:

cn

738

739

o

741

Cjl

cn

744

tn

SO

747

cc

o>

750

jn

752

753

tri

755

756

!ri

758

759

760

so

762

Antisense Sequence (5’ to 3’)

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGfsaGfagaAfgUfccaCfcAfcgaGfuscsu

PusdGsagagaaguccadCcacgaguscsu

o O y o Q Q o O 3

< U o O O O d λ <

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

asAfsaUfugagaGfaagUfcCfaccAfcsgsa

asAfsaUfuGfaGfaGfaagUfcCfascsc

asAfsAfUfuGfaGfaGfaagUfcCfaCfcacsgsa

as AfsasU fuGfaGfaGfa AfgU fcCfaCfcusu

< U o o o o d OS <

asAfsaUfuGfagaGfaagUfcCfaCfcAfcsgsa

asAfsauugaGfaGfaagUfcCfaccacsgsa

PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc

asAfsAfuuGfaGfaGfaagUfCfcaCfcacsgsa

as AfsaU fuGfaGfaGfa AfgU fcCfaCfcsusu

d < U d o d W) d o d o d o d λ

asAfsaUfugaGfagaagUfcCfaccacsgsa

Pas AfsaUfuGfaGfaGfaagUfcCfascsc

asAfsAfUfuGfaGfaGfaagUfCfcaCfcacsgsa

Pas AfsaU fuGfaGfaGfa AfgUfcCfaCfcsusu

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

asAfsaUfuGfaGfaGfaagUfcCfaccacsgsa

asAfsauuGfagAfgaagUfcCfaccacsgsa

asAfsaUfuGfaGfaGfaagUfcCfaCfcacsgsa

asAfsAfUfugaGfaGfaagUfCfcaCfcacsgsa

Antisense Oligo Name

A-127906

A-127924

A-127932

A-127940

A-127956

A-127977

A-127987

A-127992

A-127951

A-127956

A-127970

A-127978

A-127988

A-127993

A-127953

A-127956

A-127979

A-127989

A-127994

A-127954

A-127956

<N OS <N <

A-127980

A-127991

A-127995

SEQ ID NO:

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

tri

542

543

tri

545

546

tri

Sense Sequence (5’ to 3’)

ascsucguggugGfacuuc(Tgn)cucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugdGacuuc(Tgn)cucaL96

ascsucGfuGfguGfGfaCfuucucucaL96

gsusggugGfaCfUfUfcUfcucAfauuuL96

gsusggugGfaCfU fU fcucuCfaauuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

SO Os d d < £ £ u o 3

gsusgguggacUfUfcucucaauuuL96

Y44GfgUfgGfaCfuUfcUfcUfcAfaUfuUfusuY44

gsusggugGfaCfUfUfcUfcucaauuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

SO Os d d d < d d d £ £ £ o

gsusgguggacUfUfcucucaauuuL96

Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44

gsusggugGfaCfU fU fcucucaauuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

SO Os d d d d d d £ £ o 3

gsusgguggacUfUfcucucaauuuL96

Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44

gsusgguggaCfuUfcucucaauuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96

gsusgguggacUfUfcucucaauuuL96

Sense Oligo Name

A-127916

A-127905

A-127917

A-127944

A-127961

A-127969

A-127955

A-127986

A-127996

A-127950

A-127962

A-127955

A-127984

A-127996

A-127952

A-127963

A-127955

A-127986

A-127996

A-127952

A-127964

A-127955

A-127990

A-127996

Duplex Name

AD-63980

AD-63981

AD-63982

AD-63983

AD-63985

AD-63986

AD-63987

AD-63988

AD-63989

AD-63990

AD-63991

AD-63992

AD-63993

AD-63994

AD-63995

AD-63996

AD-63997

AD-63999

o o o SO Q <

AD-64001

AD-64002

AD-64003

AD-64004

AD-64005

AD-64006

AD-64007

MEI 27037625V.1

110

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

763

765

766

so

768

769

o

771

CN

cn

774

SO

777

[S

OS

780

oo

782

783

785

786

[S

788

Antisense Sequence (5’ to 3’)

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

< U o O O O λ <

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

asAfsauuGfagaGfaagUfcCfaccAfcsgsa

asAfsauuGfagagaagUfcCfaccacsgsa

asAfsAfUfuGfaGfaGfaagUfcCfaCfcacsgsa

asdAsAfuugaGfaGfaagdTdCcaCfcacsgsa

PasAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

< U o O O ^+3 O λ

asAfsauuGfaGfaGfaagUfcCfaccacsgsa

asdAsauugagagaagdTccaccacsgsa

asAfsAfuuGfaGfaGfaagUfCfcaCfcacsgsa

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

< 43 U Sf3 o £) O s£3 O Sf3 O λ

asAfsaUfugaGfaGfaagUfcCfaccAfcsgsa

PasdAsauugagagaagdTccaccacsgsa

asAfsAfUfuGfaGfaGfaagUfCfcaCfcacsgsa

asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

< 43 U Sf3 o £) W) O s£3 O Sf3 O λ

asAfsaUfugaGfagaagUfcCfaccAfcsgsa

asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc

asAfsAfUfugaGfaGfaagUfCfcaCfcacsgsa

u £ 43 O O W) u s£3 O d o W) u

asUfsuGfuGfaGfgAfuuuUfuGfuCfaAfcsasa

usUfsgUfgAfgGfaUfuuuUfgUfcAfaCfasasg

usAfsaAfaUfuGfaGfagaAfgUfcCfaCfcsasc

Antisense Oligo Name

A-127956

A-127973

A-127981

A-127992

A-127998

A-127958

A-127956

A-127974

A-127982

A-127993

A-127956

A-127975

A-127983

A-127994

A-127956

A-127976

A-127985

A-127995

A-128002

A-128364

A-128378

A-128394

SEQ ID NO:

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

tn

572

573

Sense Sequence (5’ to 3’)

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusgguggacuUfcucucaauuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96

gsusgguggacdT dT cucucaauuuL96

Y44GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusgguggaCfuUfcucuc(Agn)auuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusgguggacudTcucuc(Agn)auuuL96

SO Os 1 § < 43 £ £ £ O U Q Op o

gsusggUfgGfaCfUfUfcUfcucAfauuUfL96

gsusgguggacuUfcucuc(Agn)auuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

gsusgguggacudTcucuc(Agn)auuuL96

SO Os 1 § < 43 D 43 D 43 £ £ 42 O U O Op o

gsusggUfgGfaCfUfUfcUfcucAfauuuL96

gsusgguggacudTcucuc(Agn)auuuL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

SO Os d d £ £ £ £ £ 42 O

gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96

GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96

GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96

UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96

GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96

Sense Oligo Name

A-127955

A-127965

A-127955

A-127990

A-127997

A-127957

A-127966

A-127955

A-127968

A-127990

A-127959

A-127967

A-127955

A-127968

A-127990

A-127960

A-127968

A-127955

A-127984

A-127990

A-128001

A-128363

A-128377

A-128393

Duplex Name

AD-64008

AD-64009

AD-64010

AD-64011

AD-64012

AD-64013

AD-64014

AD-64015

AD-64016

AD-64017

AD-64018

AD-64019

AD-64020

AD-64021

AD-64022

AD-64023

AD-64024

AD-64025

AD-64026

AD-64027

AD-64028

AD-64272

AD-64274

AD-64275

AD-64276

MEI 27037625V.1

111

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

789

790

os

792

793

o>

795

796

OS

798

799

800

801

802

803

804

805

806

807

808

809

810

OO

812

813

OO

P)

PC

P)

ΡΌ

PJO

2

PJO

P)

cd

P)

PC

cd

2

cd

PC

cd

P)

cd

P)

cd

Cd

Pi

u

c3

P)

cd

P)

Pi

P)

cd

©

cd

01

Pl

cd

Pl

cd

PJ

5’ to 3’)

^+3 o <

s£3 o s2 <

d> < d o d

fgCfaGfas

d < d < d

d> o d> o d

d O d < _fp

'cUfaGfas

d < d O d

faAfaAfas

y < < cd

faAfaAfcs

fgGfcAfg:

fgAfgGfa

faCfaAfg:

O y P _rM

d O d d

fcCfaGfcs

d d O d

d < d u

d d d

d < PC y d

d P d P cd

d d d

d d O d

fgUfcAfa

y pj

< d>

o d

< _fPi

< Ρΰ

P d

Ρΰ

O d

O ,cd

o ,cd

< .PC

< d

d

< d

,cd

o d

< d

d _foc

P

o _fPC

o d

o _fPC

faG

□ d

0) 5

O

P)

p Cd Pi)

< P)

acAl

o

< Ρΰ

PC PC

P) cd

< P)

caAl

P cd PD

cd

PC

cd

d P)

O PC

auA:

u cd

u Pl

uc A

P cd

P) Pl

< PC P)

©*

^+3

si3

_fPp

_rPi

d

_fPi

cd

d

,cd

d

_fPi

d

d>

d

&

u

d

p

u

o

<

u

o

P

p

o

<

o

u

P

<

u

<

<0

0)

,cd

d

Ρΰ

_rPi

d

y

d

y

_rPi

d

d>

d

y

d

c

u

o

p

u

<

o

P

o

P

<

u

<

P

y

<

o

<

0)

£

_fPp

,P1

d

,C3

d

,cd

d

M)

_fPA

d

,cd

d

PC

_f01

d

ts

p

y

<

o

u

P

o

P

o

5

P

u

y

P

u

y

P

fi

,cd

_fp

d

,C3

d

_fp

_rPJL

d

_fp

,cd

d

_fPC

,cd

d

y

u

d

<

o

u

P

u

P

u

o

P

o

P

o

y

P

-S?

_pp

_P)

d

-S?

d

-PC

d

-PC

d

-Pp

-pp

d

-Pp

d

u

y

Q

<

P

o

y

C3

ώ

cd

PC

a) g fi Λ

OO

so

o

so

O

so

OO

so

04

OO

o

O

o

SO

so

OO

04

OO

o

Z

o

04

co

OO

os

H

04

co

so

OO

so

OO

o

H

OO

04

co

>sj

co

>sj

co

>sj

co

>sj

co

tS ©

OO

S M

04

A Oli

y

A-l

y

A-l

O' Q

DO

so

OO

Os

o

04

CO

DO

SO

OO

0's

o

04

CO

DO

SO

OO

Os

W Q

p·*.

OO

OS

Os

os

Os

os

Os

os

Os

(Λ M Z

DO

D)

SO C\ d

SO Os d

so Os d

SO Os d

fL96

SO Os d

fL96

SO Os d

fL96

SO Os d

fL96

SO Os d

< ^Op

< ^PC

< d

<

P d

fuC

< d

<

< d

P d

< d

<

< ,cd

d

<

□

<

d

<

< d

u

<

rn

O d

o d

o PC

O d

< 5

< d

u y

d

o _fPi

faA

fuC

< d

d _fPC

s

u

O Pi

d

d d

fcG

d d

faU

o d

o

< cd

© w

^Cd

d

O

fuU

d

_fPi

< Ρΰ

o _fPi

faA

fcU

< d

d

s

d d

d

o ,cd

d _fp

P ,cd

o

O

P ,cd

d

o d

u ,cd

un 0)

o ^Op

o d

£

u Cd

d

§

d

O

d d

fcA

fuU

u d

o

u cd

P ,cd

d

u d

U d

iiCf

U d>

y ,cd

o y

d

u y

ς> c

p

u

P

<

o

u

(J

u

P

u

U

P

u

y

o

u

P

u

0)

_fpj

,cd

d

_rP)

_rPD

d

,cd

d

_r01

d

_r01

y

d

5 ©*

£

(J

p

s

P

p

s

<c

s

y

<c

p

P

s

P

s

y

<c

s

y

s

P

y

s

y

P

p

y

s

p

P

<c

y

<c

y

s

y

p

y

<c

0)

<

y

J

P

o

<

u

P

o

P

<

u

P

o

<

P

o

P

o

u

y

s

d

_fp

d

,cd

cd

d

_fp

,cd

d>

_fp

d>

d

,cd

0) r/s

o

u

P

u

P

u

P

u

o

P

o

u

P

u

P

o

u

P

y

_ff5

d

,C3

d

,cd

d

_fpp

d

p

u

P

o

<

P

u

P

u

P

u

P

o

P

y

u

_fp

_fPC

d

_fp

d

rd*

d

rd*

d

_fpp

d

_fp

d

p

P

u

P

o

P

u

P

o

u

P

o

P

o

P

y

P

y

-P)

d

-PC

-Op

d

5

y

P

<

u

o

P

u

P

o

u

P

u

o

u

o

P

s

P

co

DO

Os

DO

0's

DO

co

O'

co

Os

0's

DO

Os

co

o §

o

04

CO

p·*.

Os

o

04

co

SO

OO

so

OO

os

co

so

OO

04

>sj

co

>sj

co

>sj

CO

co

>sj

co

OO

s

04

y

<

y

g 0>

OO

Os

o

04

co

DO

so

O'

o

04

co

DO

OO

Os

o

04

co

DO

— s

p·*.

OO

O'

0's

O'-

O'

Os

o

O

o

a «

04

co

CO

co

S ►S Q ^z

SO

Q

<

MEI 27037625V.1

112

WO 2018/195165

PCT/US2018/028U6

SEQ ID NO:

815

816

oo

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

Antisense Sequence (5’ to 3’)

usAfsaGfgCfaCfaGfcuuGfgAfgGfcUfusgsa

usAfsuAfgCfaGfcAfggaUfgAfaGfaGfgsasa

asAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu

asGfsaAfgAfaCfcAfacaAfgAfaGfaUfgsasg

□c O £ < £ < o u < O O 3

asGfsaAfcCfaAfcAfagaAfgAfuGfaGfgscsa

usAfsaGfaUfaGfgGfgcaUfuUfgGfuGfgsusc

asGfsuAfuGfgAfuCfggcAfgAfgGfaGfcscsa

PasUfsuGfuGfaGfgAfuuuUfuGfuCfaAfcsasa

PusUfsgUfgAfgGfaUfuuuUfgUfcAfaCfasasg

PusAfsaAfaUfuGfaGfagaAfgUfcCfaCfcsasc

PusCfsgAfaUfcCfaCfacuCfcAfaAfaGfascsa

PusAfsgCfuUfgGfaGfgcuUfgAfaCfaAfgsasc

PusCfscGfcAfgUfaUfggaUfcGfgCfaGfasgsg

PusAfscCfaCfaUfcAfuccAfuAfuAfaCfusgsa

PusAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc

PusAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg

PasUfsgAfaCfaAfgAfgauGfaUfuAfgCfgsasg

PgsAfsaGfuCfcAfcCfacgAfgUfcUfaGfascsu

PusUfscCfgCfaGfuAfuggAfuCfgGfcAfgsasg

PusAfsgAfaGfaAfcCfaacAfaGfaAfgAfusgsa

PusCfscCfcUfaGfaAfaauUfgAfgAfgAfasgsu

PusGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc

PasUfsuUfuUfgUfcAfacaAfgAfaAfaAfcscsc

PusAfsaCfaAfgAfgAfugaUfuAfgGfcAfgsasg

Antisense Oligo Name

A-128404

A-128420

A-128432

A-128376

A-128392

A-128406

A-128422

A-128434

A-128445

A-128453

A-128461

A-128469

A-128477

A-128483

A-128446

A-128454

A-128462

A-128470

A-128478

A-128484

A-128455

A-128471

A-127907

A-128485

A-128448

A-128456

SEQ ID NO:

600

601

602

603

604

605

606

607

608

609

610

5

612

613

5

615

616

5

618

619

620

621

622

623

624

625

Sense Sequence (5’ to 3’)

AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96

CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96

CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96

CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96

CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96

CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96

CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96

GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96

GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96

UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96

GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96

UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96

AfscsUfgUfuCfaAfGfCfcUfcCfaAfgCfuAfL96

UfscsUfgCfcGfaUfCfCfaUfaCfuGfcGfgAfL96

AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96

AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96

CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96

GfscsCfuAfaUfcAfUfCfuCfuUfgUfuCfaUfL96

UfscsUfaGfaCfuCfGfUfgGfuGfgAfcUfuCfL96

CfsusGfcCfgAfuCfCfAfuAfcUfgCfgGfaAfL96

AfsusCfuUfcUfuGfUfUfgGfuUfcUfuCfuAfL96

<2 σ> d < O d³O ,cd D d 5 5 S u d u d u

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96

GfsusUfuUfuCfuUfGfUfuGfaCfaAfaAfaUfL96

CfsusGfcCfuAfaUfCfAfuCfuCfuUfgUfuAfL96

Sense Oligo Name

A-128403

A-128419

A-128431

A-128375

A-128391

A-128405

A-128421

A-128433

A-128363

A-128377

A-128393

A-128407

A-128423

A-128435

A-123463

A-128379

A-128395

A-128409

A-128425

A-128437

A-128381

A-128411

A-127905

A-128001

A-128367

A-128383

Duplex Name

AD-64307

AD-64308

AD-64309

AD-64310

AD-64311

AD-64312

AD-64313

AD-64314

AD-64315

AD-64316

AD-64317

AD-64318

AD-64319

AD-64320

AD-64321

AD-64322

AD-64323

AD-64324

AD-64325

AD-64326

AD-64328

AD-64330

AD-64331

AD-64332

AD-64333

AD-64334

MEI 27037625V.1

113

WO 2018/195165

PCT/US2018/028U6

SEQ ID NO:

oo

842

843

oo

845

846

oo

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

Antisense Sequence (5’ to 3’)

PusAfscUfcUfgUfgGfuauUfgUfgAfgGfasusu

PusUfsgAfgGfaUfuUfuugUfcAfaCfaAfgsasa

PasAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa

PasGfsgCfaGfaGfgUfgaaAfaAfgUfuGfcsasu

PusAfsuGfcUfgUfaGfcucUfuGfuUfcCfcsasa

PusAfsaGfaAfcCfaAfcaaGfaAfgAfuGfasgsg

PusAfsaGfaUfgAfgGfcauAfgCfaGfcAfgsgsa

PasAfscGfcCfgCfaGfacaCfaUfcCfaAfcsgsa

PusAfsgGfcAfuAfgCfagcAfgGfaUfgAfasgsa

PusAfsgGfaUfuUfuUfgucAfaCfaAfgAfasasa

PusAfsaAfaCfgCfcGfcagAfcAfcAfuCfcsasg

PusAfsaUfaCfcAfcAfucaUfcCfaUfaUfasasc

PgsAfsgGfcAfuAfgCfagcAfgGfaUfgAfasgsa

PusAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc

PusAfsuUfgUfgAfgGfauuUfuUfgUfcAfascsa

PusUfsuGfcGfuCfaGfcaaAfcAfcUfuGfgscsa

PusAfsaGfgCfaCfaGfcuuGfgAfgGfcUfusgsa

PusAfsuAfgCfaGfcAfggaUfgAfaGfaGfgsasa

PasAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu

PasGfsaAfgAfaCfcAfacaAfgAfaGfaUfgsasg

PusAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg

PasGfsaAfcCfaAfcAfagaAfgAfuGfaGfgscsa

PusAfsaGfaUfaGfgGfgcaUfuUfgGfuGfgsusc

PasGfsuAfuGfgAfuCfggcAfgAfgGfaGfcscsa

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

Antisense Oligo Name

A-128464

A-128472

A-127958

A-128486

A-128449

A-128465

A-128473

A-128479

A-128487

A-128450

A-128466

A-128474

A-128480

A-128488

A-128451

A-128459

A-128467

A-128475

A-128481

A-128452

A-128460

A-128468

A-128476

A-128482

A-127906

SEQ ID NO:

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

642

643

645

646

648

649

650

651

Sense Sequence (5’ to 3’)

UfscsCfuCfaCfaAfUfAfcCfaCfaGfaGfuAfL96

CfsusUfgUfuGfaCfAfAfaAfaUfcCfuCfaAfL96

GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96

GfscsAfaCfuUfuUfUfCfaCfcUfcUfgCfcUfL96

GfsgsGfaAfcAfaGfAfGfcUfaCfaGfcAfuAfL96

UfscsAfuCfuUfcUfUfGfuUfgGfuUfcUfuAfL96

CfsusGfcUfgCfuAfUfGfcCfuCfaUfcUfuAfL96

GfsusUfgGfaUfgUfGfUfcUfgCfgGfcGfuUfL96

UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuAfL96

UfsusCfuUfgUfuGfAfCfaAfaAfaUfcCfuAfL96

GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96

UfsasUfaUfgGfaUfGfAfuGfuGfgUfaUfuAfL96

UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuCfL96

GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96

<2 σ> d < < u u d u 43 < < u o

CfscsAfaGfuGfuUfUfGfcUfgAfcGfcAfaAfL96

AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96

CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96

CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96

CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96

CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96

CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96

CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96

GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96

ascsucguggugdT acuu(Cgn)ucucaL96

Sense Oligo Name

A-128399

A-128413

A-127955

A-128439

A-128369

A-128401

A-128415

A-128427

A-128441

A-128371

A-123487

A-128417

A-128429

A-128443

A-128373

A-128389

A-128403

A-128419

A-128431

A-128375

A-128391

A-128405

A-128421

A-128433

A-129379

Duplex Name

AD-64335

AD-64336

AD-64337

AD-64338

AD-64339

AD-64341

AD-64342

AD-64343

SO Q <

AD-64345

AD-64347

AD-64348

AD-64349

AD-64350

AD-64351

AD-64352

AD-64353

AD-64354

AD-64355

AD-64356

AD-64357

AD-64358

AD-64359

AD-64360

AD-64700

MEI 27037625V.1

114

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

867

868

869

870

oo

872

873

oo

875

876

oo

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

Antisense Sequence (5’ to 3’)

PusgsagagaagdTccadCcacgaguscsu

usGsagadGaaguccaCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaaguccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usdGsadGagaaguccadCcacgaguscsu

usgsagadGaagdTccadCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaagdTccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usdGsagadGaaguccadCcacgaguscsu

PusgsagadGaagdTccadCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaagdTccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usdGsagagadAguccadCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaagdTccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

PusdGsagagaagdTccadCcacgaguscsu

usdGsagadGaaguccadCcacgaguscsu

usdGsagadGaagdTccadCcacgaguscsu

Antisense Oligo Name

A-129387

A-129395

A-129385

A-129389

A-127906

A-129388

A-129396

A-129385

A-129391

A-127906

A-129389

A-129397

A-129385

A-129391

A-127906

A-129390

A-129385

A-129391

A-127906

A-129398

A-129389

A-129391

SEQ ID NO:

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

<5

672

673

<5

675

676

<5

Sense Sequence (5’ to 3’)

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugdGacuucdAcucaL96

ascsucguggdT gdT acuucd AcucaL96

ascsucguggugdT acuucdAcucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggdT gdGacuuc(T gn)cucaL96

ascsucguggugdGacuu(Cgn)ucucaL96

ascsucguggdT gdT acuucd AcucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggdT gdGacuucd AcucaL96

ascsucguggugdGacuucdAcucaL96

ascsucguggugdGacuucu(Cgn)ucaL96

ascsucguggdT gdGacuuc(T gn)cucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugdGacuuc(Tgn)cucaL96

ascsucguggdT gdT acuucd AcucaL96

ascsucguggdT gdGacuuc(T gn)cucaL96

ascsucguggugdGacuucY34cucaL96

ascsucguggugdGdAcuuc(Tgn)cucaL96

ascsucguggugdGacuuc(Tgn)cucaL96

ascsucguggugdGacuu(Cgn)ucucaL96

ascsucguggdT gdGacuucd AcucaL96

Sense Oligo Name

A-127905

A-129376

A-129381

A-129380

A-127905

A-129382

A-129373

A-129381

A-127905

A-129384

A-129376

A-129374

A-129382

A-127905

A-127917

A-129381

A-129382

A-129375

A-129383

A-127917

A-129373

A-129384

Duplex Name

AD-64701

AD-64702

AD-64703

AD-64704

AD-64705

AD-64706

AD-64707

AD-64708

AD-64709

AD-64710

AD-64711

AD-64712

AD-64713

AD-64714

AD-64715

AD-64716

AD-64717

AD-64718

AD-64719

AD-64720

AD-64721

AD-64722

AD-64723

AD-64725

AD-64726

AD-64727

MEI 27037625V.1

115

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

893

894

895

896

897

898

899

006

901

902

903

904

905

906

907

908

Antisense Sequence (5’ to 3’)

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usGsagagaagdTccadCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaaguccadCcacgaguscsu

usdGsagadGaagdTccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagagaagdTccaCcacgaguscsu

PusdGsagagaagdTccadCcacgaguscsu

usdGsagadGaaguccadCcacgaguscsu

usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu

usgsagagaagdTccadCcacgaguscsu

usGsagagaagdTccaCcacgaguscsu

usdGsagagaagdTccadCcacgaguscsu

usdGsagadGaaguccadCcacgaguscsu

Antisense Oligo Name

A-127906

A-129392

A-129385

A-129389

A-129391

A-127906

A-129385

A-129393

A-129398

A-129389

A-127906

A-129386

A-129394

A-129385

A-129389

SEQ ID NO:

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

Sense Sequence (5’ to 3’)

ascsucguggugdGacuucdAcucaL96

ascsucguggdT gdGacuucd AcucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

Y34ascsucguggugdGacuuc(T gn)cucaL96

ascsucguggugdGacuucdAcucaL96

ascsucguggdT gdT acuucd AcucaL96

ascsucguggugdGacuucdCcucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

Y34ascsucguggugdGacuuc(T gn)cucaL96

ascsucguggdT gdGacuuc(T gn)cucaL96

ascsucguggugdGacuucdGcucaL96

AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96

ascsucguggugdGacuu(Cgn)ucucaL96

ascsucguggdT gdGacuucd AcucaL96

Sense Oligo Name

A-129376

A-129384

A-127905

A-129399

A-129376

A-129381

A-129377

A-127905

A-129399

A-129382

A-129378

A-127905

A-129373

A-129384

Duplex Name

AD-64728

AD-64729

AD-64730

AD-64731

AD-64732

AD-64733

AD-64734

AD-64735

AD-64736

AD-64737

AD-64738

AD-64739

AD-64740

AD-64741

AD-64742

AD-64743

’S > ft

Λ S φ

4>

C

4) σ

4> Z/j c ft

Z/j

4) ζβ

C φ

C φ ζβ

C φ Z/j

O w a	δ	oo m	Os m	o
	z	Os	Os	OS



		ϋ	ϋ	ϋ
		u	u	u

-w		o	o	o
		u	u	u
tn
4)		o	o	o
		u	u	u
4)
□		u	u	u
σ* OJ
(Λ
4)		ϋ	ϋ	ϋ
ζ/2 CJ
4)		ϋ	ϋ	ϋ

β		ο	ο	ο
c
ο w a	δ	OS o	Ο	-Η
	z	OS	OS	OS

		o	ο	ο

		o	ο	ο

rh		o	ο	ο
©

In		o	o	o

		ϋ	ϋ	ϋ
©		ϋ	ϋ	ϋ
3
σ*		u	u	u
4) ζβ		ϋ	ϋ	ϋ

ζΛ
&
%
Q		Os
X		rc	rc	OS
4)		so	so	SO
s		Q	Q	Q
Q

MEI 27037625V.1

116

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

o>

04 OS

cn OS

os

in OS

ΚΟ OS

σ>

ΟΟ OS

OS OS

o in Os

in Os

04 in Os

cn in Os

ΙΟ OS

ιη ιη OS

ΚΩ ιη OS

ϊη OS

ΟΟ ιη OS

Os in Os

o ΚΩ Os

5 Os

04 ΚΩ Os

cn ΚΩ Os

Os

in ΚΩ Os

ΚΩ ΚΩ Os

o ϋ < ϋ u

CGAUU

CGAGUCU

CGAUU

CGAGUUU

UGCACUU

UGCACAC

UGCAC

UGCACAC

CACAUCC

UGCACAC

UGCUU

ACCAC

CCAGCAG

ACCACGA

CCAGCAG

ACCAC

ACCACGA

CCAUU

ACCACGA

CCAGCUU

CCACCAC

< o o

CO

<

Ο

O

<

Ο

<

Ο

<

O

<

O

<

3

o -w

o

<J

Ο

<

ό

<

U

Ο

U

Ο

U

o

U

o

u

<-

o

<J

ο

<

υ

u

<

IT)

<

ο

u

ϋ

Ο

ο

Ο

u

<

4)

o

ο

υ

u

o

Ο

ο

υ

<

ο

<

ο

<

ϋ

<

u

<J

υ

u

ϋ

u

ο

υ

<

ο

<

ο

<

ο

<

u

ϋ

<

u

<

u

□

ϋ

u

ο

<

ο

<

ο

<

ο

<

ϋ

<

u

<

ο

u

ϋ

ο

<

ο

<

u

ϋ

<

u

<

u

CZj

<

ο

<

ο

<

ο

<

ο

<

ο

<

u

4)

ϋ

ο

u

ο

<

ο

<

ο

<

u

ο

<

u

<

ζ/2 s*

<

ο

u

ο

<

ο

u

<

ο

ϋ

ο

<

ο

u

ο

<

β

ο

<

X

ο

<

O' Q

04

co

in

ΚΩ

οο

OS

o

04

cn

ιη

ΚΩ

οο

Os

o

04

cn

in

ΚΩ

W Q

1 I

1 1

1 I

1 |

_t (

04

cn

(Λ M Z

Os

os

Os

OS

os

Os

os

Os

OS

Os

< ο ο ο

UCUCA

UCUCAUU

UCUCUCA

UCUCA

UCUCUCA

ACCUCUA

CUCUA

ACCUCUG

νηνηηηη

ACCUCUG

CUCUA

ηηηνν

CUCAAUU

UCAAUUU

CUCAAUU

nnnvv

UCAAUUU

nnvvv

UCAAUUU

CUAAAUU

vnnnnvv

vnnnv

ο

U

3

U

3

o

<J

Ο

ο

Ο

υ

ο

3

U

3

o

U

o

<

©

ο

o

Ο

ο

<

ο

υ

ο

<

Ο

o

O

<

o

υ

ο

L>

Ο

L>

o

ο

o

Ο

o

in

ο

o

u

Ο

ο

o

ο

υ

ο

o

H

4)

ο ο

< u

ϋ ο

< ο

ο ο

u o

<J

ο ο

υ ο

ο ο

υ

υ <

ο

U <

u

o

H

o

U

u

o H

©

ο

ϋ

ο

u

ο

<

u

<

U

<

u

O

ο

o

ο

u

o

ϋ

L>

u

o

<

©*

ο

u

ο

L>

ο

<

υ

<

u

ϋ

u

<

ο

ϋ

ο

<

ο

<

ο

L>

u

L>

u

L>

u

4) V2

ο ο

o

ο ο

ο

ο ο

u ο

o <

υ ο

GU

υ ο

ο <

υ

ο ο

u ο

u

ϋ ϋ

GU

U U

u ο

u

GA

&

υ

<J

υ

u

3

υ

ο

u

O

u

O

%

<

ο

u

ο

<

ο

o

u

o

u

Q

οο

KO

οο

κο

cn

04

co

ο

υη

KO

Os

oo

OS

cn

in

cn

KO

κο

ο

os

οι

CO

04

οο

os

κο

o

04

KO

oo

o

oo

X

os cn κο

-655

-639

m κο

-653

-654

-655

-654

-643

-642

-655

-639

-653

-652

m KO

-640

-652

-653

-640

-653

in KO

-653

cu s

Q

ο

Q

<

MEI 27037625V.1

117

WO 2018/195165

PCT/US2018/028116

MEI 27037625V.1

118

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:	1019	1020	1021	1022	1023	1024
Antisense Sequence (5' to 3')	asdAsuugagagdAagudCcaccasusu	asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa	asdAsuugagagdAagudCcaccagcsusu	PusAfsaaaUfuGfAfgagaAfgUfccaccsasc	usAfsaaaUfuGfAfgagaAfgUfccaccsasc	usdAsaaauugadGagadAguccasusu
SEQ ID NO:	066	991	992	993	994	995
Sense Sequence (5' to 3')	usgsgudGgucdTucucuaaauuL96	GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96	csgsuggudGgucdTucucuaaauuL96	gsgsuggaCfuUfCfUfcucaAfUfuuuaL96	gsgsuggaCfuUfCfUfcucaAfUfuuuaL96	usgsgacuacdTcucaaauuuaL96
DuplexID	AD-65389	AD-64008	AD-65377	AD-65409	AD-65403	AD-65385

SEQ ID NO:	1036	1037	1038	1039	1040	o	1042	cc o
Antisense Sequence Unmodified (5’ to 3’)	UGAGAGAAGUCCACCACGAUU	UGAGAGAAGUCCACCACGAUU	UGAGAGAAGUCCACCACGAUU	UAGAGGUGAAGCGAAGUGCACUU	UAGAGGUGAAGCGAAGUGCACUU	UAGAGGUGAAGCGAAGUGCACUU	AAUUGAGAGAAGUCCACCAGCAG	u o < u u < u u o < < o < o < o < <
Antisense ID	A-131904	A-131904	A-130364	A-131905	A-131905	A-130442	A-130372	co o cc <
SEQ ID NO:	1025	1026	1027	1028	1029	1030	1031	<N cc O
Sense Sequence Unmodified (5' to 3')	UCGUGGUGGACUUCUCUCA	UCGUGGUGGACUUCUCUCA	UCGUGGUGGACUUCUCUCA	GUGCACUUCGCUUCACCUCUA	GUGCACUUCGCUUCACCUCUA	GUGCACUUCGCUUCACCUCUA	CGUGGUGGACUUCUCUCAAUU	< < < u u H u o o o o o u
Sense ID	A-130366	A-130366	A-130366	A-130441	A-130441	A-130441	A-130371	So cc o cc <
Duplex ID	AD-65381	AD-66019	AD-65375	AD-65427	AD-66110	AD-65421	AD-65407	cn IT) SO Q <

119

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:	o	1045	1046
Antisense Sequence Unmodified (5’ to 3’)	UAAAAUUGAGAGAAGUCCACCAC	UAAAAUUGAGAGAAGUCCACCAC	UAAAAUUGAGAGAAGUCCACCAC
Antisense ID	A-131906	A-131906	A-130389
SEQ ID NO:	1033	1034	1035
Sense Sequence Unmodified (5' to 3')	GGUGGACUUCUCUCAAUUUUA	GGUGGACUUCUCUCAAUUUUA	GGUGGACUUCUCUCAAUUUUA
Sense ID	A-130388	A-130388	A-130388
Duplex ID	AD-65409	AD-66111	AD-65403

MEI 27037625V.1

120

WO 2018/195165

PCT/US2018/028116 o

&

o o a

SEQ ID NO:	1066	1067	1068
Antisense Sequence (5' to 3')	PusAfsaaaUfuGfAfgagaAfgUfccaccsasc	VPusAfsaaaUfuGfAfgagaAfgUfccaccsasc	usAfsaaaUfuGfAfgagaAfgUfccaccsasc
Antisense ID	A-131906	A-131906	A-130389
SEQ ID NO:	1055	1056	1057
Sense Sequence (5' to 3')	gsgsuggaCfuUfCfUfcucaAfUfuuuaL96	gsgsuggaCfuUfCfUfcucaAfUfuuuaL96	gsgsuggaCfuUfCfUfcucaAfUfuuuaL96
Sense ID	A-130388	A-130388	A-130388
Duplex ID	AD-65409	AD-66111	AD-65403

ν w c ν □ σ ν (Λ (Λ ν

tn

C ν

C « ν

tn

C v tn =

v x K

SEQ ID NO:

irj

<o

1117

OO

CN

1120

CT

1122

1123

CT

1125

1126

CT

OO CT

Antisense Sequence (5’ to 3’)

AGAGGUGAAGCGAAGUGCACACG

UCAGAGGUGAAGCGAAGUGCACA

UAGGUGAAGCGAAGUGCACACGG

AGGUGAAGCGAAGUGCACACGGU

UAGAGGUGAAGCGAAGUGCACAC

UGUGAAGCGAAGUGCACACGGUC

UUGCAGAGGUGAAGCGAAGUGCA

UGUGCAGAGGUGAAGCGAAGUGC

UACCAAUUUAUGCCUACAGCCUC

UACGUGCAGAGGUGAAGCGAAGU

UGACGUGCAGAGGUGAAGCGAAG

ACGUGCAGAGGUGAAGCGAAGUG

UAUGAGAAGGCACAGACGGGGAG

o o o o u < o < u < u o o < < o < o < o <

Antisense OligoName

A-131860

A-131878

A-131866

A-131862

A-128444

A-131858

A-131868

A-131876

A-123526

A-131874

A-131872

A-131870

A-128396

CT CN cc oo CT <

SEQ ID NO:

1069

1070

o

1072

1073

o

1075

1076

o

1078

1079

1080

1081

CT oo o

Sense Sequence (5’ to 3’)

UGUGCACUUCGCUUCACCUCU

UGCACUUCGCUUCACCUCUGA

GUGUGCACUUCGCUUCACCUA

CGUGUGCACUUCGCUUCACCU

GUGCACUUCGCUUCACCUCUA

CCGUGUGCACUUCGCUUCACA

CACUUCGCUUCACCUCUGCAA

ACUUCGCUUCACCUCUGCACA

GGCUGUAGGCAUAAAUUGGUA

UUCGCUUCACCUCUGCACGUA

UCGCUUCACCUCUGCACGUCA

CUUCGCUUCACCUCUGCACGU

CCCCGUCUGUGCCUUCUCAUA

< u < u u u u o o u o u u

Sense Oligo Name

A-131859

A-131877

A-131865

A-131861

A-128443

A-131857

A-131867

A-131875

A-123525

A-131873

A-131871

A-131869

A-128395

05 CC OO CT <

DuplexID

AD-65776

AD-65782

AD-65792

AD-65781

AD-64304

AD-65771

AD-65758

AD-65777

AD-61567

AD-65772

AD-65767

AD-65763

AD-64281

cc SO Q <

MEI 27037625V.1

121

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:

1129

1130

CO

1132

1133

CO

1135

1136

CO

1138

1139

o

1141

04

1144

5

M2

1147

σ>

1150

DO

1152

1153

DO

O

o

<

o

u

O

o

O

<

u

o

u

<

o

<-

rj

u

<

u

o

u

O

u

<

ϋ

<

u

<

<4-

(J

o

O

o

u

<

u

<

u

o

u

(J

<4-

Q

<

o

u

o

u

o

<

o

<

o

U

<

(J

<4-

u

<

o

u

o

u

<

o

u

<

u

<4-

(J

u

o

<

u

o

u

o

<

o

<

o

<

u

(J

u

o

u

<

o

<

o

<

u

<

u

Q

(J

C )

u

<

o

u

o

<

o

<

o

<

o

u

<

u

o

u

<

w

o

u

o

<

u

o

u

o

<

o

<

u

<

o

u

<

u

<

u

<

u

o

u

<

u

o

u

<

u

<

o

<

ϋ

u

<

u

<

©

u

o

u

o

u

o

u

o

u

L)

<

u

<

u

<

u

0)

ϋ

<

u

o

u

<

o

O

<

u

<

u

5

u

<

o

u

ϋ

<

u

o

u

<

o

<

u

<

u

<

0)

o

<

o

u

o

u

<

u

<

(j

<

o

u

<

o

Ή

o

u

<

u

<

o

u

o

<

u

<

u

o

<

u

<

0)

<

u

o

<

o

<

u

<

u

<

fi

<

o

u

o

<

u

<

u

<

u

<

u

<

u

o

<

o

<

o

<

u

<

u

<

u

<

u

<

o

<

o

<

u

C )

<

u

<

o

<

α

<

o

<

u

o

<

u

<

u

<

u

<

u

<

u

<

u

<

oo

04

o

so

04

so

oo

04

o

oo

o

so

04

oo

so

o

04

g «

co

kj

DO

co

st;

kj

kJ

04

DO

04

_t (

o

04

O

o

_t (

04

_t (

CO

o

04

1 I

04

DO

5 z

oo

OO

oo

DO

OO

oo

DO

OO

oo

OO

oo

OO

oo

OO

5Λ ©

co

04

co

04

co

δ

<

Λ ··

co

DO

so

f—.

oo

O'

o

04

co

DO

so

[—.

oo

O'

o

04

co

DO

so

[—.

oo

Μ Ο

oo

OO

oo

O'

o

O

o

£Sz

o

<

JUUU

ACCU

2UUA

JCGA

AAAG

UUCA

CAAA

CUUA

won

UGGA

CUUA

UUUA

GUUU

UGUU

< < o o

UUUA

AAGA

< u <

< o < o

< < <

AAAG

< o

rAUUA

< o < <

GUAA

(J

u

U

u

<

o

O

<

O

<

o

3

<

3

<

(j

<

u

o

<

o

<

(J

<£

o

<;

U

<

u

<

o

u

<

o

<

co

<

(J

u

(J

u

<

u

<

u

o

<

u

<

O

<

U

©

<

δ

u

δ

<

u

o

u

<

o

u

o

O

<

o

<

o

(J

<

o

<

o

u

o

<

u

<

u

<

o

<

O

<

o

un

o

<£

u

o

(j

<

o

u

<

o

u

<

o

<

o

<

o

(J

<

u

<

o

<

o

<

o

<

o

<

o

<

o

O

<

s

<

ΰ

<

u

o

<

o

<

o

<

u

o

<

o

<

o

<

s

u

<

u

<

u

o

<

o

<

o

<

o

<

o

<

5

u

o

u

<

o

u

o

<

u

<

u

o

<

σ

<

o

u

o

u

<

u

<

o

<

o

©

u

<

o

u

<

u

<

o

<

o

<

o

u

<

u

o

u

<

u

o

<

o

<

u

<

u

o

u

o

<

u

<

o

<

o

u

o

<

fi

u

<

o

u

<

u

<

u

<

o

u

<

u

o

<

o

u

<

o

Os

DO

co

DO

co

DO

co

O'

O\

DO

O'

co

kJ

kj

CO

so

kj

kJ

04

DO

04

1 I

o

04

o

os

1 I

_t (

co

o

04

o

_t (

04

DO

Ό

oo

OO

oo

OO

oo

DO

OO

oo

DO

oo

OO

oo

OO

<u

t 1

CO

t 1

CO

t 1

1 (

t 1

t

1 §

co

CO

co

CO

04

CO

04

CO

co

CO

B « M Z

<

/S

o

so

DO

o

so

DO

04

DO

oo

co

DO

O'

O\

oo

co

O'

co

Os

M

OS

SO

oo

OO

oo

so

DO

SO

DO

oo

so

SO

DO

SO

so

DO

oo

DO

Os

DO

t 1

DO

t 1

DO

SO

CL

|

5

Q

<

MEI 27037625V.1

122

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:	1155	1156		1158	1159	1160
Antisense Sequence (5’ to 3’)	AGUACAAAGACCUUUAAUCUAAU	UACAAAGACCUUUAAUCUAAUCU	UACCUUUAAUCUAAUCUCCUCCC	UUGCAGAGAGUCCAAGAGUCCUC	UAUUGCAGAGAGUCCAAGAGUCC	UAGUACAAAGACCUUUAAUCUAA
Antisense OligoName	A-131830	A-131824	A-131854	A-131848	A-131834	A-131840
SEQ ID NO:	1109	o	1111	04	CO	1114
Sense Sequence (5’ to 3’)	UAGAUUAAAGGUCUUUGUACU	AUUAGAUUAAAGGUCUUUGUA	GAGGAGAUUAGAUUAAAGGUA	GGACUCUUGGACUCUCUGCAA	ACUCUUGGACUCUCUGCAAUA	AGAUUAAAGGUCUUUGUACUA
Sense Oligo Name	A-131829	A-131823	A-131853	A-131847	A-131833	A-131839
DuplexID	AD-65760	AD-65784	AD-65757	AD-65775	AD-65780	AD-65756

&

ο ο α

SEQ ID NO:

1207

1208

1209

1210

Off

1212

1213

1214

1215

1216

Off

1218

1219

Antisense Sequence (5’ to 3’)

asGfsaGfgUfgAfaGfcgaAfgUfgCfaCfascsg

usCfsaGfaGfgUfgAfagcGfaAfgUfgCfascsa

usAfsgGfuGfaAfgCfgaaGfuGfcAfcAfcsgsg

asGfsgUfgAfaGfcGfaagUfgCfaCfaCfgsgsu

usAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc

usGfsuGfaAfgCfgAfaguGfcAfcAfcGfgsusc

usUfsgCfaGfaGfgUfgaaGfcGfaAfgUfgscsa

usGfsuGfcAfgAfgGfugaAfgCfgAfaGfusgsc

usAfscCfaAfuUfuAfugcCfuAfcAfgCfcsusc

usAfscGfuGfcAfgAfgguGfaAfgCfgAfasgsu

usGfsaCfgUfgCfaGfaggUfgAfaGfcGfasasg

asCfsgUfgCfaGfaGfgugAfaGfcGfaAfgsusg

usAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg

Antisense Oligo Name

A-131860

A-131878

A-131866

A-131862

A-128444

A-131858

A-131868

A-131876

A-123526

A-131874

A-131872

A-131870

A-128396

SEQ ID NO:

so

1162

1163

1164

1165

1166

SO

1168

1169

o

1171

off

CO

Sense Sequence (5’ to 3’)

UfsgsUfgCfaCfuUfCfGfcUfuCfaCfcUfcUfL96

UfsgsCfaCfuUfcGfCfUfuCfaCfcUfcUfgAfL96

GfsusGfuGfcAfcUfUfCfgCfuUfcAfcCfuAfL96

CfsgsUfgUfgCfaCfUfUfcGfcUfuCfaCfcUfL96

GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96

CfscsGfuGfuGfcAfCfUfuCfgCfuUfcAfcAfL96

CfsasCfuUfcGfcUfUfCfaCfcUfcUfgCfaAfL96

AfscsUfuCfgCfuUfCfAfcCfuCfuGfcAfcAfL96

GfsgsCfuGfuAfgGfCfAfuAfaAfuUfgGfuAfL96

UfsusCfgCfuUfcAfCfCfuCfuGfcAfcGfuAfL96

UfscsGfcUfuCfaCfCfUfcUfgCfaCfgUfcAfL96

CfsusUfcGfcUfuCfAfCfcUfcUfgCfaCfgUfL96

CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96

Sense Oligo Name

A-131859

A-131877

A-131865

A-131861

A-128443

A-131857

A-131867

A-131875

A-123525

A-131873

A-131871

A-131869

A-128395

Duplex ID

AD-65776

AD-65782

AD-65792

AD-65781

AD-64304

AD-65771

AD-65758

AD-65777

AD-61567

AD-65772

AD-65767

AD-65763

AD-64281

123

WO 2018/195165

PCT/US2018/028116

Q go S z

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

Antisense Sequence (5’ to 3’)

usAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg

usAfsaAfaAfgUfuGfcauGfgUfgCfuGfgsusg

asAfsaAfgUfuGfcAfuggUfgCfuGfgUfgscsg

asGfsgUfgAfaAfaAfguuGfcAfuGfgUfgscsu

usAfsaGfgUfcGfgUfcguUfgAfcAfuUfgscsa

usCfsgAfcGfuGfcAfgagGfuGfaAfgCfgsasa

csUfsuUfgAfaGfuAfugcCfuCfaAfgGfuscsg

usGfsaAfgUfaUfgCfcucAfaGfgUfcGfgsusc

usUfsuGfaAfgUfaUfgccUfcAfaGfgUfcsgsg

usAfsaGfuAfuGfcCfucaAfgGfuCfgGfuscsg

usUfscAfcGfgUfgGfucuCfcAfuGfcGfascsg

usCfscAfaGfaGfuCfcucUfuAfuGfuAfasgsa

usAfsaGfaGfuCfcUfcuuAfuGfuAfaGfascsc

usAfsaAfcAfaAfcAfgucUfuUfgAfaGfusasu

asAfsaCfaAfaCfaGfucuUfuGfaAfgUfasusg

asAfscAfaAfcAfgUfcuuUfgAfaGfuAfusgsc

usUfscCfuCfcCfaGfucuUfuAfaAfcAfasasc

usAfsaAfcAfgUfcUfuugAfaGfuAfuGfcscsu

usCfsuUfuAfaAfcAfaacAfgUfcUfuUfgsasa

usAfsgUfcUfuUfaAfacaAfaCfaGfuCfususu

usCfsuCfcCfaGfuCfuuuAfaAfcAfaAfcsasg

usUfsuAfaUfcUfaAfucuCfcUfcCfcCfcsasa

csUfsuUfaAfuCfuAfaucUfcCfuCfcCfcscsa

asAfsuCfuAfaUfcUfccuCfcCfcCfaAfcsusc

usAfsaUfcUfaAfuCfuccUfcCfcCfcAfascsu

usCfsuUfuAfaUfcUfaauCfuCfcUfcCfcscsc

Antisense Oligo Name

A-128392

A-131838

A-131842

A-131850

A-131836

A-131864

A-131846

A-131844

A-123522

A-131856

A-131828

A-131812

A-131804

A-123524

A-131802

A-131800

A-131818

A-131820

A-131816

A-131832

A-131808

A-131806

A-131826

A-131810

A-131814

A-131822

SEQ ID NO:

SD

1177

oo

os

1180

OO

1182

1183

1184

1185

1186

OO

1188

1189

1190

Os

1192

1193

1194

1195

1196

os

1198

OS Os

Sense Sequence (5’ to 3’)

CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96

CfscsAfgCfaCfcAfUfGfcAfaCfuUfuUfuAfL96

CfsasCfcAfgCfaCfCfAfuGfcAfaCfuUfuUfL96

CfsasCfcAfuGfcAfAfCfuUfuUfuCfaCfcUfL96

CfsasAfuGfuCfaAfCfGfaCfcGfaCfcUfuAfL96

CfsgsCfuUfcAfcCfUfCfuGfcAfcGfuCfgAfL96

AfscsCfuUfgAfgGfCfAfuAfcUfuCfaAfaGfL96

CfscsGfaCfcUfuGfAfGfgCfaUfaCfuUfcAfL96

GfsasCfcUfuGfaGfGfCfaUfaCfuUfcAfaAfL96

AfscsCfgAfcCfuUfGfAfgGfcAfuAfcUfuAfL96

UfscsGfcAfuGfgAfGfAfcCfaCfcGfuGfaAfL96

UfsusAfcAfuAfaGfAfGfgAfcUfcUfuGfgAfL96

UfscsUfuAfcAfuAfAfGfaGfgAfcUfcUfuAfL96

AfscsUfuCfaAfaGfAfCfuGfuUfuGfuUfuAfL96

UfsasCfuUfcAfaAfGfAfcUfgUfuUfgUfuUfL96

AfsusAfcUfuCfaAfAfGfaCfuGfuUfuGfuUfL96

UfsusGfuUfuAfaAfGfAfcUfgGfgAfgGfaAfL96

GfscsAfuAfcUfuCfAfAfaGfaCfuGfuUfuAfL96

CfsasAfaGfaCfuGfUfUfuGfuUfuAfaAfgAfL96

AfsgsAfcUfgUfuUfGfUfuUfaAfaGfaCfuAfL96

GfsusUfuGfuUfuAfAfAfgAfcUfgGfgAfgAfL96

GfsgsGfgGfaGfgAfGfAfuUfaGfaUfuAfaAfL96

GfsgsGfgAfgGfaGfAfUfuAfgAfuUfaAfaGfL96

GfsusUfgGfgGfgAfGfGfaGfaUfuAfgAfuUfL96

UfsusGfgGfgGfaGfGfAfgAfuUfaGfaUfuAfL96

GfsgsGfaGfgAfgAfUfUfaGfaUfuAfaAfgAfL96

Sense Oligo Name

A-128391

A-131837

A-131841

A-131849

A-131835

A-131863

A-131845

A-131843

A-123521

A-131855

A-131827

A-131811

A-131803

A-123523

A-131801

A-131799

A-131817

A-131819

A-131815

A-131831

A-131807

A-131805

A-131825

A-131809

A-131813

A-131821

Duplex ID

AD-64311

AD-65790

AD-65761

AD-65786

AD-65785

AD-65787

AD-65770

AD-65766

AD-61555

AD-65762

AD-65755

AD-65788

AD-65768

AD-61561

AD-65764

AD-65753

AD-65765

AD-65769

AD-65759

AD-65774

AD-65778

AD-65773

AD-65789

AD-65783

AD-65754

AD-65779

MEI 27037625V.1

124

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:	1246	1247	1248	1249	1250	1251	1252
Antisense Sequence (5’ to 3’)	usUfsaCfaAfaGfaCfcuuUfaAfuCfuAfasusc	asGfsuAfcAfaAfgAfccuUfuAfaUfcUfasasu	usAfscAfaAfgAfcCfuuuAfaUfcUfaAfuscsu	usAfscCfuUfuAfaUfcuaAfuCfuCfcUfcscsc	usUfsgCfaGfaGfaGfuccAfaGfaGfuCfcsusc	usAfsuUfgCfaGfaGfaguCfcAfaGfaGfuscsc	usAfsgUfaCfaAfaGfaccUfuUfaAfuCfusasa
Antisense Oligo Name	A-131852	A-131830	A-131824	A-131854	A-131848	A-131834	A-131840
SEQ ID NO:	1200	1201	1202	1203	1204	1205	1206
Sense Sequence (5’ to 3’)	UfsusAfgAfuUfaAfAfGfgUfcUfuUfgUfaAfL96	UfsasGfaUfuAfaAfGfGfuCfuUfuGfuAfcUfL96	AfsusUfaGfaUfuAfAfAfgGfuCfuUfuGfuAfL96	GfsasGfgAfgAfuUfAfGfaUfuAfaAfgGfuAfL96	GfsgsAfcUfcUfuGfGfAfcUfcUfcUfgCfaAfL96	AfscsUfcUfuGfgAfCfUfcUfcUfgCfaAfuAfL96	AfsgsAfuUfaAfaGfGfUfcUfuUfgUfaCfuAfL96
Sense Oligo Name	A-131851	A-131829	A-131823	A-131853	A-131847	A-131833	A-131839
Duplex ID	AD-65791	AD-65760	AD-65784	AD-65757	AD-65775	AD-65780	AD-65756

SEQ ID NO:	1263	1264	1265	1266	1267	1268	1269	1270	CN	1272
’ to 3’)					nnv	nnv	GUU	GUU	GUU	GUU
					o	o	3	3
	O	O	O	O		<	U	U	u	U
4)					o	o	u	u	u	u
c	u	u	o	o	u	u			u>	u>
							u	u	<	<
©	o	o	o	o	u	u	u	u	o	o
2			u	u		<			u	u
P	o	o				<	u	u	u>	u>
4)	u	u	u	u	u	u	u	u
	u	u			o	o			u	u
4)					u	u	<	<	<	<
3			u	u		<	o	o	<	<
c	u	u	o	o		<	u	u	<	<
			u	u	u	u			<	<
4)	u	u							<	<
ζ/2 gj					u	u	u	u	u	u
4)			u	u	u	u	<	<
	u	u			<	<	<	<	u	u
2			u	u	u	u	<	<	u	u
C					<	<	<	<	<	<
δ z Q	cn			so		oo	OS	o		<N
	IT)	ι/Ί	ι/Ί	IT)	tn	IT)	IT)	so	so	so
	CN	CN	CN	CN	(N	(N	(N	(N	(N	(N
ζβ
5’ to 3’)					ucu	UCU	nnn	nnn	ecu	ecu
			o	o	o	o				<
Ό	o	o	<	<	U	U			o	o
4) IS			o	o	<	<	<	<
					o	o	<	<
Ό ©	o	o					o	o
g			o	o	C)	C)	u	u
©	o	o	u	u	o	o			ο	ο
			u	u	u	u	<	<	o	o
©					u	u			<	<
	o	o					o	o	<	<
s	u	u	o	o			<	<	o	o
©	u	u			o	o	o	o	u	u
σ			o	o	<	<	u	u
4) ζβ	u	u	u	u	o	o	<	<	<	<
					u	u	o	o	o	o
ζΛ	o	o	u	u	u	u>	o	o	o	o
s					u	u	<	<	<	<
'Si	u	u	u	u			o	o	o	o
a	oo	Os	o			cn			so
	o	o					1			1
	oo	oo	OO	OO	OO	oo	OO	OO	oo	OO
	SO	so	so	so	so	so	so	so	so	so
	so	so	so	so	so	so	so	so	so	so
a ©	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q
Q					<	<	<	<	<	<

MEI 27037625V.1

125

WO 2018/195165

PCT/US2018/028116

SEQ ID NO:	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292
Antisense Sequence Modified (5’ to 3’)	usAfsgauGfaGfAfaggcAfcAfgacsusu	UfsAfsgauGfaGfAfaggcAfcAfgacsusu	usGfsugaAfgCfGfaaguGfcAfcacsusu	UfsGfsugaAfgCfGfaaguGfcAfcacsusu	asGfsaggUfgAfAfgcgaAfgUfgcacasusu	AfsGfsaggUfgAfAfgcgaAfgUfgcacasusu	asAfsaagUfuGfCfauggUfgCfuggugsusu	AfsAfsaagUfuGfCfauggUfgCfuggugsusu	asGfsgugAfaAfAfaguuGfcAfuggugsusu	AfsGfsgugAfaAfAfaguuGfcAfuggugsusu
SEQ ID NO:	1273	1274	1275	1276	cN	1278	1279	1280	1281	1282
Sense Sequence Modified (5’ to 3’)	gsuscuGfuGfCfCfuucucaucuaL96	gsuscuGfuGfCfCfuucucaucuaL96	gsusguGfcAfCfUfucgcuucacaL96	gsusguGfcAfCfUfucgcuucacaL96	usgsugcaCfuUfCfGfcuucaccucuL96	usgsugcaCfuUfCfGfcuucaccucuL96	csasccagCfaCfCfAfugcaacuuuuL96	csasccagCfaCfCfAfugcaacuuuuL96	csasccauGfcAfAfCfuuuuucaccuL96	csasccauGfcAfAfCfuuuuucaccuL96
DuplexID	AD-66808	AD-66809	AD-66810	AD-66811	AD-66812	AD-66813	AD-66814	AD-66815	AD-66816	AD-66817

126

WO 2018/195165

PCT/US2018/028116

Table 12: HBV Target Sequences, noting target sites on Accession No. X02763.1. (Activity data and exemplary chemical modifications available at W02012/024170, incorporated herein by reference)

Target Sequence	Target Site	SEQ ID NO:
UCGUGGUGGACUUCUCUCA	1663	1293
GUGGUGGACUUCUCUCAAU	1665	1294
GCCGAUCCAUACUGCGGAA	2669	1295
CCGAUCCAUACUGCGGAAC	2670	1296
CAUCCUGCUGCUAUGCCUC	1818	1297
UGCUGCUAUGCCUCAUCUU	1823	1298
GGUGGACUUCUCUCAAUUU	1667	1299
UGGUGGACUUCUCUCAAUU	1666	1300
UAGACUCGUGGUGGACUUC	1658	1301
UCCUCUGCCGAUCCAUACU	2663	1302
UGCCGAUCCAUACUGCGGA	2668	1303
UGGAUGUGUCUGCGGCGUU	1783	1304
CGAUCCAUACUGCGGAACU	2671	1305
CGCACCUCUCUUUACGCGG	2934	1306
CUGCCGAUCCAUACUGCGG	2667	1307
CGUGGUGGACUUCUCUCAA	1664	1308
CUGCUGCUAUGCCUCAUCU	1822	1309
CCUGCUGCUAUGCCUCAUC	1821	1310
CUAGACUCGUGGUGGACUU	1657	1311
UCCUGCUGCUAUGCCUCAU	1820	1312
GACUCGUGGUGGACUUCUC	1660	1313
AUCCAUACUGCGGAACUCC	2673	1314
CUCUGCCGAUCCAUACUGC	2665	1315
GAUCCAUACUGCGGAACUC	2672	1316

127

WO 2018/195165

PCT/US2018/028116

Target Sequence	Target Site	SEQ ID NO:
GAAGAACUCCCUCGCCUCG	567	1317
AAGCCUCCAAGCUGUGCCU	54	1318
AGAAGAACUCCCUCGCCUC	566	1319
GGAGUGUGGAUUCGCACUC	455	1320
CCUCUGCCGAUCCAUACUG	2664	1321
CAAGCCUCCAAGCUGUGCC	53	1322
UCCAUACUGCGGAACUCCU	2674	1323
CAGAGUCUAGACUCGUGGU	1651	1324
AAGAAGAACUCCCUCGCCU	565	1325
GAGUGUGGAUUCGCACUCC	456	1326
UCUAGACUCGUGGUGGACU	1656	1327
GCUGCUAUGCCUCAUCUUC	1824	1328
AGUCUAGACUCGUGGUGGA	1654	1329
CUCCUCUGCCGAUCCAUAC	2662	1330
UGGCUCAGUUUACUAGUGC	2077	1331
GUCUAGACUCGUGGUGGAC	1655	1332
UUCAAGCCUCCAAGCUGUG	51	1333
CUAUGGGAGUGGGCCUCAG	2047	1334
CUCGUGGUGGACUUCUCUC	1662	1335
CCUAUGGGAGUGGGCCUCA	2046	1336
AAGAACUCCCUCGCCUCGC	568	1337
UCUGCCGAUCCAUACUGCG	2666	1338
AGAGUCUAGACUCGUGGUG	1652	1339
GAAGAAGAACUCCCUCGCC	564	1340
UCAAGCCUCCAAGCUGUGC	52	1341
AGCCUCCAAGCUGUGCCUU	55	1342

128

WO 2018/195165

PCT/US2018/028116

Target Sequence	Target Site	SEQ ID NO:
AGACUCGUGGUGGACUUCU	1659	1343

Table 13. Various HBV siNA sense and antisense sequences corresponding to the identified target sequences in Table la. (Activity data and exemplary chemical modifications available at WO2012/024170, incorporated herein by reference)

Target Site	SEQ ID NO:	Sense Sequence	Antisense Sequence	SEQ ID NO:
1663	1344	UCGUGGUGGACUUCUCUCA	UGAGAGAAGUCCACCACGA	1395
1665	1345	GUGGUGGACUUCUCUCAAU	AUUGAGAGAAGUCCACCAC	1396
2669	1346	GCCGAUCCAUACUGCGGAA	UUCCGCAGUAUGGAUCGGC	1397
2670	1347	CCGAUCCAUACUGCGGAAC	GUUCCGCAGUAUGGAUCGG	1398
1818	1348	CAUCCUGCUGCUAUGCCUC	GAGGCAUAGCAGCAGGAUG	1399
1823	1349	UGCUGCUAUGCCUCAUCUU	AAGAUGAGGCAUAGCAGCA	1400
1667	1350	GGUGGACUUCUCUCAAUUU	AAAUUGAGAGAAGUCCACC	1401
1666	1351	UGGUGGACUUCUCUCAAUU	AAUUGAGAGAAGUCCACCA	1402
1658	1352	UAGACUCGUGGUGGACUUC	GAAGUCCACCACGAGUCUA	1403
2663	1353	UCCUCUGCCGAUCCAUACU	AGUAUGGAUCGGCAGAGGA	1404
2668	1354	UGCCGAUCCAUACUGCGGA	UCCGCAGUAUGGAUCGGCA	1405
1783	1355	UGGAUGUGUCUGCGGCGUU	AACGCCGCAGACACAUCCA	1406
2671	1356	CGAUCCAUACUGCGGAACU	AGUUCCGCAGUAUGGAUCG	1407
2934	1357	CGCACCUCUCUUUACGCGG	CCGCGUAAAGAGAGGUGCG	1408
2667	1358	CUGCCGAUCCAUACUGCGG	CCGCAGUAUGGAUCGGCAG	1409
1664	1359	CGUGGUGGACUUCUCUCAA	UUGAGAGAAGUCCACCACG	1410
1822	1360	CUGCUGCUAUGCCUCAUCU	AGAUGAGGCAUAGCAGCAG	1411
1821	1361	CCUGCUGCUAUGCCUCAUC	GAUGAGGCAUAGCAGCAGG	1412
1657	1362	CUAGACUCGUGGUGGACUU	AAGUCCACCACGAGUCUAG	1413
1820	1363	UCCUGCUGCUAUGCCUCAU	AUGAGGCAUAGCAGCAGGA	1414
1660	1364	GACUCGUGGUGGACUUCUC	GAGAAGUCCACCACGAGUC	1415

129

WO 2018/195165

PCT/US2018/028116

Target Site	SEQ ID NO:	Sense Sequence	Antisense Sequence	SEQ ID NO:
2673	1365	AUCCAUACUGCGGAACUCC	GGAGUUCCGCAGUAUGGAU	1416
2665	1366	CUCUGCCGAUCCAUACUGC	GCAGUAUGGAUCGGCAGAG	1417
2672	1367	GAUCCAUACUGCGGAACUC	GAGUUCCGCAGUAUGGAUC	1418
567	1368	GAAGAACUCCCUCGCCUCG	CGAGGCGAGGGAGUUCUUC	1419
54	1369	AAGCCUCCAAGCUGUGCCU	AGGCACAGCUUGGAGGCUU	1420
566	1370	AGAAGAACUCCCUCGCCUC	GAGGCGAGGGAGUUCUUCU	1421
455	1371	GGAGUGUGGAUUCGCACUC	GAGUGCGAAUCCACACUCC	1422
2664	1372	CCUCUGCCGAUCCAUACUG	CAGUAUGGAUCGGCAGAGG	1423
53	1373	CAAGCCUCCAAGCUGUGCC	GGCACAGCUUGGAGGCUUG	1424
2674	1374	UCCAUACUGCGGAACUCCU	AGGAGUUCCGCAGUAUGGA	1425
1651	1375	CAGAGUCUAGACUCGUGGU	ACCACGAGUCUAGACUCUG	1426
565	1376	AAGAAGAACUCCCUCGCCU	AGGCGAGGGAGUUCUUCUU	1427
456	1377	GAGUGUGGAUUCGCACUCC	GGAGUGCGAAUCCACACUC	1428
1656	1378	UCUAGACUCGUGGUGGACU	AGUCCACCACGAGUCUAGA	1429
1824	1379	GCUGCUAUGCCUCAUCUUC	GAAGAUGAGGCAUAGCAGC	1430
1654	1380	AGUCUAGACUCGUGGUGGA	UCCACCACGAGUCUAGACU	1431
2662	1381	CUCCUCUGCCGAUCCAUAC	GUAUGGAUCGGCAGAGGAG	1432
2077	1382	UGGCUCAGUUUACUAGUGC	GCACUAGUAAACUGAGCCA	1433
1655	1383	GUCUAGACUCGUGGUGGAC	GUCCACCACGAGUCUAGAC	1434
51	1384	UUCAAGCCUCCAAGCUGUG	CACAGCUUGGAGGCUUGAA	1435
2047	1385	CUAUGGGAGUGGGCCUCAG	CUGAGGCCCACUCCCAUAG	1436
1662	1386	CUCGUGGUGGACUUCUCUC	GAGAGAAGUCCACCACGAG	1437
2046	1387	CCUAUGGGAGUGGGCCUCA	UGAGGCCCACUCCCAUAGG	1438
568	1388	AAGAACUCCCUCGCCUCGC	GCGAGGCGAGGGAGUUCUU	1439
2666	1389	UCUGCCGAUCCAUACUGCG	CGCAGUAUGGAUCGGCAGA	1440
1652	1390	AGAGUCUAGACUCGUGGUG	CACCACGAGUCUAGACUCU	1441
564	1391	GAAGAAGAACUCCCUCGCC	GGCGAGGGAGUUCUUCUUC	1442

130

WO 2018/195165

PCT/US2018/028116

Target Site	SEQ ID NO:	Sense Sequence	Antisense Sequence	SEQ ID NO:
52	1392	UCAAGCCUCCAAGCUGUGC	GCACAGCUUGGAGGCUUGA	1443
55	1393	AGCCUCCAAGCUGUGCCUU	AAGGCACAGCUUGGAGGCU	1444
1659	1394	AGACUCGUGGUGGACUUCU	AGAAGUCCACCACGAGUCU	1445

131

WO 2018/195165

PCT/US2018/028116

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

Claims

We claim:

1. An RNAi agent and an HBV vaccine comprising a protein-based vaccine and a nucleic acid-based vaccine for use in treatment of hepatitis B virus (HBV) infection or a method for treating a subject having an HBV infection, comprising sequentially administering to the subject having an HBV infection:

a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;

b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and

c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; thereby treating the subject.

2. The use or method of claim 1, wherein the RNAi agent comprises at least one modified nucleotide.

3. The use or method of claim 1 or 2, wherein the nucleic acid-based vaccine comprises an expression vector construct encoding the second HBcAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof.

4. The use or method of any of claims 1-3, wherein at least two doses of the RNAi agent are administered to the subject.

5 immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and

c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBeAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof,

5. The use or method of any of claims 1-4, wherein the RNAi agent is administered to the subject such that the level of HBsAg in the serum of the subject is decreased by at least 0.5 log 10 lU/ml.

6. The use or method of any of claims 1-5, wherein the level of HBsAg in the serum of the subject is decreased by at least a 0.5 loglO lU/ml prior to administration of a first dose of the protein based vaccine.

133

WO 2018/195165

PCT/US2018/028116

7. The use or method of any of claims 1-6, wherein the level of HBsAg in the serum of the subject is decreased by at least a 1 log 10 lU/ml prior to administration of a first dose of the protein based vaccine.

8. The use or method of any of claims 1-7, wherein the level of HBsAg in the serum of the subject is decreased by at least a 2 log 10 lU/ml prior to administration of a first dose of the protein based vaccine.

9. The use or method of any of claims 1-8, wherein the level of HBeAg in the serum of the subject is decreased by at least a 1 log 10 lU/ml prior to administration of a first dose of the protein based vaccine.

10. The use or method of any of claims 1-9, wherein the level of HBsAg in the serum of the subject is decreased by at least a 2 log 10 lU/ml and the the level of HBeAg in the serum of the subject is decreased by at least a 1 log 10 lU/ml prior to administration of a first dose of the protein based vaccine.

11. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

12. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

13. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

14. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

15. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of HBeAg level to 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

134

WO 2018/195165

PCT/US2018/028116

16. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of HBeAg level to 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

17. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 500 lU/ml or less and a serum HBeAg level of 500 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

18. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 200 lU/ml or less and a serum HBeAg level of 200 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

19. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 100 lU/ml or less and a serum HBeAg level of 100 lU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.

20. The use or method of any of claims 1-19, wherein a dose of the RNAi agent is administered to the subject no more than once per week.

21. The use or method of any of claims 1-19, wherein a dose of the RNAi agent is administered to the subject no more than once every four weeks.

22. The use or method of any one of claims 1-21, wherein the RNAi agent is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg; or 0.5 mg/kg to 50 mg/kg; or 10 mg/kg to 30 mg/kg.

23. The use or method of of any one of claims 1-21, wherein the RNAi agent is administered to the subject at a dose selected from the group consisting of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg.

24. The use or method of any of claims 1-23, wherein the first HBeAg polypeptide, or immunogenic fragment thereof, comprises at least one HBeAg determinant and the first HBsAg polypeptide, or immunogenic fragment thereof, comprises at least one HBsAg determinant.

25. The use or method of any one of claims 1-24, wherein the second HBeAg polypeptide, or immunogenic fragment thereof, comprises at least one HBeAg determinant and the second HBsAg polypeptide, or immunogenic fragment thereof, comprises at least one HBsAg determinant.

135

WO 2018/195165

PCT/US2018/028116

26. The use or method of claim 24 or 25, wherein the first and/or second HBsAg determinant comprises an amino acid sequence at least 90% identical to amino acids 124 to 147 of SEQ ID NO: 22.

27. The use or method of claim 24 or 25, wherein the first and/or second HBsAg determinant comprises an amino acid sequence at least 90% identical to amino acids 99 to 168 of SEQ ID NO: 23.

28. The use or method of claim 24 or 25, wherein the first and/or second HBcAg determinant comprises an amino acid sequence comprising amino acid residue 80 of SEQ ID NO: 24.

29. The use or method of claim 28, wherein the sequence comprising amino acid 80 of SEQ ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24.

30. The use or method of claim 28, wherein the first and/or second HBcAg determinant comprises an amino acid sequence comprising amino acid residue 138 of SEQ ID NO: 24.

31. The use or method of claim 28, wherein the sequence comprising amino acid 80 of SEQ ID NO: 14 comprises an amino acid sequence at lest 90% identical to at least amino acids 128 to 143 of SEQ ID NO: 24.

32. The use or method of any of claims 28 or 31, wherein the first and/or second HBcAg determinant comprises an amino acid sequence at least 90% identical to at least 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 24.

33. The use or method of claim 25, wherein the determinant of HBcAg comprises a sequence at least 90% identical to amino acids 18 to 143 of SEQ ID NO: 24.

34. The use or method of any one of claims 1-33, wherein the a dose of the protein-based vaccine administered to the subject comprises about 0.1 pg to about 1.0 mg of the first HBcAg polypeptide, or immunogenic fragment thereof, and a dose of about 0.1 pg to about 1.0 mg of the first HBsAg polypeptide, or immunogenic fragment thereof.

35. The use or method of any of claims 1-34, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and the first HBsAg polypeptide, or immunogenic fragment thereof, are present in a single protein-based vaccine formulation.

136

WO 2018/195165

PCT/US2018/028116

36. The use or method of any of claims 1-35, wherein the protein-based vaccine further comprises an adjuvant.

37. The use or method of claim 36, wherein the adjuvant stimulates a balanced Thl/Th2 response.

38. The use or method of claim 36, wherein the adjuvant is selected from the group consisting of monophosphoryl lipid A (MPL), poly(I:C), polylCLC adjuvant, CpG DNA, polylCLC adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)), alum, virosomes, cytokines, IL-12, AS02, AS03, AS04, MF59, ISCOMATRIX®, IC31®, or Rig-I ligand.

39. The use or method of claim 36, wherein the adjuvant is selected from the group consisting of a polyhC adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant.

40. The use or method of any of claims 1-39, wherein a dose of the protein based vaccine is administered to the subject at least two times.

41. The use or method of claim 40, wherein a dose of the protein-based vaccine is administered to the subject no more than once every two weeks.

42. The use or method of any of claims 1-41, wherein a dose of the protein-based vaccine is administered to the subject no sooner than the day on which a final dose of the RNAi agent has been administered to the subject.

43. The use or method of claim 42, wherein a dose of the protein-based vaccine is administered to the subject on the same day as a final dose of the RNAi agent has been administered to the subject.

44. The use or method of any of claims 1-42, wherein the a dose of the protein-based vaccine is administered to the subject no later than one month after a final dose of the RNAi agent has been administered to the subject.

45. The use or method of any of claims 1-42, wherein a dose of the protein-based vaccine is administered to the subject no later than three months after a final dose of the RNAi agent has been administered to the subject.

137

WO 2018/195165

PCT/US2018/028116

46. The use or method of any of claims 1-45, wherein the level of HBsAg in the serum of the subject is determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

47. The use or method of any of claims 1-45, wherein the level of HBeAg in the serum of the subject is determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

48. The use or method of any of claims 1-45, wherein the level of HBsAg and the level of HBeAg in the serum of the subject are determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.

49. The use or method of any of claims 1-45, wherein the nucleic acid-based vaccine comprises at least one expression vector construct encoding the second HBeAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof.

50. The use or method of claim 49, wherein the at least one expression construct comprises a promoter that promotes expression of the second HBeAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof.

51. The use or method of claim 49, wherein the at least one expression construct comprises a first and second promoter, the first promoter promoting expression of the second HBeAg polypeptide, or immunogenic fragment thereof, and the second promoter promoting expression of the second HBsAg polypeptide, or immunogenic fragment thereof.

52. The use or method of claim 50 or 51 wherein at least one the promoters is selected from the group consisting of a respiratory syncytial virus (RSV) promoter, a cytomegalovirus (CMV) promoter, a PH5 promoter, and an Hl promoter.

53. The use or method of any of claims 1-52, wherein the expression construct comprises a viral vector.

54. The use or method of claim 53, wherein the viral vector is selected from the group consosting of an adenovirus vector; a retrovirus vector, a lentiviral vector, a moloney murine leukemia virus vector,an adeno- associated virus vector; a herpes simplex virus vector; a SV 40 vector; a polyoma virus vector; a papilloma virus vector; a picornavirus vector; a pox virus vector, an

138

WO 2018/195165

PCT/US2018/028116 orthopox virus vector, a vaccinia virus vector, a modified vaccinia virus Ankara (MVA) vector, an avipox vector, a canary pox vector, a fowl pox vector, and an Epstein Barr virus vector.

55. The use or method of claim 53, wherein the viral vector is an MV A vector.

56. The use or method of any one of claims 1-55, wherein a dose of the nucleic acid-based vaccine administered to the subject comprises a tissue-culture infectious dose (TCID₅₀) of 10⁶ to 10¹⁰TCID50; or 10⁶ to 10⁹ TCID50; or 10⁶ to 10⁸ TCID₅₀.

57. The use or method of any of claims 1-56, wherein a dose of the nucleic acid-based vaccine is administered to the subject no sooner than two weeks after administration of a final dose of the protein-based vaccine is administered to the subject.

58. The use or method of any of claims 1-57, wherein the level of HBsAg in the serum of the subject after administration of at least one dose of the RNAi agent is determined prior to administration of a dose of the nucleic acid-based vaccine.

59. The use or method of any of claims 1-58, wherein a first dose of the nucleic acid-based vaccine is administered to the subject when the level of HBsAg in the serum of the subject is further decreasd to at least 0.5 log 10 lU/ml following administration of at least one dose of the protein-based vaccine.

60. The use or method of any of claims 1-59, wherein a single dose of the nucleic-acid based vaccine is administered to the subject.

61. The use or method of any of claims 1-60, further comprising administering a nucleot(s)ide analog to the subject.

62. The use or method of claim 61, wherein at least one dose of the nucleot(s)ide analog is administered to the subject prior to administration of the RNAi agent to the subject; or multiple doses of the nucleot(s)ide analog are administered to the subject.

63. The use or method of claim 61 or 62, wherein the nucleot(s)ide analog is selected from the group consisting of Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir, besifovir (ANA-3 80/LB-803 80), and tenofvir-exaliades (TLX/CMX157).

139

WO 2018/195165

PCT/US2018/028116

64. The use or method of any one of claims 1-63, wherein the level of serum HBsAg in the subject is below 3000 lU/ml, 4000 lU/ml, or 5000 lU/ml prior to administration of the RNAi agent.

65. The use or method of any of claims 1-64, wherein the level of serum HBsAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.

66. The use or method of any of claims 1-64, wherein the level of serum HBeAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.

67. The use or method of any of claims 1-64, wherein the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.

68. The use or method of any of claims 1-67, further comprising administering an immune stimulator to the subject.

69. The use or method of claim 68, wherein immune stimulator is selected from the group consisting of pegylated interferon alfa 2a (PEG-IFN-alpha-2a), Interferon alfa-2b, PEG-IFN-alpha-2b, Interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor, Myrcludex, an oligonucleotide that inhibits the secretion or release of HBsAg, REP 9AC, a capsid inhibitor, Bay41-4109, NVR-1221, a cccDNA inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-L1 inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.

70. The use or method of any one of claims 1-69, wherein the subject is human.

71. The use or method of any of claims 1-70, wherein the RNAi agent inhibits expression of four HBV transcripts.

72. The use or method of any of claims 1-70, wherein the RNAi agent inhibits expression of at least three HBV transcripts.

73. The use or method of any of claims 1-72, wherein the RNAi agent is selected from any one of the iRNA agents in Appendix A.

140

WO 2018/195165

PCT/US2018/028U6

74. The use or method of claim 73, wherein the RNAi agent is selected from any one of the RNAi agents in Tables 2-11 in Appendix A.

75. The use or method of any of claims 1-74, wherein the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597, 206-228, 207-229, 210-232, 212-234, 214-236, 215-237, 216-238, 226-248, 245-267, 250-272, 252-274, 253-275, 254-276, 256-278, 258-280, 263285, 370-392, 373-395, 375-397, 401-423, 405-427, 410-432, 411-433, 422-444, 424-446, 425-447, 426-448, 731-753, 734-756, 1174-1196, 1250-1272, 1255-1277, 1256-1278, 1545-1567, 1547-1569, 1551-1571, 1577-1597, 1580-1598, 1806-1825, 1812-1831, 1814-1836, 1829-1851, 1831-1853, 18571879, 1864-1886, 2259-2281, 2298-2320, or 2828-2850 of SEQ ID NO: 1 (NC_003977.1).

76. The use or method of any of claims 1-75, wherein the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).

77. The use or method of any of claims 1-75, wherein the RNAi agent targets nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).

78. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of5’UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) or 5’AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26).

79. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of5’UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) or 5’AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26).

80. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5’-UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) or 5’AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26).

81. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of5’GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27) or 5’-CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

141

WO 2018/195165

PCT/US2018/028116

82. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of5’GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27) or 5’-CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

83. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises the nucleotide sequence of 5’-GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27) or 5’CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

84. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5’UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) and the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5’-GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27).

85. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5’UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) and the sense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5’-GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27).

86. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5’-UGUGAAGCGAAGUGCACACUU-3’ (SEQ ID NO: 25) and the sense strand comprises the nucleotide sequence of 5’-GUGUGCACUUCGCUUCACA-3’ (SEQ ID NO: 27).

87. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5’AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of5’CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

88. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises a at least 19 contiguous nucleotides of the nucleotide sequence of 5’AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of5’CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

142

WO 2018/195165

PCT/US2018/028116

89. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5’-AGGUGAAAAAGUUGCAUGGUGUU-3’ (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises the nucleotide sequence of5’CACCAUGCAACUUUUUCACCU-3’ (SEQ ID NO: 28).

90. The use or method of any of claims 1-89, wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3’-terminus.

91. The use or method of claim 90, wherein the ligand is one or more GalNAc derivatives attached through a monovalent linker, bivalent branched linker, or trivalent branched linker.

92. The use or method of claim 91, wherein at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3’-terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2’-amino-modified nucleotide, a 2’-O-allylmodified nucleotide, 2’-C-alkyl-modified nucleotide, 2’-hydroxly-modified nucleotide, a 2’methoxyethyl modified nucleotide, a 2’ -O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5’-phosphate, and a nucleotide comprising a 5’-phosphate mimic.

93. The use or method of any of claims 1-92, wherein at least one strand of the RNAi agent comprises a 3’ overhang of at least 1 nucleotide.

94. The use or method of any of claims 1-92, wherein at least one strand if the RNAi agent comprises a 3’ overhang of at least 2 nucleotides.

95. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 15-30 nucleotide pairs in length.

96. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 17-23 nucleotide pairs in length.

143

WO 2018/195165

PCT/US2018/028116

97. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 17-25 nucleotide pairs in length.

98. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 23-27 nucleotide pairs in length.

99. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 19-21 nucleotide pairs in length.

100. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 21-23 nucleotide pairs in length.

101. The use or method of any of claims 1-92, wherein each strand of the RNAi agent has 15-30 nucleotides.

102. The use or method of any of claims 1-92, wherein each strand of the RNAi agent has 19-30 nucleotides.

104. The use or method of claim 90, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic

144

WO 2018/195165

PCT/US2018/028116

wherein X is O or S.

105. The use or method of any of claims 1-75 wherein the RNAi agent is AD-66810 or AD-

66816.

106. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least four genotypes of HBV.

107. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least six genotypes of HBV.

108. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least seven genotypes of HBV.

109. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least four genotypes of HBV.

110. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least six genotypes of HBV.

111. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least seven genotypes of HBV.

145

WO 2018/195165

PCT/US2018/028116

112. A kit for treating a subject having an HBV infection, the kit comprising:

b) a protein-based vaccine comprising a first HBV core antigen (HBeAg) polypeptide, or

10 wherein the second HBeAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBeAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; and

d) instructions for use according to the uses or methods of any one of claims 1-111.